Visualization and Quantification of Cancer-associated Enzymes with Fluorescent Small-molecule Substrate Probes by Shen, Zhenhua
Louisiana State University 
LSU Digital Commons 
LSU Doctoral Dissertations Graduate School 
6-13-2018 
Visualization and Quantification of Cancer-associated Enzymes 
with Fluorescent Small-molecule Substrate Probes 
Zhenhua Shen 
Louisiana State University and Agricultural and Mechanical College 
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations 
 Part of the Analytical Chemistry Commons 
Recommended Citation 
Shen, Zhenhua, "Visualization and Quantification of Cancer-associated Enzymes with Fluorescent Small-
molecule Substrate Probes" (2018). LSU Doctoral Dissertations. 4614. 
https://digitalcommons.lsu.edu/gradschool_dissertations/4614 
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It 
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU 
Digital Commons. For more information, please contactgradetd@lsu.edu. 
 
 
VISUALIZATION AND QUANTIFICATION OF CANCER-ASSOCIATED 


















Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the degree of 





















  M.S., Zhengzhou University, 2013 




















This dissertation is dedicated  
 
With love to my grandparents and parents 
 
Who unconditionally love, believe, and support me 
 
And to my brother and sister 
 
































First and foremost, I would like to thank my advisor, Prof. Robin L. McCarley, for his 
continuous guidance, and constant support throughout my graduate study. I am very grateful to 
him for allowing me to become a part of the McCarley research group. Without his guidance, the 
completion of my dissertation would not have been possible. He is not only an intelligent and 
enthusiastic scientist, always curious about the unknown and the truth, but also a caring person 
who always encourages his students to achieve their best. I am very fortunate to have him as my 
doctoral advisor. 
I would like to thank the members of my advisory committee, Dr. Kevin Smith, and Dr. 
Kermit Murray for their assistance throughout my graduate program. I also thank my Dean’s 
representatives Dr. Brent Christner and Dr. Philip Jung for attending my general exam and my 
final defense, respectively. 
 I would like to thank all my colleagues in the McCarley research group who helped me 
during my research projects. I particularly thank Dr. Bijeta Prasai who aided me from the beginning 
of my research to the end of my dissertation. Her friendship, broad scientific knowledge, and 
motivation were invaluable to the completion of my degree. I would like to thank the past members 
of the McCarley research lab, Dr. Quinn Best and Dr. Suraj Hettiarachchi for rigorous scientific 
discussion during the initial phase of my projects. I would like to thank Ansonia Badgett for being 
the best company in this long journey. The sorrows and happiness we experienced together will 
be remembered forever. I would like to thank Milcah S. Jackson for carefully reading and editing 
my documents. I feel grateful to have had the chance to meet and spend time with all of the 
current members of the McCarley research group. I would also like to thank the Department of 
Chemistry for providing such a great scientific environment and advanced facilities without which 
my research could not be completed. 
Finally, I want to thank my family for their unconditional support, love, and 




TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ............................................................................................................. iii 
 
LIST OF TABLES ....................................................................................................................... vi 
 
LIST OF FIGURES ................................................................................................................... vii 
 
LIST OF SCHEMES ................................................................................................................. xiii 
 
LIST OF ABBREVIATIONS AND SYMBOLS ........................................................................... xiv 
 
ABSTRACT .............................................................................................................................. xxi 
 
CHAPTER 1. INTRODUCTION ................................................................................................... 1  
1.1        Research Goals and Aims .............................................................................................. 1  
1.2        Molecular Imaging in Cancer .......................................................................................... 3 
1.3        Optical Imaging and Its Applications ............................................................................... 6 
1.4        Fluorophores ................................................................................................................ 12 
1.5        Fluorescent Probes in Cancer Imaging and Design Strategies ..................................... 25 
1.6        Enzyme-Activatable Fluorescent Probes ...................................................................... 31 
1.7        NAD(P)H:quinone Oxidoreductase 1 (NQO1) ............................................................... 32 
1.8        Visualization of -Galactosidase with Different Imaging Modalities ............................... 39 
1.9        References ................................................................................................................... 54 
 
CHAPTER 2. A NEAR-INFRARED, WAVELENGTH-SHIFTABLE, TURN-ON FLUORESCENT 
PROBE FOR THE DETECTION AND IMAGING OF CANCER TUMOR CELLS ....................... 79 
2.1        Introduction .................................................................................................................. 79  
2.2        Experimental Section ................................................................................................... 82 
2.3        Results and Discussion ................................................................................................ 96 
2.4        Conclusion ................................................................................................................. 132 
2.5        References ................................................................................................................. 134 
 
CHAPTER 3. A NEAR-INFRARED, FAST-RESPONSIVE, AND ON-ON FLUORESCENT PROBE 
TO VISUALIZE AN INTRACELLULAR CANCER-ASSOCIATED QUINONE REDUCTASE IN 
CELLS AND MULTICELLULAR TUMOR SPHEROIDS .......................................................... 143 
3.1        Introduction ................................................................................................................ 143  
3.2        Experimental Section ................................................................................................. 145 
3.3        Results and Discussion .............................................................................................. 152 
3.4        Conclusion and Outlook ............................................................................................. 165 
3.5        References ................................................................................................................. 167 
 
CHAPTER 4. A RATIOMETRIC FLUORESCENT PROBE FOR THE DETECTION AND IMAGING 
OF ENDOGENOUS BETA-GALACTOSIDASE IN OVARIAN CANCER CELLS ...................... 171  
4.1        Introduction ................................................................................................................ 171  
4.2        Experimental Section ................................................................................................. 175 
4.3        Results and Discussion .............................................................................................. 181 
4.4        Conclusion ................................................................................................................. 197 




CHAPTER 5. A RATIOMETRIC AND NEAR-INFRARED FLUORESCENT PROBE FOR 
SELECTIVE DETECTION AND QUANTIFICATION OF CYSTEINE IN HUMAN PLASMA ..... 202 
5.1        Introduction ................................................................................................................ 202  
5.2        Experimental Section ................................................................................................. 206 
5.3        Results and Discussion .............................................................................................. 208 
5.4        Conclusion ................................................................................................................. 220 
5.5        References ................................................................................................................. 220 
 
CHAPTER 6. SUMMARY, CONCLUSION, AND OUTLOOK ................................................... 225 
6.1        Summary and Conclusion .......................................................................................... 225 
6.2        Outlook ....................................................................................................................... 228 
6.3        References ................................................................................................................. 236 
 
APPENDIX: LETTER OF PERMISSION ................................................................................. 238 
 






































LIST OF TABLES 
 
Table 1.1 Summary of Probes for Detection and Measurement of NQO1 ................................. 35 
 
Table 1.2 Summary of Probes for Detection and Measurement of -gal.................................... 40 
 
Table 2.1 Photophysical data for iBuTCy, Q3STCy, and TCy .................................................. 106 
 
Table 3.1 Photophysical data for iBuTCy, Q3STCy, and Q3NTCy in aqueous solution ............ 166 
 










































LIST OF FIGURES 
Figure 1.1 Common imaging modalities and their employed frequency ranges on the 
electromagnetic spectrum ........................................................................................................... 4 
 
Figure 1.2 Schematic representation of fluorescence-guided surgery ......................................... 9 
 
Figure 1.3 Absorption spectra of water, and oxy- and deoxy-hemoglobin in the visible to NIR 
wavelength range ...................................................................................................................... 11 
 
Figure 1.4 Schematic representation of bioluminescence mechanism. Firefly or click beetle 
luciferase enzyme expressed in cytoplasm of engineered cells catalyze the substrate luciferin to 
produce light photons in the presence of oxygen and ATP ........................................................ 12 
 
Figure 1.5 Representative materials from the three categories of fluorophores – quantum dots 
(fluorescent inorganic nanoparticles), green fluorescent proteins (genetically encoded proteins), 
and fluorescein (small organic molecules) ................................................................................. 13 
 
Figure 1.6 An ensemble of fluorescent proteins which are derived from Aequorea GFP or 
Discosoma RFP. ....................................................................................................................... 17 
 
Figure 1.7 The formation steps of the principle fluorophore in GFP ........................................... 18 
 
Figure 1.8 Core structures of common small molecule fluorophores ......................................... 21 
 
Figure 1.9 Illustration of the different modes of action for signal generation with the three 
categories of fluorescent probes ............................................................................................... 26 
 
Figure 1.10 Reductase expression in cells in response to increased oxidative stress through 
Keap1-mediated Nrf2 regulation ............................................................................................... 33 
 
Figure 2.1 HPLC of Q3STCy with absorption detection at 786 nm (top) and 254 nm 
(bottom) .................................................................................................................................... 87 
 
Figure 2.2 HPLC data of Q3STCy (left) and its respective mass spectrum (right) ...................... 88 
 
Figure 2.3 1H NMR spectrum of iBuTCy in CDCl3 and 1D gradient chemical exchange spectra of 
iBuTCy with an initial selective pulse irradiation at 1.08 ppm or 4.01 ppm ............................... 101 
 
Figure 2.4 1H NMR spectrum of Q3STCy in CDCl3 and 1D gradient chemical exchange spectra of 
Q3STCy with an initial selective pulse irradiation at 2.93 ppm or 4.04 ppm ............................. 102 
 
Figure 2.5 (A) Absorption spectra and (B) emission spectra of TCy (2 M, red), Q3STCy (2 M, 
black) and iBuTCy (2 M, dashed grey) in 1% DMSO 0.1 M PBS/0.1 M KCl solution (pH = 7.4). 
Emission spectra were measured at ex = 600 nm. T = 25 °C. ................................................ 103 
 
Figure 2.6 HOMO/LUMO Frontier Molecular Orbitals of TCy and iBuTCy ............................... 105 
 




Figure 2.8 Normalized absorption and emission spectra of iBuTCy in acetonitrile, showing the first 
excited state at 795 nm (1.56 eV). T = 25 °C........................................................................... 107 

Figure 2.9 Cyclic voltammograms of 1 mM solutions of iBuTCy (A) and Q3PA (B) in anhydrous 
acetonitrile with 0.1 M tetrabutylammonium perchlorate as supporting electrolyte; scan rate = 0.1 
V/s; T = 25 °C ......................................................................................................................... 107 
 
Figure 2.10 Time-dependent absorption spectral changes of 2 M Q3STCy in 0.1 M PBS/0.1 M 
KCl solution (pH = 7.4) initiated by the addition of hNQO1 (688 U mL–1). T = 37 °C. ............... 108 
 
Figure 2.11 Time-dependent emission spectral changes of 4 M Q3STCy in 0.1 M PBS/0.1 M KCl 
solution (pH = 7.4) initiated by the addition of hNQO1 (688 U mL–1). T = 37 °C ....................... 109 
 
Figure 2.12 Upper: High-performance liquid chromatogram for separation of mixture resulted from 
30 M Q3STCy probe treated with 688 U mL−1 hNQO1 and 100 M NADH at 37 °C for 20 min.  
Lower: Mass spectra of corresponding peaks in the chromatogram ........................................ 110 
 
Figure 2.13 The fluorescence intensity at 755 nm of 4 M Q3STCy solution (ex = 605 nm) was 
recorded with (red line) or without (black line) the addition of hNQO1 (688 U mL–1) at the 20-min 
time point. T = 37 °C ............................................................................................................... 111 
  
Figure 2.14 Kinetic plot of hNQO1 (0.5 × 10–6 g mL–1, 250 U mL–1) with Q3STCy as a substrate in 
aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA. T = 37 
°C............................................................................................................................................ 112 
 
Figure 2.15 (A) Plot of fluorescence intensity at 755 nm for TCy (2 M, ex = 600 nm) and at 803 
nm for Q3STCy (2 M, ex = 600 nm and 725 nm) in 0.1 M PBS/0.1 M KCl with 1% DMSO at 
various pH values (4.5–9.5). T = 25 °C ................................................................................... 113 
 
Figure 2.16  Fluorescence intensity at 755 nm (ex = 600 nm) of 4 M TCy in 0.1 M PBS/0.1 M 
KCl (pH = 7.4) with 1 mM corresponding reducing agent. T = 25 °C ....................................... 114 
 
Figure 2.17 Normalized fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 M) in 0.1 
M PBS/0.1 M KCl solution (pH = 7.4) after incubation with a given reducing agent for 20 min at 
37 °C. ...................................................................................................................................... 115 
 
Figure 2.18 Fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 M) in 0.1 M PBS/0.1 
M KCl solution (pH = 7.4). T = 37 °C ....................................................................................... 117 
 
Figure 2.19 Western blots of protein extracts (20–21 g each) from H596, H596 (+), HT-29, and 
SHIN3 cells.  -Actin was used as a standard ......................................................................... 118 
 
Figure 2.20 hNQO1-specific activities of protein extracts from H596, H596 (+), HT-29, and SHIN3 
cells. DCPIP was used as the substrate .................................................................................. 118 
 
Figure 2.21 Fluorescence and differential interference contrast (DIC) images of H596 (negative), 
SHIN3 (positive), H596 (+) (positive), and HT-29 (positive) cells using confocal microscopy. Scale 




Figure 2.22 Fluorescence and DIC images of HT-29 (positive) and H596 (negative) cells using 
wide-field microscopy. Scale bar = 20 m ............................................................................... 121 
                                                                      
Figure 2.23 (A) Fluorescence and DIC images of dicoumarol-free and dicoumarol-treated 
(hNQO1 inhibitor) HT-29 cells using confocal microscopy. Scale bar = 20 m; (B) Mean cytosolic 
fluorescence intensity of dicoumarol-free and dicoumarol-treated HT-29 cells ........................ 122 
 
Figure 2.24 Live cell fluorescence and DIC images of HT-29 cells using confocal microscopy. 
Scale bar = 20 m ................................................................................................................... 123 
 
Figure 2.25 Cell viability of HT-29 cells treated with 1 M and 2 M Q3STCy and TCy for 3 h. 
Percentage values are the average of three independent measurements. Error Bars are ± one 
standard deviation ................................................................................................................... 124 
  
Figure 2.26 Fluorescence and DIC images of living HT-29 MCTSs (23 days old, 970 ± 24 m 
diameter) in a phenol-free RPMI-1640 medium using wide-field microscopy. The MCTSs were 
exposed to 5 M Q3STCy at 37 ºC for different times. ............................................................. 126 
 
Figure 2.27 Corresponding fluorescence increase of the MCTSs in Figure 2.26. Fluorescence 
intensity is the average of measurements from four different spheroids, with error bars of ± one 
standard deviation ................................................................................................................... 127 
 
Figure 2.28 (A) Fluorescence spectra of a 12.5 M Q3STCy solution in PBS/FBS (50%:50%); (B) 
Mass spectra of solution from A achieved by electrospray ionization-mass spectrometry ....... 128 
 
Figure 2.29 Visualization of peritoneal metastases in SHIN3 mouse model of human ovarian 
cancer via fluorescence spectral imaging of mesentery at 1 h post intraperitoneal administration 
of Q3STCy (300 L of 100 M probe in pH 7.4 PBS). Scale bar = 5 mm ................................. 131 
   
Figure 3.1 Absorption and emission spectra of 2 × 10–6 M Q3NTCy (A) and 3 × 10–6 M TCy (B)  in 
0.1 M PBS solution (pH = 7.4) with DMSO (2%, v/v) as co-solvent. T = 25 °C ........................ 153 
 
Figure 3.2 Time-dependent absorption spectra of Q3NTCy (4 M) in 0.1 M PBS solution (pH = 
7.4) initiated by the addition of hNQO1 (2 g mL–1, 1000 U mL–1). The spectra were measured 
every 4 min. T = 25 °C ............................................................................................................ 155 
 
Figure 3.3 (A) Time-dependent emission spectra of Q3NTCy (4 M, ex = 655 nm) in 0.1 M PBS 
solution (pH = 7.4) initiated by the addition of hNQO1 (2 g mL–1, 1000 U mL–1). (B) The 
corresponding fluorescence intensity ratio (F765/F798) change. T = 25 °C ................................. 156 
 
Figure 3.4 (A) Time-dependent emission spectra of Q3NTCy (2 M, ex = 655 nm) in FBS/PBS 
(20%:80%, v/v) initiated by the addition of hNQO1 (1 g mL–1, 500 U mL–1). (B) The corresponding 
fluorescence intensity ratio (F745/F810) change. T = 25 °C ........................................................ 156 
 
Figure 3.5 (A) Fluorescence spectra of a 25 M Q3NTCy solution (ex = 660 nm) in PBS (20 mM, 
pH = 7.4) or PBS/FBS (50%:50%); (B) Mass spectra of 25 M Q3NTCy upon exposure to the 




Figure 3.6 The fluorescence intensity at 755 nm of 5 M Q3NTCy and 5 M Q3STCy (ex = 600 
nm) in aqueous solutions (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA was 
recorded with and without the addition of hNQO1 at the 5-min time point. T = 25 °C .............. 158 
 
Figure 3.7 Kinetic plot of hNQO1 (1 g mL–1, 500 U mL–1) with Q3STCy (A) and Q3NTCy (B) as 
substrates in the aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% 
BSA. T = 25 °C. ...................................................................................................................... 158 
 
Figure 3.8 Confocal and differential interference contrast (DIC) images of H596, A549, and HT-
29 cell lines. Scale bar = 20 m .............................................................................................. 161 
 
Figure 3.9 Wide-field and DIC images of HT-29, A549, and H596 cells. All the cells were 
incubated with 5 M Q3NTCy for 20 min. Fluorescence images were captured with Cy7 (765–855 
nm; 50 ms exposure) and Cy5 (662–738 nm; 500 ms exposure) filters sequentially ............... 162 
 
Figure 3.10 Immunohistochemistry of 5-day-old and 30-day-old MCTS sections. Scale bar = 
100 m .................................................................................................................................... 163 
 
Figure 3.11 Fluorescence images of 5-day-old and 30-day-old MCTS sections. The 20-m-thick 
MCTS sections were incubated with 5 M Q3NTCy for 10 min. Scale bar = 100 m ............... 164 
 
Figure 3.12 Molecular structures of Q3NNTCy and Q3NTCy-O ................................................ 167 
 
Figure 4.1 Design concept of the -galactosidase-responsive ratiometric fluorescent probe 
GalNap ................................................................................................................................... 175 
 
Figure 4.2 Schematic representation of Nap reporter release, triggered by -gal .................... 182 
 
Figure 4.3 Absorption and emission spectra of 5 × 10–6 M GalNap (A)  and Nap (B)  in 0.1 M PBS 
solution (pH = 7.4) with 1% DMSO as co-solvent. T = 25 °C ................................................... 183 
  
Figure 4.4 Absorption and emission spectra of 2 × 10–6 M MeNap in PBS buffer (pH = 7.4) with 
1% DMSO as co-solvent. T = 25 °C ........................................................................................ 184 
 
Figure 4.5 Absorption (A, 5 M GalNap) and emission (B, 2 M GalNap, ex = 415 nm) spectra 
before and after the addition of -gal (3 U mL–1) for 1 h in 0.1 M PBS solution (pH = 7.4). T = 25 
°C ........................................................................................................................................... 185 
 
Figure 4.6 Fluorescence spectral changes of GalNap (2 M) triggered by -gal (3 U mL–1) in 1% 
DMSO 0.1 M PBS (pH = 7.4) solution with different excitation wavelengths: (A) 380 nm, (B) 400 
nm, (C) 410 nm, (D) 415 nm, and (E) 430 nm. T = 25 °C ....................................................... .186 
 
Figure 4.7 Fluorescence response (ex = 450 nm, em = 500 nm) of GalNap (5 M) to the addition 
of -gal (3 U mL–1) at 4 min in 0.1 M PBS buffer (pH = 7.4).  T = 25 °C ................................... 187 
 
Figure 4.8 Kinetic plot of -gal (4 × 10–6 g mL–1, 3 U mL–1) with GalNap as substrate in 0.1 M PBS 
buffer (pH = 7.4). ..................................................................................................................... 188 
  
Figure 4.9 Normalized fluorescence spectra of 5 × 10–6 M GalNap (blue line) and 5 × 10–6 M Nap 




Figure 4.10 Schematic derivation of ratiometric fluorescence response of probe toward analytes 
of interest ................................................................................................................................ 189 
 
Figure 4.11 Prediction curve of response of GalNap toward -gal concentrations or time ....... 191 
 
Figure 4.12 Fluorescence spectral change of GalNap (15 M, ex = 415 nm) with time with the 
addition of -gal (1, 2, 3, 4, 6, 8, 10, and 12 U mL–1) in PBS solution (pH = 7.4). T = 25 °C .... 192 
 
Figure 4.13 Plot of the emission intensity ratios (F535–600 nm/F430–495 nm) of GalNap (15 M) against 
time (up) or the concentration of -gal enzyme (1–12 U mL–1), in pH = 7.4, 0.1 M PBS, ex = 415 
nm; T = 25 °C .......................................................................................................................... 193 
 
Figure 4.14 Differential interference contrast (DIC) and confocal fluorescence images of OVCAR3 
(-gal expressing) and HEp2 (-gal non-expressing) cells incubated with 10 M GalNap for 60 
min at 37 °C. Scale bars = 50 m ........................................................................................... 194 
 
Figure 4.15 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2 
(negative) incubated with GalNap (10 M) for 60 min at 37 °C. Scale bars = 40 m ............... 196 
 
Figure 4.16 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2 
(negative) cells incubated with MeNap (10 M) for 60 min at 37 °C. Scale bars = 30 m ........ 197 
 
Figure 5.1 Absorption (black) and emission (red) spectra of CysTCy (A, 2 M) and TCy (B, 2 M) 
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 25 °C ...................................................... 209 
 
Figure 5.2 Time-dependent (every 5 min for a 120-min time period) absorption (A) and emission 
(B) spectral changes of CysTCy (2 M) upon addition of Cys (40 M) in 20% (v:v) ethanol in PBS 
(20 mM, pH = 7.4). T = 37 °C .................................................................................................. 210 
 
Figure 5.3 Plot of fluorescence intensity of CysTCy (2 M, ex = 725 nm) at 808 nm in 20% (v:v) 
ethanol in PBS (20 mM, pH = 7.4) at various pH (4.5–9.5). T = 37 °C ..................................... 212 
 
Figure 5.4 Color changes (A), absorption spectra changes (B), and emission spectra changes (C) 
of CysTCy (2 M) upon 2 h incubation without addition or with addition of corresponding Cys, 
Hcy, and GSH in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C............................... 212 
 
Figure 5.5 Time-dependent fluorescence of 2 M CysTCy (ex = 600 nm and em = 750 nm) 
incubated with or without addition of corresponding Cys (50 M), Hcy (50 M), or GSH (250 M) 
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C ...................................................... 213 
 
Figure 5.6 (A) Time-dependent fluorescence spectra (ex = 675 nm) of CysTCy in the 
simultaneous presence of Cys and GSH in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 
°C. (B) The corresponding fluorescence ratio as a function of increasing time ........................ 214 
 
Figure 5.7 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 h incubation 
with different concentrations of Cys in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C; (B) 




Figure 5.8 Time-dependent fluorescence (A) of 2 M CysTCy (ex = 600 nm and em = 750 nm) 
incubated with or without addition of Cys (50 M). Fluorescence spectra changes of 2 M CysTCy 
(B, ex = 600 nm; C, ex = 675 nm) in the presence of Cys (50 M). T = 37 °C ........................ 217 
 
Figure 5.9 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 h incubation 
with different concentrations of Cys; (B) Corresponding fluorescence ratio (F763/F808) for 1-h 
incubation of Cys with different Cys concentrations. T = 37 °C ............................................... 219 
 
Figure 5.10 (A) Time-dependent emission spectral changes of CysTCy (2 M, ex = 675 nm). (B) 
Two independent emission spectra of CysTCy upon 1-h incubation. T = 37 °C ....................... 220 
 
Figure 6.1 Depiction of mechanism of singlet oxygen (1O2) formation by exciting a PS with light in 
the presence of molecular oxygen........................................................................................... 228 
  
Figure 6.2 (A) Design of an hNQO1-responsive aPS, Q3Pyro. (B) Absorption spectra and (C) 
emission spectra (ex = 405 nm) of Q3Pyro (5 M), Q1Pyro (5 M), and Pyro (5 M) in 50% (v:v) 
methanol: 20 mM PBS (pH = 7.4). T = 25 °C .......................................................................... 230 
 
Figure 6.3 Time-dependent (10-min interval) change in absorption spectra of DPBF (40 M) upon 
a light irradiation (665 ± 10 nm) in the presence of (A) Pyro (5 M), (B) Q3Pyro (5 M), or (C) 
Q1Pyro (5 M). (D) Relative 1O2 production rate. T = 25 °C ..................................................... 231 
 
Figure 6.4 The fluorescence intensity at 670 nm of solutions of Q3Pyro and Q1Pyro (5 M, ex = 
400 nm) in 5% (v:v) DMSO in 20 mM PBS (pH = 7.4) was recorded with and without the addition 
of hNQO1 (4 g mL–1, 2000 U mL–1) at the 20-min time point. T = 37 °C ................................ 232 
 
Figure 6.5 Fluroescence and differential interference contrast (DIC) images of H596 (-) and H596 
(+) cells using confocal microsopy. Scale bar = 20 m ............................................................ 234 
 
Figure 6.6 Fluorescence and DIC images of live H596 (+) cells treated with Q3Pyro and organelle 
trackers. Scale bar is 15 m or 20 m ..................................................................................... 235 
 
Figure 6.7 H596 (-) cell viability (A) in dark and (B) with light irradiation (665 nm LED, 0.5 J cm–2) 
of Q3Pyro and Pyro of various concentrations determined by MTT assay, compared with untreated 


















LIST OF SCHEMES 
 
Scheme 2.1 Synthetic route for the hNQO1-activatable probe, Q3STCy, and the electronically 
similar analogue, iBuTCy .......................................................................................................... 82 
 
Scheme 2.2 Proposed TCy reporter release path by reaction of Q3STCy with 
hNQO1 ..................................................................................................................................... 98 
 
Scheme 3.1 Proposed activation mechanism of Q3NTCy by hNQO1 ...................................... 145 
 
Scheme 3.2 Synthetic scheme of Q3NTCy .............................................................................. 146 
  
Scheme 4.1 Synthetic route for GalNap probe and the electronically similar analogue 
MeNap .................................................................................................................................... 176 
 
Scheme 5.1 Proposed Mechanism of the CysTCy Probe Reacting with Cysteine ................... 205 
 

































LIST OF ABBREVIATIONS AND SYMBOLS 
 
AA  Ascorbic acid 
 
AIE  Aggregation-induced emission 
 
aPS  Activatable photosensitizer 
 
ARE  Antioxidant response element 
 




BphPs  Bacterial phytochromes 
BSA  Bovine serum albumin 
 
BV   Biliverdin 
CCD  Charged-coupled device 
 
13C NMR Carbon nuclear magnetic resonance 
 
CPR  Cytochrome P-450 
 
CPRG   chlorophenol red--D-galactopyranoside 
 
CT  Computed tomography 
 
Cy3  Cyanine 3 
 
Cy5  Cyanine 5 
 
Cy7  Cyanine 7 
 
Cys   Cysteine 
 
CV  Cyclic voltammetry 
 
DAPI  4',6-Diamidino-2-phenylindole, dihydrochloride 
 
DCM  Dichloromethane 
 
DCPIP  Dichlorophenolindophenol 
 
DDAOG 9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl)--D-galactopyranoside 
DFT  Density functional theory 
 




DIEA   N,N-Diisopropylethylamine 
 
DMF  Dimethylformamide 
 
DMSO  Dimethyl sulfoxide 
 
DPBF  1,3-diphenylisobenzofuran 
 
d-PeT   Donor-excited PeT 
DTT   Dithiothreitol 
 
E1/2   Half-wave potential 
 
EA   Ethyl acetate 
 
EDCI  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 
EDTA  Ethylenediaminetetraacetic acid 
 
EGFR   Epidermal growth factor receptor  
 
EO9  Indoloquinone (Apaziquone) 
 
Eox   Oxidation potential 
 
Ered   Reduction peak 
 
EPR  Enhanced permeability and retention 
 
ER  Endoplasmic reticulum 
 
ESA  Excited state absorption  
ESIPT  Excited state intramolecular proton transfer 
ESI-TOF Electrospray ionization–time-of-flight 
 
ETU   Energy transfer upconversion 
 
FAD  Flavin adenine dinucleotide 
 
FADH2  Reduced flavin adenine dinucleotide 
 
FBS  Fetal bovine serum 
 
FDA   The US Food and Drug Administration 
 




18FDG  2-deoxy-2-[18F]fluoro-D-glucose 
 
FINP  Fluorescent inorganic nanoparticle 
 
FITC   Fluorescein isothiocyanate 
FGS  Fluorescence-guided surgery 
FP  Fluorescent protein 
FRET  Förster resonance energy transfer 
 
GFP  Green fluorescent protein 
 
GGT   -glutamyltranspeptidase 
 
GSH  Glutathione 
 
HCl  Hydrogen chloride 
 
Hcy   Homocysteine 
 
HER2  Human epidermal growth factor receptor 
 
HMRG  Hydroxymethyl rhodamine green 
1H NMR  Proton nuclear magnetic resonance 
 
hNQO1  Human NAD(P)H:quinone oxidoreductase-1 
 
HO-1   Heme oxygenase 1 
 
HOMO  Highest-occupied molecular orbital 
 
HPDITCP  1,1’,3,3,3’,3’-hexamethyl-3,5-propylene-4-(dimethylamino)-2,2’-  
indotricarbocyanine perchlorate 
 
HPLC  High-performance liquid chromatography 
 
HRP  Horseradish peroxidase 
 
HSA   Human serum albumin 
ICG  Indocyanine green  
 
ICT  Internal charge transfer 
 
IFP  NIR fluorescent FP 
 




kcat  Catalytic constant 
 
kcat/Km  Enzyme catalytic efficiency (bimolecular rate constant) 
 
KCl  Potassium chloride 
 
Keap1  Kelch-like ECH-associated protein 1 
 
Km  Michaelis constant 
 
KOH  Potassium hydroxide 
 
LAS X  Leica Application Suite X 
 
LOD   Limit of detection 
 
LUMO  Lowest occupied molecular orbitals 
 
mAbs  Monoclonal antibodies 
 
MB   Methylene blue 
 
MCTS  Multicellular tumor spheroids 
 
MeOH  Methanol 
 
MHz   Megahertz 
 
MMC  Mitomycin C 
 
MMP  Matrix metalloproteinase 
 
MMP-2 Matrix metalloproteinase-2 
MMP-7 Matrix metalloproteinase-7 
mNQO1  Mouse NAD(P)H:quinone oxidoreductase-1 
 
MRI  Magnetic resonance imaging 
 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
 
MUG   4-Methylumbelliferyl--D-galactopyranoside 
 
m/z   Mass-to-charge ratio 
 
NaCl  Sodium chloride 
 




NADPH Reduced nicotinamide adenine dinucleotide phosphate 
 
NIR  Near-infrared 
 
NMPABA  N-methyl-p-aminobenzyl alcohol 
 
NOE   Nuclear Overhauser effect 
 
NQO1  NAD(P)H:quinoneoxidoreductase-1 
 
NQO2  NAD(P)H:quinone oxidoreductase-2 
 
Nrf2  Nuclear factor erythroid 2-related factor 2  
 
hNQO1 human NAD(P)H:quinoneoxidoreductase-1 
 
NSCLC Non-small cell lung carcinoma 
 
O2   Oxygen 
 
1O2  Singlet oxygen 
 
3O2  Triplet oxygen 
 
OCT  Optical coherence tomography 
 
ONPG  Ortho-Nitrophenyl--galactoside 
 
PA  Photon avalanche 
 
PARACEST Paramagnetic chemical exchange saturation transfer 
PBS  Phosphate-buffered saline 
 
PCCC   Pearson correlation coefficient for colocalization 
 
PDE   Photodynamic eye 
 
PDT  Photodynamic therapy 
 
PEG  Poly(ethylene glycol) 
 
PeT  Photo-induced electron transfer 
 
PET  Positron emission tomography 
 
PFA  Paraformaldehyde 
 
PMT  Photomultiplier tube 
 




ppm  Parts per million 
 
PS  Photosensitizer 
 
PSMA   Prostate-specific membrane antigen 
 
q  Quartet 
 
QD  Quantum dot 
 
Q3PA   Quinone propionic acid 
 
QR2  NRH:quinone oxidoreductase 2 
 
RFU   Relative fluorescence unit 
 
RG   Resorufin--D-galactopyranoside 
 
rNQO1  Rat NAD(P)H:quinoneoxidoreductase-1 
 
ROI  Region of interest 
 
ROS  Reactive oxygen species 
 
RPMI  Roswell Park Memorial Institute Medium 
 
s   Singlet 
 
S0  Ground state  
 
S1  Excited singlet state 
 
SBR  Signal-to-background ratio 
 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
 
t   Triplet 
 
T1  Triplet state 
 
TBR  Target-to-background ratio 
 
TPZ  Tirapazamine 
 
THF   Tetrahydrofuran 
 
TLC   Thin-layer chromatography 
 




US  Ultrasonography 
 
UV  Ultraviolet 
 
UV-Vis  Ultraviolet-visible 
 
VEGF  Vascular endothelial growth factor  
 
Vmax  Maximum turnover rate 
 
VT   Variable-temperature 
 
X-gal   5-bromo-4-chloro-3-indolyl--D-galactopyranoside 
 
1D  One-dimensional 
 
2D  Two-dimensional 
 
2-DG  2-Deoxy-D-glucose 
 
3D  Three-dimensional 
 
5-ALA   5-Aminolevulinic acid   
 
-gal  -galactosidase 
 
  Chemical shift 
 
  Molar extinction coefficient 
 
G  Gibbs free energy change 
 
   Quantum yield 
  Light wavelength 
 
ex  Excitation wavelength 
 














Fluorescence imaging can be used both as a tool to diagnose diseases and guide 
treatment in clinical settings, and as a technique to monitor dynamic events or biological species 
in basic research. Therefore, there is a great need for the development of a multitude of 
fluorescent probes that can be incorporated with fluorescence imaging techniques to track and 
report endogenous enzymes with high specificity and selectivity. In contrast to always-on and 
targeted always-on fluorescent probes that continually emit light, activity-based substrate probes 
either emit low numbers of photons or are completely quenched. They can be converted to highly 
fluorescent reporters by specific upregulated enzymes, thus offering a high target-to-background 
ratios contrast. Fluorescent probes have a promising impact in fluorescence-guided cytoreductive 
surgery, but complete resection in every patient is highly unlikely. Probes that emit near-infrared 
(NIR) light are more suitable for in vivo imaging. Therefore, in this work, hNQO1-activatable NIR 
imaging probes (Q3STCy and Q3NTCy) with different eliminating linker and different affinities for 
hNQO1 were developed. These probes were successful in imaging clinically relevant multicellular 
tumor spheroids (MCTSs) possessing spatially heterogeneous NQO1 activities and in identifying 
sub-millimeter dimension metastases in a preclinical mouse model of human ovarian serous 
adenocarcinoma. To further diversify the research, ratiometric probes (GalNap and CysTy) with 
the capability to quantify the enzyme -Galactosidase and cysteine were developed. GalNap was 
used in the real-time detection of -Galactosidase in human ovarian cancer cells and CysTy was 
used to detect cysteine in human plasma. As an initiative to contribute to effective cytoreductive 
surgery, a chemical agent (Q3Pyro) was designed and synthesized that can not only light up, but 
can also be toxic toward hNQO1-expressing tumor tissues. With various imaging and cell assays, 






1.1  Research Goals and Aims 
Rapid, selective, and noninvasive reporting of disease-linked enzymatic activities and 
functions in complex biological processes will lead to a better understanding of tumorigenesis at 
the molecular level and development of precision medicine applications in oncology.1-4 
Collaborative work amongst engineering, chemistry, and biology is necessary to decipher their 
mysterious functions in living systems. Compared to traditional clinical imaging modalities (i.e., 
MRI, CT, and PET), fluorescence imaging has a relatively shallow penetration depth. However, 
due to its high spatiotemporal resolution and high sensitivity, fluorescence imaging is gaining 
immense popularity, both as a powerful clinical tool to diagnose diseases and guide treatment, 
and as an imaging technique to monitor dynamic biological species/events in basic research.5-6 
Therefore, there is a great need for the development of a multitude of reactivity-based fluorescent 
substrate probes to incorporate with fluorescence imaging techniques so as to track and report 
endogenous enzymes with high sensitivity and selectivity. Unlike always-on and targeted always-
on fluorescent probes that emit light regardless of the presence of enzymes, reactivity-based 
probes that weakly emit can be converted to highly fluorescent reporters by upregulated enzymes, 
thus offering the advantages of low background fluorescence signal, fluorescence signal 
amplification in the targeted area, and high tumor-to-background ratios. The overall goal of my 
research is to develop enzyme-activatable (i.e., NQO1 and -galactosidase) fluorescent substrate 
probes for differentiating diseased tumor cells from healthy cells in vitro and in vivo, and exploring 
their potential applications for quantifying enzymes of interest. 
NQO1 is a two-electron reductase, whose expression is 2- to 50-fold higher in numerous 
human solid tumors (e.g., pancreas, colon, breast, ovarian, and non-small cell lung carcinoma) 
than the surrounding normal tissue.7 NQO1 has been traditionally used as a cancer biomarker for 
developing targeted anticancer drugs.8 Recently, the upregulation of NQO1 in malignant cells has 
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led to the development of quinone-based, NQO1-activatable fluorescent probes.9-13 However, 
these NQO1-specific probes absorb and emit light in the visible energy range. Near-infrared light 
has the advantages of high tissue penetration depth, low tissue autofluorescence, and low tissue 
absorption, all which are more attractive for in vivo imaging applications.  
The first aim of my research was to design and synthesize a fluorescent probe, Q3STCy, 
that emits near-infrared light upon its NQO1 activation to yield a fluorescence active reporter, and 
to examine its applicability for visualizing NQO1-expressing cells and small tumors. The crafted 
NQO1-specific fluorescent probe has a tripartite structure (trigger, linker, and reporter). Upon 
NQO1-catalyzed reduction, the probe exhibited a fast and large fluorescence increase, thus 
allowing the immediate differentiation of NQO1-expressing cells from NQO1-non-expressing cells 
in two-dimensional (2D) cell culture with high integrity. Because 2D cell culture lacks features of 
real tumor microenvironments, a three-dimensional (3D) multicellular spheroid (MCTS) model can 
better mimic tumor characteristics. The usefulness of Q3STCy was validated by the successful 
imaging of clinically relevant MCTSs possessing spatially heterogeneous NQO1 activities, and 
fluorescence-assisted identification of sub-millimeter dimension metastases in a preclinical 
mouse model of human ovarian serous adenocarcinoma.   
However, Q3STCy had a relatively slow reporter production rate and an off-on 
fluorescence mode. To overcome these drawbacks, my next aim was to develop a fluorescent 
probe with rapid reporter production rate triggered by NQO1 and possessing unique NQO1-
response modes. I used a rigid and fast-eliminating linker to replace the flexible linker in Q3STCy, 
and developed a second NQO1-selective fluorescent probe, Q3NTCy. In this design, both the 
probe and the reporter exhibited strong NIR fluorescence in different energy ranges of the 
electromagnetic spectrum, thus the probe/reporter pair act as an on-on imaging system. 
Subsequent enzyme evaluation and reporter release determination of Q3NTCy confirmed that its 
NQO1-initiated signal generation was faster than Q3STCy. Celluar imaging via confocal 
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microscopy further demonstrated the ability of Q3NTCy in the differentiation of hNQO1-expressing 
cell lines from an hNQO1-nonexpressing cell line in both off-on and on-on fluorescence modes. 
My final aim was to develop a ratiometric fluorescence-based probe to explore its 
applications in quantifying cancer-associated enzymes. Different from intensity-based probes, 
ratiometric fluorescent probes can simultaneously give two signals that originate from the 
unreacted probe and its reacted reporter, and they have the advantages of eliminating problems 
stemming from variabilities in excitation and emission efficiencies, sample environment (e.g., pH 
and polarity), and distribution of the probe.14 -Galactosidase (-gal) is an important transgene 
reporter enzyme that is widely used to study gene transcription in biological systems. Because of 
the upregulation of -gal in senescent cells and in primary ovarian cancer cells, it has been 
explored as a biomarker to develop small-molecule fluorogenic probes for detecting and imaging 
senescent cells and ovarian cancer cells. The use of a -gal–responsive ratiometric fluorescent 
probe can potentially provide a simple and sensitive way to quantify the concentration of -gal 
under cellular conditions. I developed a novel and well-described ratiometric fluorescent probe, 
GalNap, capable of achieving the real-time detection and imaging of the endogenous -gal in 
human ovarian cancer cell lines in both off-on and ratiometric modes.   
1.2  Molecular Imaging in Cancer 
The advancement of multiple non-invasive molecular imaging modalities has greatly 
contributed to the world’s understanding of pathological processes, and aided in effective disease 
diagnostics and therapeutics.15-18 For example, molecular imaging techniques allow us to know 
the size and location of tumors, the expression levels of specific molecules (e.g., enzymes and 
other proteins), and physiological processes and cellular metabolism (e.g., blood flow and glucose 
uptake).19 The most commonly used imaging modalities include X-ray computed tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasonography (US), 
and optical imaging. The imaging modalities are complementary rather than competitive. The 
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imaging modalities exploit the different levels of energy in the electromagnetic spectrum that 
interact with the human body to generate images, Figure 1.1.20 Although CT, MRI, and US can 
acquire anatomical information based solely on energy-tissue interactions, exogenous contrast 
agents for them and other imaging modalities are necessary to be administered to enhance the 
image contrast and monitor the species/events of interest.  
  
Figure 1.1 Common imaging modalities and their employed frequency ranges on the 
electromagnetic spectrum.20    
Each of these modalities has its advantages and limitations.16 By processing the X-ray 
signal, CT can generate three-dimensional images of the scanned anatomical structures.21 Due 
to its high scan speed and relatively high resolution, CT is one of the most commonly used clinical 
imaging techniques for cancer diagnosis. Although it is especially suitable for acquiring skeletal 
structure information, CT alone is not sensitive enough to image soft tissues. The administration 
of iodinated contrast agents at high concentrations (~ 10–2 M) is necessary to improve the image 
contrast of soft tissues with millimeter resolution. MRI has evolved as an alternative imaging 
technique that is superior to CT.22 Under high magnetic field conditions, the MR signal is 
generated by exciting ubiquitous hydrogen nuclei present in the human body with radio frequency 
energy. The collected MR signal is processed to construct three-dimensional MR images. The 
ionizing radiation used in CT is not applied in MRI, thus making MRI a safer imaging technique. 
Because MRI is very sensitive to soft tissues, it is an ideal technique for obtaining physiological 
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information of soft tissues. To improve the MR image contrast, paramagnetic contrast agents (e.g., 
gadolinium chelates and iron nanoparticles) are often administrated to alter the spin properties of 
hydrogen nuclei in the targeted tissue area. The properties of hydrogen nuclei can be influenced 
by the MR contrast agents at long distance (up to 50 times the dimension of the paramagnetic 
particle).16, 23 Therefore, a smaller amounts of MR contrast agents (M) are required than that for 
CT.  
PET is a highly sensitive imaging technique. Gamma rays emitted indirectly by 
radionuclides (e.g., 18F and 11C) are detected and utilized to construct three-dimensional PET 
images. Monitoring the distribution of radionuclide-labeled biological molecules can provide 
physiological and pathological information (glucose uptake and cancer metastasis).24 PET is often 
integrated with CT or MRI, the latter providing information about the location of the targeted 
biological events/species.  
Another clinically used imaging modality is US that exploits reflected ultrasound pulses 
(1–10 MHz) to generate real-time images.25 US is often used to image soft tissue structures 
(muscles, vessels, tumors, and internal organs) and diagnose diseases and visualize pathological 
tissues. Microbubbles can be used as contrast agents for US to study the angiogenesis of 
tumors.26 Other emerging imaging techniques such as mass spectrometry imaging and 
photoacoustic imaging are also playing important roles in the field of oncology.27-28  
Fulfilling the current requirements for imaging systems will not only enable doctors to 
better determine the location, stage, and size of a tumor, but also provide knowledge about the 
expression and activity of specific molecules, cells, and biological processes at the molecular 
level.29 Although the above-mentioned methodologies have achieved great success in clinical 
diagnosis and staging of cancer, not all of them are suitable for molecular imaging due to their 
lack of selectivity and high limit of detection. For example, the disease-associated species,  such 
as enzymes and proteins, are present in very low concentrations (nanomolar to picomolar).30 PET 
is an imaging technique with high sensitivity. However, it suffers from low spatial resolution (1–2 
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mm), radiation exposure, high cost, long acquisition time, and a shortage of radionuclide-labeled 
biological molecules.16 The decay of radioactive contrast agents causes handling to be an 
inconvenience. 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), the most available PET contrast agent, 
is not ideal for cancer imaging due to its high uptake in many normal tissues.31 Moreover, the 
above-mentioned imaging modalities are mainly used as preoperative diagnostic techniques. It is 
difficult to incorporate them into the intraoperative workflow to collect real-time information with 
high spatial resolution.5  
In contrast, optical imaging techniques are emerging as powerful tools with the potential 
to satisfy current molecular imaging requirements.29 Photons emitted by either endogenous or 
exogenous molecules are collected to construct a two or three-dimensional image. Optical 
techniques can detect picomolar or even femtomolar concentrations of fluorescent or 
bioluminescent molecules.32 Depending on the applications, optical imaging can reach 
micrometer resolution for in vivo imaging and nanometer resolution for super-resolution optical 
microscopy.29 High sensitivity and high spatial resolution of optical imaging make it possible to 
visualize abnormal cellular pathways and early disease progression at the molecular level.33 Other 
advantages of optical imaging include utilization of non-ionizing radiation, economic efficacy, real-
time imaging, and ease of integrating with interventional surgery.  
1.3  Optical Imaging and Its Applications 
Optical imaging is a collective group of techniques that detect light. It dates back to the 
12th century when people combined two refractive lens to observe far and enlarged objects.34 The 
buildup of compound microscopes to observe tiny biological specimens has greatly contributed 
to the advancement of the life sciences. Currently, optical imaging has gained immense popularity 
due to it being a powerful clinical tool to diagnose diseases, guide treatment, and as an imaging 
technique to monitor dynamic biological species/events in basic research.32, 35-36  As other imaging 
modalities require contrast agents to improve their imaging ability, optical imaging techniques 
benefit from the use of endogenous and exogenous molecules that can interact with light 
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(absorption, fluorescence, phosphorescence, and bioluminescence) as a contrast agent to 
generate images.37 In this section, I will focus on fluorescence and bioluminescence imaging and 
their applications.  
 1.3.1  Fluorescence Imaging 
 Fluorescence imaging generates images that rely on the photons emitted by energetically 
excited fluorescent molecules. In this method, the targeted molecules present in samples are 
excited by a light source at an appropriate wavelength, and they subsequently emit light at longer 
wavelength.32 The emitted photons are detected by charge-coupled device (CCD) or 
photomultiplier tube (PMT) to generate images, which are interpreted to get the dynamic 
distribution information of the observed species/events.  
Both endogenous and exogenous fluorescent molecules can be the targeted molecules 
to be measured. Endogenous fluorescent molecules include nicotinamide adenine dinucleotide 
(NADH), flavin adenine dinucleotide (FAD), and porphyrins. Through monitoring the fluorescence 
of NADH and FAD, their dynamic metabolic pathway can be observed and studied to unravel their 
functional roles in their native state.38 The endogenous existence of porphyrins in some types of 
tumors has been used to differentiate tumors from healthy tissues under the ultraviolet illumination 
conditions.39-40 Although the autofluorescence from endogenous molecules is useful for the 
determination of abnormal tissue morphology and lesions, only limited numbers of endogenous 
fluorescent molecules are present in living subjects. Exogenously introduced fluorescent 
molecules (e.g., fluorescein and indocyanine green) are the most commonly used contrast agents 
in both basic research and clinical practice. Fluorophores and their design strategies for 
fluorescence imaging will be discussed later. 
Depending on the applications, fluorescence imaging techniques with various detection 
scales (microscopic and macroscopic) have been developed. For example, the development of 
confocal and super-resolution microscopy with high spatial resolution enables molecular-level 
study of gene expression, protein functions, and cellular metabolism.41-43 On the other hand, 
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macroscopic imaging such as optical coherence tomography, can be used to visualize cancer, 
precancerous lesions, and heart disease for small animal whole-body imaging.36 One of the 
clinical applications of fluorescence imaging is to guide surgeons in determining the boundary 
between diseased tissues and healthy tissues, as well as to identify and remove small foci of 
tumors.5, 44-46 Currently, several endoscopic and robot-assisted imaging techniques have been 
available in the intraoperative assessment of patients.5   
1.3.2  Fluorescence-Guided Surgery (FGS) 
 Although great biomedical advancement has been made in the field of oncology, surgery 
remains one of the most employed and effective techniques for the treatment of cancer.47 The 
degree of cancer removal has a significant influence on cancer recurrence and patient survival 
rate. The residual cancer cells after surgery are the main cause of poor patient outcomes. In the 
current surgical workflow, removal of tumors heavily relies on surgeon visual inspection and 
palpation, thus limiting the complete resection of small-sized tumors. CT, MRI, and PET are 
conventionally used as preoperative imaging modalities for cancer diagnosis and surgery 
planning. Recently, intraoperative CT and MRI have been developed for the guidance of 
neurosurgical resection during surgery.48 However, the imaging systems are expensive, big in 
size, and their use interrupts surgical workflow.46 Also, they have a low spatiotemporal resolution, 
limiting their differentiation of small-sized tumors (< 1 mm) in real-time. In this regard, 
fluorescence-guided surgery (FGS) has been developed for enabling surgeon ability to resect 
tumors in a fast, precise, and complete manner, Figure 1.2.49-50  
 FGS was first applied to localize a brain tumor during neurosurgery based on the passive 
accumulation of sodium fluorescein in malignant tissues in the 1940s.51 In 1992, Folli et al. 
exploited antibody-conjugated fluorescein to target colorectal carcinomas in patients, which 
became the first clinical trial with targeted fluorescence imaging.52 Recently, Van Dam et al 
achieved the intraoperative visualization of ovarian cancer cells with a folate-conjugated 
fluorescein agent by taking advantage of the overexpression of folate receptor- in epithelial 
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ovarian cancers.53 In recent years, FGS has been widely used in select applications, including 
determination of diseased and healthy margins, sentinel lymph nodes mapping, identification of 
tumors, plastic surgery, monitoring of cardiovascular diseases, lymphatic imaging, ureter imaging, 
bile-duct imaging, and angiography.46 In comparison with other imaging modalities, FGS has a 
high spatial resolution, provides real-time and economic efficacy, and it is easily incorporated into 
the surgical workflow. Its progress depends on the advancement of imaging instruments and 
availability of fluorescent contrast agents.  
Currently, several FGS instruments with different excitation/emission filters have been 
approved by the US Food and Drug Administration (FDA).54 The first FDA-approved FGS 
instrument is The Novadap SPY system (2005), and it was used to monitor skin perfusion and 
blood flow with indocyanine green (ICG) as the contrast agent.  After that, several new imaging 
systems such as the Hamamatsu PDE system, the fluobeam 800 clinical imaging device, and the 
VS3-IR-MMS system were developed and FDA-approved for various imaging applications. 
 




Despite the availability of numerous FDA-approved imaging systems, there are only four FDA-
approved non-targeted imaging agents for clinical use, including ICG, methylene blue (MB), 
fluorescein, and the imaging precursor 5-aminolevulinic acid (5-ALA). Their imaging abilities rely 
on their passive non-specific biological distribution. Efforts to develop more FDA-approved 
fluorescent molecular agents will greatly benefit the FGS area, and their clinical use can be 
immediately achieved considering the availability of imaging systems.1 
Although many fluorophores are commercially available, most of them emit light in the 
visible region of the electromagnetic spectrum (350–650 nm) with even shorter excitation 
wavelengths. Light in the ultraviolet (UV) and visible range suffers from several drawbacks such 
as phototoxicity, overlap with tissue autofluorescence, large tissue absorption, and shallow tissue 
penetration. Although light in the green emission range is useful for superficial surface imaging of 
tissues, it is not suitable for the in vivo deep tissue imaging. In contrast, near-infrared (NIR) light 
(650–900 nm) has optimal imaging properties and is desired for in vivo imaging applications.5, 55-
57 Biological tissue has the least absorption in the NIR range. Visible light (< 650 nm) is highly 
absorbed by endogenous molecules (e.g., oxy- and deoxy-hemoglobin) and infrared light (> 900 
nm) is absorbed by water and lipids, Figure 1.3.4 Although visible light can only penetrate tissues 
with a dimension of micrometers, NIR light has an enhanced tissue penetration depth (millimeters 
and up to centimeters) due to reduced tissue absorption, thereby enabling NIR light to be suitable 
for deep tissue imaging.58-59 Another advantage of NIR light is that the biological tissues have very 
low autofluorescence in the NIR range. Endogenous fluorophores (e.g., NADH, FAD, and 
porphyrins) present in the biological tissues emit strong fluorescence mainly in the UV and visible 
range. Employment of fluorophores emitting NIR light can avoid overlap with background 
autofluorescence, thus resulting in a very high target signal-to-background contrast. Because NIR 
light is invisible to unaided human eyes, the use of NIR fluorophores in surgery will not alter the 
intraoperative white-light image of the cut area, thus allowing the surgeon to perform the normal 
surgical procedure without color interference. Considering the discussed advantages of NIR light, 
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development of molecular agents that emit light in the optimal “NIR window” are in great demand 
for the pre-clinical and clinical whole-body imaging.  
 
Figure 1.3 Absorption spectra of water, and oxy- and deoxy-hemoglobin in the visible to NIR 
wavelength range.4 
1.3.3  Bioluminescence Imaging 
 Bioluminescence is another useful optical technique for imaging of tissue in small 
laboratory animals.29, 60 The bioluminescence signal (photons) is generated by the simultaneous 
presence of luciferase, enzymatic substrate luciferin, adenosine triphosphate (ATP), Mg2+, and 
O2; Figure 1.4. In this process, luciferase catalyzes the oxidation of luciferin, the latter producing 
photons in the visible range ( = 537 nm). Although numerous types of luciferases are available 
for bioluminescence, such as the firefly (Photinus pyralis) luciferase, the marine copepod 
(Gaussia princeps) luciferase, and the sea pansy (Renilla reniformis) luciferase, firefly luciferase 
is the most commonly used one due to its rapid reaction rate and high luminescence efficiency.60-
61 In contrast with fluorescence imaging, bioluminescence imaging does not require excitation 
light, thus making the route free of phototoxicity and autofluorescence effect. Due to the minimal 
background bioluminescence of tissues and enzyme-catalyzed signal amplification, 
bioluminescence is a very sensitive technique for in vivo imaging.32 This technique has found its 
broad application for studying gene transcription,62-64 tracking tumor growth and metastasis,65-66 
imaging of infectious diseases,67-69 and so on.70 However, several drawbacks of bioluminescence 
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remain. The light produced by firefly luciferase has a broad emission spectrum with a peak around 
560 nm, thus making it prone to tissue absorption. Luciferase variants with longer emission 
wavelengths are preferred to increase their tissue penetration depth. Compared to fluorescence, 
the number of photons produced by bioluminescence is small, thus requiring the CCD detector to 
be very sensitive. Specialized CCD detectors in a light-tight box under super-cooled conditions 
are required to reduce noise and increase signal.71 Considering the light-production process is 
influenced by the presence of many species, detector efficiency, and tissue attenuation, the 
collected light intensity might not quantitatively represent the expression level of luciferase.60 The 
requirement of luciferase gene transfection hinders its application in humans. Despite the 
disadvantages, bioluminescence is still a powerful tool to study biological processes in pre-clinical 
animal models.32 
 
Figure 1.4 Schematic representation of bioluminescence mechanism. Firefly or click beetle 
luciferase enzyme expressed in cytoplasm of engineered cells catalyze the substrate luciferin to 
produce light photons in the presence of oxygen and ATP.  
1.4  Fluorophores 
Fluorophores are a group of fluorescent molecules capable of re-emitting photons upon 
excitation by light. They act as signal-generating reporters in the design of molecular imaging 
agents and determine the efficiency and sensitivity of the monitoring process for the biological 
species/events. Generally, fluorophores are divided into three types—inorganic nanoparticles 
(e.g., semiconductor quantum dots (QDs) and upconversion nanoparticles),72-74 genetically 
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encoded proteins (e.g., green fluorescent protein (GFP)),75 and small organic molecules (e.g., 
fluorescein, ICG, and MB),76 Figure 1.5.  
 
Figure 1.5 Representative materials from the three categories of fluorophores – quantum dots 
(fluorescent inorganic nanoparticles), green fluorescent proteins (genetically encoded proteins), 
and fluorescein (small organic molecules). 
1.4.1  Fluorescent Inorganic Nanoparticles (FINPs) 
Over the last few decades, a large variety of fluorescent nanoparticles have been 
developed and applied in materials science and biomedical research.77-79 Fluorescent 
nanoparticles are a group of fluorescent materials with a size in the nanometer range. There are 
two general categories of fluorescent nanoparticles: organic-based nanoparticles (polymer- and 
lipid-based nanocarriers containing fluorescent organic dyes) and inorganic nanoparticles.80 
Fluorescent inorganic particles (FINPs) are prepared with inorganic materials, mainly including 
QDs, silica nanoparticles, upconversion nanoparticles, noble metal nanoparticles, and carbon 
dots.81 Their fluorescence is generated either from their intrinsic electronic properties or from the 
encapsulation of fluorescent species. Due to the characteristic optical properties of FINPs, such 
as high photostability, high fluorescence efficiency, tunable excitation/emission wavelengths, 
narrow emission bands, and fluorescence not being affected by the biological microenvironment, 
they have been explored as fluorescent reporters in various applications, such as in vivo 
fluorescence imaging,79 intracellular analyte sensing,82 photodynamic therapy,83-84 and 
immunoassays.81, 85 The enhanced permeability and retention (EPR) effect is a well-established 
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phenomenon in which nanometer-sized particles tend to passively accumulate in tumor sites. 
FINPs with an appropriate size (> 5 nm) can be coupled to the EPR effect so as to detect and 
image tumors.86 Although the EPR effect for small-sized (< 5 nm) FINPs is counterbalanced by 
their diffusion out from tumor sites, they can be conjugated with tumor-targeting ligands to 
enhance their tumor imaging ability and improve the signal-to-background ratio.72  
QDs have outstanding fluorescence properties and have been one of the most studied 
and employed FINPs.87-89 QDs are small semiconductor particles composed of elements from the 
II-VI, III-V, and IV-VI periodic groups, such as ZnO, ZnS, CdSe, InP, and PbS. The sizes of QDs 
(typically 2–12 nm) are comparable to the exciton Bohr radius, resulting in the quantum 
confinement effect.81 The created band gaps of QDs are directly correlated to QD size. The bigger 
is QD size, the smaller the energy level of the band gap. Therefore, QDs with the same 
composition can emit light with different wavelengths if their size is properly adjusted. Due to the 
advantages of QDs, such as broad absorption band, narrow and size-tunable emission band, and 
good photostability, QDs are attractive in various applications for bioimaging and biomedical 
diagnostics.90-91 The hydrodynamic sizes of QDs greatly affect how the QDs are expelled by the 
body. Although QDs with small sizes (5–6 nm) are eliminated rapidly through urinary excretion 
and thus have low toxicity, QDs with bigger sizes stay in reticuloendothelial system organs such 
as liver and spleen for a long time and are cleared through hepatobiliary excretion, thus leading 
to high toxicity.92-93 To improve the biocompatibility of QDs, QDs can be coated with hydrophilic 
polymers (e.g., poly(ethylene glycol) (PEG)). The propensity of QDs to nonspecifically bind to 
proteins is reduced by the coatings, thus yielding QDs having less non-specific cellular uptake 
and longer circulation times.94 QDs can also be conjugated with targeting ligands to improve their 
selective accumulation in the targeted area.95 Although organic coatings and targeting ligands 
improve the biological performance of QDs, they also increase their size, thus making them more 
toxic in some cases. Another toxicity concern hindering the further clinical applications of QDs is 
the existence of toxic elements (e.g., cadmium and arsenic) in their composition. To overcome 
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this problem, development of QDs with appropriate sizes and without heavy metal doping may 
make their clinical applications more promising.96-97 Silicon QDs do not contain heavy metals, but 
they exhibit size-dependent fluorescence; they are an alternative to conventional QDs.98 The 
drawback for silicon QDs is that their fluorescence efficiencies are weak in comparison to 
conventional QDs. Reducing the size of silicon QDs and doping with impurities are the main 
strategies to improve their fluorescence performance.99-100    
Upconversion nanoparticles (UCNPs) are another class of FINPs with unique optical 
properties.101-103 UCNPs consist of an inorganic host and trivalent lanthanide dopants (Ln3+), and 
usually have sizes less than 100 nm. The emission of UCNPs arises from the 4f-4f or 4f-5d 
transitions of the lanthanide dopants. In contrast with other fluorophores, UCNPs can emit short-
wavelength light when excited by multiple photons of a longer wavelength. Because Ln3+ ions 
have various energy levels of 4f orbitals and 4f-4f transitions, the upconversion emission of 
UCNPs is caused by different mechanisms, mainly excited state absorption (ESA), photon 
avalanche (PA), and energy transfer upconversion (ETU).104 Among the Ln3+ ions, ytterbium 
(Yb3+), erbium (Er3+), thulium (Tm3+), and holmium (Ho3+) have relatively high upconversion 
efficiencies, thus resulting them being the mostly used dopants in UCNPs. The selection of host 
materials is also critical to maintain or enhance the upconversion efficiency of UCNPs. The host 
materials should have high light transparency and low phonon frequency.101 In this regard, rare 
metal fluorides are often used as the host material. The upconversion phenomenon was first 
recognized in the 1960s and has been applied in solid-state lasers and solar cells.105 The 
advancement of nanotechnology over the last decade has greatly broadened the applications of 
UCNPs in biological fields, including biological labeling,106 photodynamic therapy,84 multimodal 
imaging,107-108 cell and tissue imaging,109 and in vivo animal imaging.110-111 UCNPs have several 
beneficial optical properties for these applications. The optical properties of UCNPs includes 
narrow absorption and emission bands, long luminescence lifetimes, and high photostability.  
More importantly, UCNPs can be excited by NIR light, thus resulting in a low background 
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autofluorescence signal. Chatterjee et al. first studied the in vivo imaging of UCNPs 
(polyethyleneimine-coated NaYF4:Yb,Er nanoparticles) in small animals and found that UCNPs 
exhibited strong fluorescence with deep tissue penetration and high photostability.110 However, 
several disadvantages of UCNPs hinder their further applications. UCNPs are usually too large 
and their cellular toxicity is high due to heavy metal leakage. In addition, the water solubility of 
UCNPs is often very low; although surface modification can increase their water solubility, this 
method is time-consuming, increases particles sizes, and it potentially affects the luminescence 
efficiency.103 Because UCNPs normally have low luminescence efficiencies at present, 
development of UCNPs with smaller dimensions and brighter luminescence will greatly contribute 
to their further applications in imaging avenues. 
Noble metal nanoparticles and carbon dots are two other groups of FINPs. Although there 
is no valence-conduction bandgap in bulk-sized metals, the bandgap exists in metals having 
dimensions in the nanometer range due to structural discontinuity, thus leading them to fluoresce 
upon appropriate excitation.112 Gold, silver, and recently copper, are broadly investigated noble 
metals to form fluorescent nanoparticles. Sensing and intracellular imaging applications of noble 
metal nanoparticles have also been widely studied.113 Difficulty in precise control of the size, and 
low fluorescence efficiency of noble metal nanoparticles are the main challenges for their 
development. Carbon dots are a new type of FINPs that have attracted lots of attention recently. 
Although the reason that carbon dots are fluorescent remains unclear, several possible 
mechanisms have been proposed, such as quantum confinement effect and the presence of 
defects on the surface.114-115 Because carbon dots have the advantages of tunable 
absorption/emission wavelengths, biocompatibility, photostability, low molecular weight, and low 
toxicity, they are also used in sensing and imaging.116  
1.4.2  Fluorescent Proteins (FPs) 
Another large family of fluorophores is that based on FPs, which have become an essential 
tool for current cell biology study.117 Since the green fluorescent protein from Aequorea victoria 
17 
 
jellyfish (avGFP, ex = 395, 475 nm, em = 508 nm, and  = 0.8) was genetically encoded and 
expressed in cells in 1994, great efforts have been made to engineer and explore more FPs with 
improved biochemical and fluorescent properties.117-118 Besides avGFP and its mutants, the 
discovery of more prototypical FPs and their mutants (e.g., DsRed, mFruit, eqFP, TagRFP, to 
name a few) greatly enriched the FP family. Currently, a large variety of FPs emitting light covering 
the entire visible light spectrum are available, Figure 1.6.75 
 
Figure 1.6 An ensemble of fluorescent proteins which are derived from Aequorea GFP or 
Discosoma RFP. Their emission light covers the entire visible light spectrum from 440 nm to 650 
nm. This photo is a time exposure of fluorescence excited at different wavelengths and viewed 
through different cutoff filters.75  
The fluorescence of GFPs originates from the small-molecule imidazolinone derivatives 
embedded within the FPs.118 The principle fluorophore of GFP is formed by three adjacent amino 
acids—serine, tyrosine, and glycine at the positions of 65, 66, and 67, Figure 1.7. Its location at 
the center of a rigid and hydrophobic -barrel consists of 11 -sheets, which play crucial roles in 
the formation and fluorescence of the fluorophore.119 The amino group of Gly-67 first attack the 
carbonyl group of Ser-65, resulting in a heterocyclic ring system. Subsequent oxidation by O2 
gives the fluorescent conjugated imidazolinone fluorophores. The fluorophore formation process 
is known as protein maturation. Although the synthetic analogs of the imidazolinone derivatives 
are non-fluorescent by themselves, they are highly fluorescent in GFPs, due to their restricted 
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molecular structure.120 Therefore, changes of the environment around the fluorophore can greatly 
alter its photophysical properties (absorption/emission wavelength, fluorescence efficiency, and 
photostability). Mutations of the FP residues are often employed to improve the fluorescent 
properties of FPs (e.g., higher brightness ( × ) and longer emission wavelength), optimize the 
maturation rate of FPs at 37 °C, enhance protein expression, and prevent oligomerization.121-124 
For example, the single point mutation S65T in GFP greatly increased the brightness and 
photostability of the mutant.125 The F64L mutation of GFP (EGFP) significantly improved the GFP 
maturation rate at 37 °C, thus making efficient the formation of fluorescent GFP under cell-
culturing conditions.126 
 
Figure 1.7 The formation steps of the principle fluorophore in GFP.127 
Because most FPs themselves are fluorescent without the need of cofactors or substrates, 
they are excellent tools to visualize biological structures and processes, and monitor gene 
expression in cells and living organisms.117, 128 Methods for their expression in bacteria, mammals, 
and human cells have been established. By fusing specific gene products expressing proteins of 
interest with gene sequences of FPs and transfecting the fused gene sequences into cells, the 
localization, movement, and turnover information of the targeted proteins in cells can be 
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monitored. FPs can also be modified to act as biosensors to report biological events,129 measure 
calcium ions,130 sense transmembrane voltage,131 and ablate cells.132-133 For example, by 
connecting CFP and YFP with a kinase C specific peptide, Violin et al. reported a genetically 
encoded reporter, which can reversibly detect kinase C activity in Hela cells.134 A genetically 
encoded singlet-oxygen-generator protein, miniSOG, was reported by Qi et al. to selectively 
induce cell ablation with light in Caenorhabditis elegans.133 Despite their useful applications, there 
remain several concerns with the utilization of FPs. FPs have relatively large dimensions (2–4 nm) 
and molecular weight (~ 25 KD), potentially interfering the function of targeted proteins. Compared 
to other fluorophores, FPs have low photostability, thus they easily lose their signaling ability. The 
overexpression of FPs relative to endogenous proteins in cells can disrupt the cellular physiology, 
and thereby being toxic. To acquire fluorescence of FPs in cells, gene sequences of FPs must be 
transfected into host cells, thus making FPs unsuitable for clinical applications. 
The last two decades have led to tremendous success in the engineering of a wide array 
of GFPs with improved properties, including high brightness, good photostability, efficient 
expression in cells, reduced oligomerization and toxicity, and increased resistance to 
environmental perturbations (e.g., pH, ionic concentrations, and solvent polarity); these effects 
have resulted in their extensive applications in cell biology. However, most of them fluoresce in 
the visible light energy range, and engineering of various NIR fluorescent FPs (IFPs) remains a 
big challenge.57 Because IFPs can not be obtained through modifications of GFPs, other 
prototypical FPs, such as bacterial phytochromes (BphPs), have been investigated as templates 
to engineer IFPs.117 Biliverdin (BV) can bind to BphPs and is the fluorophore responsible for their 
fluorescence. Like the principle fluorophore for GFPs, BV is non-fluorescent by itself and becomes 
fluorescent upon binding to BphPs. Based on the template, Shu et al. developed IFP1.4 (ex = 
684 nm, em = 708 nm, and  = 0.07) and first applied it for deep tissue imaging in mammalian 
animals.135 IFP 2.0, the improved version of IFP1.4, was applied to monitor neuronal processes 
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in Drosophila larvae and image brain tumors in mice.136 iRFP (ex = 690 nm, em = 713 nm, and 
 = 0.06) was also engineered from RpBphP2 and used for imaging mouse liver.137 Although it 
has a slightly lower fluorescence efficiency than IFP1.4, it exhibited higher brightness in cells due 
to its more effective binding to endogenous BV. However, one drawback of BphP-derived IFPs is 
that their fluorescence relies on the concentration of BV. Therefore, the exogenous addition of 
BV, or co-expression of heme oxygenase 1 (HO-1) that produces BV by metabolizing heme, is 
required. Besides the BphP-derived IFPs, a new group of IFPs was engineered from an 
allophycocyanin -subunit (APC), such as smURFP (ex = 642 nm, em = 670 nm, and  = 
0.18).138 
1.4.3  Small Organic Molecular Fluorophores 
 Small organic fluorophores have been a powerful tool for visualizing biological 
species/events in cells and living organisms, ever since the discovery of the first organic 
fluorophore, quinine sulfate, in 1845.139 Before the advent of genetically encoded fluorophores in 
the 1990s, small organic fluorophores were the only choices for labeling biomolecules and 
staining cells. Without a doubt, small organic fluorophores have paved the way for, and will 
continue to contribute to our understanding of the dynamic and complex biological processes in 
living subjects.76, 140-146  
Small organic fluorophores typically have molecular weights less than 1500 Da and 
dimensions less than 1 nanometer, thus allowing their attachment to proteins of interest without 
affecting the functions and nature of the proteins. Their widespread applications also benefit from 
their immediate availability, either from large commercial supplies or from facile synthesis in the 
laboratory. By applying modern organic chemistry strategies, their well-defined chemical 
structures can be easily and efficiently modified to provide the desired optical and chemical 
properties. Many biosensors can be constructed by attaching fluorophores to specific functional 
groups including pH-responsive groups, receptor-targeting moieties, enzymatic substrates, and 
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metal-chelating components. Although countless fluorescent molecules with various applications 
are now present, most of them are based on a small number of fluorescent platforms with 
conjugation structures, Figure 1.8.140 Among them, the most investigated fluorescent platforms in 
the visible and NIR range include fluorescein, rhodamine, borondipyrromethane (BODIPY), 
porphyrin, and cyanine. 
 
Figure 1.8 Core structures of common small molecule fluorophores.  
 Fluorescein is one of the most used and versatile fluorophores for biological labeling, and 
it was the first one approved by the FDA for clinical applications.147 Protein-labeling probes can 
be easily constructed by appending amino or thiol-reactive groups on the fluorescein core (e.g., 
succinimidyl and maleimidyl fluorescein derivatives, and fluorescein isothiocyanate (FITC)). 
Fluorescein has a xanthene structure with absorption/emission wavelengths in the visible light 
range. The dianion form of fluorescein is the most fluorescent form with a pKa ~ 6.4, thus allowing 
it to act as a pH sensor to monitor pH changes in cells.148 However, the pH-dependence makes 
fluorescein-based probes unsuitable for quantitative analysis. To overcome this drawback, 2’,7’-
difluoro fluorescein (Oregon Green) was developed with a lower phenolic pKa at 4.6 due to the 
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decreased electron density of the fluorescein core, thus making Oregon Green suitable for 
applications under acidic conditions. Another property of fluorescein is that it can exist in either 
an “open” fluorescent quinoid form or a “closed” non-fluorescent lactone form. Caging both sides 
of the oxygen atoms with analyte-responsive groups can make fluorescein exist in its non-
fluorescent lactone state, thus yielding non-fluorescent probes. For example, probes to detect -
galactosidase and esterase were developed based on this property.149-151 Although it had been 
believed for a long time that the carboxylic group of fluorescein was indispensable for the strong 
fluorescence of fluorescein, in 2005, Urano et al. demonstrated that the role of the carboxylic 
group is to hinder rotation of the benzene moiety.152 Replacing the carboxylic group with a methyl 
group yielded a group of fluorescein derivatives (TokyoGreens) having strong fluorescence. 
Modifications to the xanthene core of fluorescein were used to shift the absorption/emission 
wavelengths. By replacing the oxygen atom of the xanthene core with a gem-dimethyl group, 
Grimm et al. constructed carbofluorescein that exhibits red-shifted absorption/emission 
wavelengths with a high quantum efficiency under basic conditions.153 However, the pKa of 
carbofluorescein is around 7.4, thus making it suffer from severe pH influences in biological 
environments. Grimm et al. further fluorinated the carbofluofluorescein structure, thus yielding 
2’,7’-difluorocarbofluorescein (Virginia Orange) with a slightly decreased pKa at 6.75.154 
Substituting the xanthene oxygen with a dimethylsilyl group yielded another class of fluorescein 
derivatives (TokyoMagentas) with large red-shifted absorption/emission wavelengths.155-156 
Despite its widespread applications, fluorescein suffers from several disadvantages including low 
photostability, fluorescence quenching upon binding to biopolymers, broad absorption/emission 
spectra, cellular impermeability, and cellular expulsion due to its negative charge.  
 Rhodamines, another large family of fluorophores possessing xanthene structures, share 
several similar optical and chemical properties with their counterpart fluorescein. In contrast to 
fluorescein, rhodamines exhibit several advantages including longer and tunable 
absorption/emission wavelengths, pH-independence, and higher photostability. A large number 
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of rhodamine derivatives with various applications are commercially available (e.g., Rhodamine 
6G, Rhodamine 123, Rhodamine B, Texas red, Rhodamine 800, to name a few). Masking both 
amino moieties of rhodamine results in the non-fluorescent “closed” lactone form that has been 
exploited to design latent fluorescent probes to detect enzymes.157-158 The carboxylic group of 
rhodamine can be replaced with mercapto-methyl and hydroxymethyl groups to improve the 
spirocyclization efficiency.159-160 The rhodamine with the mercapto-methyl group exhibits a strong 
spirocyclization tendency due to the strong nucleophilicity of the sulfhydryl group, thus requiring 
harsh chemical reactions to open the five-membered ring and reveal its fluorescence. On the 
other hand, hydroxymethyl rhodamine green (HMRG) has a moderate spirocyclization tendency 
and has an open/closed equilibrium in aqueous solutions. By appending electron-withdrawing 
groups such as acetyl to the amino group of HMRG, the resulting HMRG analog is mainly present 
in non-fluorescent close form. This strategy is of great use for developing latent fluorescent probes 
to detect enzymes.161-162 To improve the brightness of rhodamine, the N,N-dimethylamino group 
in tetramethylrhodamine (TMR) was replaced with a rigid four-membered group azetidine, which 
resulted in a rhodamine derivative with higher fluorescence efficiency than its parent molecule 
due to inhibited nonradiative decay.163 This strategy also applies to other core fluorescent 
scaffolds (e.g., coumarin, naphthalimide, and rhodol). Similar to fluorescein, substitution of the 
xanthene oxygen atom with carbon and silicon atoms yielded carborhodamine and Si-rhodamine 
with large bathochromic shifts (respectively 55 nm and 90 nm).153, 164-165 The absorption/emission 
wavelengths of Si-rhodamine can reach the NIR range, thus making it promising for in vivo 
applications. Other atomic substitutions (e.g., P, Ge, Sn, Se, and Te) were also widely 
investigated to improve the photophysical properties of rhodamine.153  
Another effective strategy to build useful fluorescent scaffolds with unique optical and 
chemical properties is to craft hybrid fluorophores. An example is Rhodol that has a hybrid 
structure of fluorescein and rhodamine, and it has low pH-dependence, high fluorescence 
efficiency, and high photostability.166-167 In contrast to fluorescein, rhodol has only one phenolic 
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moiety, which can be masked to form the non-fluorescent closed form. By replacing the carboxylic 
group with a hydroxymethyl group, Urano et al. synthesized a series of rhodol derivatives, which 
were utilized to develop several latent fluorescent probes for the detection of enzymes.168-169 By 
extending the conjugation of the xanthene core, Lin et al. developed a series of xanthene-cyanine 
fused fluorophores (Changsha dyes) with NIR absorption/emission wavelengths.170-171 
 Since the first synthesis of BODIPY in 1968, it has played an important role in biological 
imaging.172-174 BODIPY exhibits several unique optical properties, including high photostability, 
high extinction coefficient, high quantum yield, narrow absorption/emission bands, pH-
independence, and environmental insensitivity, thus allowing it to be especially useful in protein 
labeling and multicolor imaging. These properties can be attributed to its highly rigid structure. 
BODIPY dyes are usually hydrophobic and have a net charge. These properties are beneficial for 
the binding of their ligand conjugates to receptors; however, these characteristics can also result 
in low water solubility. The biolabeling field has also benefited from the large quantity of 
commercially available amine- and thiol-reactive BODIPY dyes. For example, BODIPY dyes can 
be functionalized with succinimidyl esters, carboxylic acids, acid halides, and maleimides, suitable 
for immediate target moiety conjugation. Most of the conventional BODIPY dyes absorb and emit 
light in the visible light range. To increase their absorption/emission wavelengths, extended 
conjugation groups are often incorporated into the core structure of BODIPY.175 However, this 
strategy often leads to increased hydrophobicity, thus limiting their biological applications under 
aqueous conditions. By replacing the meso-carbon atom of BODIPY with an imine type nitrogen 
atom, the aza-BODIPY scaffold results. Aza-BODIPY attracts great attention because it has NIR 
absorption/emission wavelengths while maintaining the optical advantages of conventional 
BODIPY.  
 The cyanine dyes are a large class of fluorophore molecules, whose structures include 
two nitrogen-containing aromatic rings connected by a polymethine conjugated chain.176-177 
Depending on number of the double bonds in the polymethyl chain, cyanines can have different 
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absorption/emission wavelengths, ranging from the visible range to the NIR range (e.g., Cy3, Cy5, 
and Cy7). Numerous functionalized cyanine dyes are available for DNA and protein labeling. For 
example, cyanines can be conjugated with N-hydroxysuccinimidyl, maleimide, or isothiocyanate 
groups to form amine- and thiol-reactive labeling agents. Within the cyanine family, heptamethine 
cyanine dyes have been the most investigated, due to their NIR absorption/emission wavelengths 
that are suitable for in vivo applications.178 Most of the currently used NIR fluorescent agents are 
based on the heptamethine scaffold. Besides ICG, several heavily investigated heptamethine 
cyanine dyes are IR-780, IR-783, IR808, IRDye800-CW, ZW800-1, and MHI-148. IRDye800-CW 
and ZW800-1 have recently been approved for clinical trials. Most cyanine dyes are prone to 
aggregation in aqueous solution, leading to their decreased fluorescence efficiency. To solve this 
challenge, cyanine dyes are often modified with sulfonate groups that increase dye water solubility 
and photochemical stability, while also decrease cytotoxicity. However, it might result in a cellular 
impermeability problem. Although cyanine dyes normally have reasonable quantum yields in 
organic solvents, their quantum yields in aqueous solutions are low, because the vibration of the 
flexible polymethine chain leads to energy losses in this non-radiative pathway. Incorporation of 
chloro-cyclohexenyl or chloro-cyclopentenyl groups into the central polymethine chain rigidifies 
the cyanine structure, resulting in improved quantum yields.179-180 Further substitution of the 
chlorine atom with oxygen, sulfur, or nitrogen leads to the formation of new heptamethine 
fluorophores with unique photophysical properties.181-183  
1.5  Fluorescent Probes in Cancer Imaging and Design Strategies 
 The advancement of optical imaging modalities has revolutionized the fields of cell biology, 
biomedical research, and in vivo imaging. In the FGS area, administration of exogenous 
fluorescent probes is required to enhance the visualization of tissue structures, monitor blood and 
lymphatic flows, and determine the location of tumors and margins between healthy tissue and 
tumor lesions.44, 46, 56 Therefore, development of specific fluorescent probes to enhance 
visualization are in great demand. Although fluorescent imaging probes can be designed based 
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on all the previously discussed fluorophores, small-molecule, fluorophore-based fluorescent 
probes hold the most promise for in vivo imaging and clinical applications, and thus will be the 
focus in the following discussions. Most of the current fluorescent probes can be divided into three 
categories: passive always-on probes, targeting always-on probes, and activatable probes, 
Figure 1.9.184 
 
Figure 1.9 Illustration of the different modes of action for signal generation with the three 
categories of fluorescent probes.184 
1.5.1  Passive Always-On Fluorescent Probes 
 The target-to-background (TBR) contrasts for passive always-on probes are based on 
their passive accumulation and non-specific biodistribution in tissues. To date, all the current FDA-
approved fluorescent probes (fluorescein, ICG, MB, and 5-ALA) belong to this category. For 
fluorescence tumor imaging applications, passive always-on fluorescent probes can accumulate 
in or around tumors. Fluorescein was the first fluorophore used for tumor identification, and it can 
be used for identifying brain tumors during neurosurgery.51, 185 ICG is a well-known NIR 
fluorescent probe with very low toxicity, and it is historically employed in lymph node mapping, 
angiography, cardiac output, and hepatic function.46, 56 Because ICG is primarily removed by the 
liver, it is intraoperatively applied to identify primary hepatocellular carcinomas and hepatic 
metastases.186-187 Horowitz et al. reported that ICG accumulated in ovarian metastases upon its 
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intravenous injection.188 They proposed that the binding of ICG to proteins increases its 
hydrodynamic diameter, thus enabling accumulation of ICG in tumors due to the EPR effect. The 
dark blue dye MB can be used as an NIR fluorophore when sufficiently diluted; also, it was recently 
approved by the FDA for clinical uses. Although its accumulation mechanism in tumors is unclear, 
MB has been used to differentiate primary and metastatic insulinomas from normal pancreas 
tissues and other abdominal structures.189 5-ALA is a substrate molecule in the synthesis of the 
fluorescent protoporphyrin IX, which takes place mainly in epithelial and neoplastic tissues. It has 
been used for identifying several cancers, including gliomas,190 oral malignant lesions,191 and 
bladder cancer.192 Because 5-ALA has photodynamic activities, its use for cancer imaging should 
be carefully managed due to the high risk of skin sensitization. Although a large number of 
fluorophores are available, only two new fluorophores are currently undergoing clinical trials 
(IRDye800-CW and ZW800-1).193-194 These types of probes have no inherent specificity for tumors, 
and their success for providing meaningful tumor imaging relies heavily on the tissue clearance 
pathway of the probes.  
1.5.2  Targeting Always-On Probes 
To improve the specific accumulation of probes in targeted areas, a new approach 
requires conjugation of the fluorophores to targeting ligands (e.g., antibodies, peptides, and folic 
acids) that specifically bind to the overexpressed receptors on tumor cell membranes.1, 195 The 
targeting ligands can allow for their binding to their respective receptors upon fluorophores 
delivery to the targeted area, thus increasing the fluorophore accumulation and retention at the 
targeted site. This design strategy can also benefit from the availability of both the FDA-approved 
antibodies and fluorophores. For example, bevacizumab, an FDA-approved monoclonal antibody, 
was conjugated to IRDye800-CW, and the afforded probe has been used to visualize vascular 
endothelial growth factor (VEGF) specific tumors in clinical trials.196 Prostate-specific membrane 
antigen (PSMA),197-198 v3 integrin,199 epithelial growth factor receptor (EGFR),200 matrix 
metalloproteinase-2 (MMP-2),201 and folate receptor   are among the most investigated 
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surface receptors that have been targeted to develop fluorescent probes. Several developed 
probes based on this strategy have undergone clinical trials. One example is the intraoperative 
detection of ovarian cancer metastases with a folate-receptor-targeted fluorescent probe 
OTL38.202 With the aid of OTL38, the surgeons were able to remove 29% more malignant lesions 
that were not identified under white light illumination; during surgery, this proved the usefulness 
of targeting probes in clinical applications. Although these targeting always-on probes hold 
advantages over passive always-on probes, they still suffer from several drawbacks. The TBR 
contrast generated by this type of probe relies on the effective accumulation and retention of the 
probes, as well as rapid clearance of the unbound probes. Therefore, a long waiting time after 
their i.v. administration is typically required to acquire adequate TBR contrast. Also, the 
receptor/probe binding does not allow the fluorescence signal amplification.  The large size of the 
antibody conjugated probes often increases their circulation time in the body, thus resulting in a 
high background signal. The EPR effect that results from large probe size also interferes with 
efficiency of receptor-binding. Because the optical and chemical properties of fluorophores can 
also be altered by the large size of the conjugated antibody, the fluorescence efficiency and 
toxicity data of the fluorophores need to be further validated. The TBR contrast is also 
compromised by the low receptor expression level of tumor lesions. The number of surface 
receptors per cell is around 104, which can lead to a bound probe concentration around 17 nM, 
assuming the probe/receptor binding ratio of 1:1.30  Therefore, even though the targeting strategy 
can improve the tumor-specific accumulation of the probes, the large fluorescence background 
caused by unbound fluorescent probes can often result in low TBR values. 
1.5.3  Activatable Fluorescent Probes 
 Tumors have different physiological properties (e.g., pH, pO2, proteases, and enzymes) 
from normal tissues, which can be exploited to design activatable probes.1, 4, 6, 184, 195, 203 These 
kind of probes are nonfluorescent in their unactivated state due to various quenching mechanisms. 
However, upon interacting with a tumor-specific target, the fluorescence quenched probes are 
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activated, thus releasing highly fluorescent fluorophore. Tumor-specific enzymes can act as 
catalysts, amplifying the fluorescence signal. The lower fluorescence emission of unactivated 
probes gives decreased background, thus significantly improving the TBR contrast compared to 
always-on probes.  Weissleder et al. attached several NIR fluorophores based on Cy5.5 to a poly-
L-lysine backbone to yield a non-fluorescent probes, due to fluorophore autoquenching.204 Upon 
intravenous injection into a preclinical animal model, the probe accumulated in solid tumors, 
where was released the fluorescent fluorophores via lysosomal proteases; this approach gave 
the adequate tumor detection with a high TBR (12:1). Urano et al. developed a target-cell-specific 
activatable probe by conjugating a pH-sensitive BODIPY dye to the monoclonal antibody 
trastuzumab.205 The probe first binds to human epidermal growth factor receptor type 2 (HER2) 
upregulated in lung cancer cells, then it is internalized by cells through endocytosis, and the dyes 
becomes fluorescent in the acidic endosomes/lysosomes. LUM015 is the first activatable probe 
approved for clinical trials to detect soft-tissue sarcomas and breast cancer.206 LUM015 was 
formed by connecting a NIR Cy5 fluorophore and a QSY21 quencher with a pan-cathepsin Gly-
Gly-ARG recognition sequence. The fluorescence of LUM015 is quenched in its unactivated state 
in normal tissues. However, in a variety of tumors that overexpress a capthesin protease, the 
covalently attached QSY21 quencher is eliminated, thus revealing the fluorescence of the Cy5. 
Most of the current activatable fluorescent probes are activated with extracellular and 
membrane enzymes. The released fluorophores may diffuse out of the tumor region, leading to 
decreased tumor signal, and an increased background signal. To address the diffusion issue, 
lipids,207 PEG linkers,206 amide bonds,208 or cell-penetrating peptides209-210 have been appended 
on the probe structures to enhance signal retention. By exploiting the cell-penetrating peptide 
strategy, Tsien and his colleagues have developed several activatable probes to detect 
thrombin211 and matrix metalloproteinases (MMPs).209, 212 However, as previously discussed, the 
large size of these polymer, antibody, and peptide-based activatable probes can result in slow 
uptake into tumors and a long time (hours to days) to dequench the fluorescence, making it difficult 
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to incorporate them into the intraoperative surgical workflow. Activatable fluorescent probes 
based on small organic fluorophores with rapid tumor uptake, and effective enzymatic kinetics, 
hold the most promise to overcome the mentioned challenges. Urano et al. developed a small-
molecule substrate probe, gGlu-HMRG, to detect -glutamyltranspeptidase (GGT) that is 
overexpressed on the cell membrane in various tumor cells.161 Upon topically spraying the probe 
on implanted tumors in a living mouse, an immediate fluorescence increase in tumors (< 5 min) 
was detected endoscopically. Peritoneal administration of gGlu-HMRG also enabled the 
successful visualization of small-foci (< 1 mm in diameter) ovarian cancer metastases.  
To acquire the activatable probes with desired photochemical properties, the fluorescence 
of the developed probes needs to be modulated. This can be achieved through various 
mechanisms, such as fluorescence resonance energy transfer (FRET),213-214 photo-induced 
electron transfer (PeT),152, 215 intramolecular charge transfer (ICT),181, 216 and spirocyclization of 
xanthene dyes.160, 217 These strategies can lead to two general impacts on the fluorophore: 
quench/decrease the fluorescence intensity and shift the absorption/emission wavelengths. FRET, 
the most explored mechanism, involves two homo/hetero fluorophores in close proximity (1–10 
nm) allowing the energy to be transferred from one fluorophore (the donor) to the other (the 
acceptor) due to dipole-dipole interactions. To achieve efficient energy transfer, the emission 
spectrum of the donor is required to have a significant overlap with the absorption spectrum of 
the acceptor. If the two fluorophores are identical, they absorb energy from each other’s excited 
state leading to a diminished fluorescence of the entire system (self-quenching). If the 
fluorophores are different, the donor, in its excited state, transfers energy to the acceptor, and the 
FRET pair either emits the photons from the acceptor or the donor is quenched by the acceptor. 
In both homo- and hetero-FRET systems, breaking apart the two fluorophores by targeted 
species/events can make them fluoresce in the wavelength range of the donor. However, because 
FRET efficiency is greatly influenced by the distance between the donor and the acceptor, the 
FRET pair is sensitive to the environmental factors, such as pH, polarity, and viscosity.  
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PeT is another widely explored fluorescence quenching strategy for the development of 
activatable probes. Unlike a FRET pair that requires the existence of at least two fluorophores, 
the PeT system requires only one fluorophore, that can act as either the electron donor (d-PeT) 
or the electron acceptor (a-PeT) to complete the electron transfer with neighboring 
electron-deficient/-rich moieties. Both d-PeT and a-PeT processes can significantly decrease the 
fluorescence intensity of the fluorophore. Cleavage or changing the electronic state of the 
electron-deficient/-rich groups by specific targets can inhibit the electron transfer, thereby 
revealing the fluorescence. Fluorophores with ICT properties have both electron-donating and 
electron-withdrawing groups, and exhibit a different dipolar moment of the excited state from that 
of the ground state. Caging the electron-donating group can decrease the ICT effect, which leads 
to a different absorption/emission profile. Therefore, caging/uncaging the ICT fluorophores can 
be exploited to develop activatable fluorescent probes. Intracellular spirocyclization of xanthene 
dyes (i.e., fluorescein and rhodamine) can break their conjugation structure, leading to 
fluorescence quenching. It has become an effective strategy to develop activatable probes to 
manipulate the open/closed state of the xanthene dyes. Some other fluorescence modulation 
strategies include aggregation-induced emission (AIE), excited state intramolecular proton 
transfer (ESIPT), and the combination of these and other mechanisms.  
1.6  Enzyme-Activatable Fluorescent Probes 
 Enzymes are a large family of proteins that catalyze almost all metabolic processes in 
living organisms and play fundamental roles to sustain life. Aberrant expression and changes of 
their functionalities are related to the onset and progression of various human diseases, thus 
making crucial the accurate and sensitive tracking of enzymatic activities in a dynamic manner 
for diagnostics and treatment of the diseases. As discussed earlier, optical fluorescence imaging 
is a highly sensitive technique for the study of biological processes. Therefore, development of 
substrate molecules that can be specifically activated by the targeted enzymes will greatly aid the 
direct visualization of their catalytic activities.2, 203, 218-219  The first example of visualizing enzymatic 
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activities is alkaline phosphatase detection in mammalian tissues by precipitating the enzyme-
produced phosphate, as outlined by Gomori in 1939.220 In 1998, Tsien et al. developed a cell-
permeable fluorescent probe to measure the enzymatic activity of -lactamase in living cells, 
which opened the door for employing fluorescent substrate probes to study the physiological 
functions of enzymes in living cells and living animals.221 Currently, a variety of disease-
associated enzymes have been targeted to develop enzyme-activatable fluorescent probes. 
Some common examples of targeted enzymes are phosphatases,222-224 esterases,225-229 
peptidases,161, 230-232 -galactosidase,152, 168 -lactamase,221, 233 cysteine cathepsins,234-235 
caspases,236-237 and human NAD(P)H: quinone oxidoreductase 1 (hNQO1).9-13   
1.7  NAD(P)H: quinone Oxidoreductase 1 (NQO1) 
NQO1 (EC 1.6.99.2) is a flavinprotein with a homodimer structure, which functions as a 
two-electron reductase that catalyzes the reduction of quinones to hydroquinones using the 
reduced nicotinamide adenine dinucleotide (phosphate), NAD(P)H, as cofactor.238 Each monomer 
is composed of 273 residues and has two domains – a large catalytic domain and a small C-
terminal domain. The two monomers interlock with each other and form two catalytic pockets at 
the dimer interface, each non-covalently bounds to one adenine dinucleotide (FAD) molecule.239 
The catalysis function follows a “ping-pong” bi-bi mechanism. In this mechanism, NAD(P)H binds 
to the active site and transfers its hydride to the FAD molecule, and the resulting NAD(P)+ is 
subsequently displaced by quinone substrate molecules. The substrate molecules accept the 
hydride from the reduced FAD (FADH) and are reduced to their hydroquinone forms. Depending 
on the source, NQO1 has different amino acid sequences. For example, rat NQO1 (rNQO1) has 
a higher enzymatic activity than mouse NQO1 (mNQO1), because of a different amino acids at 
position 104 (tyrosine in rNQO1 and glutamine in mNQO1).240 Human NQO1 (hNQO1) has a 
similar catalytic efficiency compared to mNQO1, due to the 94% similarity in their structures. A 
single point nucleotide mutation (cytosine to thymidine, C609T) of the NQO1 gene leads to the 
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amino acid substitution (proline to serine, Pro187Ser) at position 187 in the protein yielding a 
variant enzyme NQO1*2.241 NQO1*2 exhibits significantly lower enzymatic activity and can be 
rapidly ubiquitinated and degraded by the proteasome, resulting in complete loss of its function. 
Because of this gene mutation, the non-small cell lung cancer cell line (H596) has no 
demonstrable NQO1 activity.242 In humans, NQO1 has been found to be widely distributed in a 
variety of cell types in widely different amounts, with the exception of the liver. NQO1 is 
predominantly localized in the cytoplasm (> 90%) of cells.243-244  
NQO1 plays multiple cytoprotective roles in living subjects, such as a radical scavenger,245 
tumor suppressor protein (p53 and p73) stabilization,246 and detoxification of a broad range of 
quinone substrates, quinone epoxides, and nitroaromatic compounds.247-248 NQO1 is reportedly 
linked to tumorigenesis, and its upregulation is indicative of the early carcinogenic process.7 
NQO1 expression is regulated through the Keap1/Nrf2/ARE pathway that combats increased 
cellular oxidative stress, Figure 1.9.249 In the normal cellular environment, the Keap1 (Kelch ECH 
associating protein 1) binds to the transcription factor Nrf2 (nuclear factor E2-related factor 2) to 
promote the degradation of Nrf2 through ubiquitination and a proteasomal degradation process. 
However, in response to increased oxidative stress, Keap1 is oxidized and loses its ability to 
target and degrade the Nrf2 transcription factor because of the oxidation of the reactive cysteine 
 
Figure 1.10 Reductase expression in cells in response to increased oxidative stress through 




sites of the Keap1 protein. The stabilized Nrf2 transcription factor accumulates in the nucleus 
where it binds to an ARE (antioxidant response element) sequence and triggers the transcription 
of NQO1.250-252  
The expression of NQO1 in numerous human solid tumors (e.g., pancreas, colon, breast, 
ovarian, and non-small cell lung carcinoma) is 2- to 50-fold higher than the surrounding normal 
tissue.7 Therefore, NQO1 has long been considered a biomarker for targeted anticancer therapy.8 
Compared to conventional anticancer drugs that usually have significant toxicity to normal tissues, 
biomarker-directed anticancer prodrugs have selective toxicity to cancerous tissues, thus having 
the potential to increase therapeutic effectiveness. Some quinone-based prodrugs (e.g., 
mitomycin C (MMC), E09, diaziqunone (AZQ), RH1, and -lapachone) can be converted to 
cytotoxic drugs by the NQO1-mediated reduction process. Although mitomycin C in its original 
state is inactive, reduction of mitomycin C by NQO1 or other reductases leads to the production 
of a reactive alkylating molecule, which crosslinks and breaks the strands of DNA.253  -
Lapachone is an NQO1-specific anticancer drug that is currently undergoing clinical trials for 
pancreatic cancer.254 -Lapachone induces high levels of superoxide through the NQO1-
mediated redox cycle, which causes damage of DNA and extensive NAD+/ATP depletion, 
ultimately leading to apoptosis of NQO1-overexpressing cells.  
Although the upregulation of NQO1 in tumors has long been established and broadly 
explored in the development and implementation of antitumor drugs, only recently has NQO1 
been exploited as a biomarker to craft profluorogenic small molecule probes pioneered by the 
McCarley research group.9-13, 158, 255-256 NQO1-activatable profluorogenic probes that target 
elevated hNQO1 in solid tumors will be of great significance for understanding enzymatic 
processes at the molecular level, developing tools to differentiate cancerous lesions from normal 
tissues during surgery, and evaluating drug action and efficacy in vivo. Because NQO1 is an 
intracellular enzyme mainly localized in the cytoplasm, the developed NQO1-specific probes are 
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internalized and activated inside cells, thus diminishing the diffusional loss of released fluorescent 
reporters, which is beneficial for attaining a high TBR ratio. Silvers et al. developed the first latent 
fluorescent probe, Q3NI, that was successfully used to differentiate NQO1-expressing and NQO1-
non-expressing cells via the unaided eye, flow cytometry, and fluorescence imaging.13 After that, 
several other NQO1-activatable turn-on fluorescent probes were developed with improved 
properties (e.g., improved TBR values and longer emission wavelength) and applied for detection 
of NQO1 in the cellular environment.9-10, 12, 256 A summary of the developed probes for detection 
of NQO1 is listed in Table 1.1. However, the probe/reporter systems have absorption/emission 
wavelengths in the visible light range, which limit their further applications in vivo. Therefore, 
development of the probe/reporter systems that emit light in the NIR range is in great demand for 
in vivo applications. Besides the development of NQO1-activatable fluorescent probes, 
development of NQO1-activatable photodynamic agents, luminescent probes, and photoacoustic 
probes will greatly benefit the fields dedicated to NQO1 detection in tissues. 
Table 1.1 Summary of Probes for Detection and Measurement of NQO1 
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1.8  Visualization of -Galactosidase with Different Imaging Modalities 
1.8.1  -Galactosidase 
-Galactosidase (-D-galactohydrolase, EC 3.2.1.23, -gal), encoded by the lacZ gene, is 
a glycoside hydrolase enzyme. Its function is to catalyze the hydrolysis of terminal linkages of -
D-galactosides, such as the disaccharide lactose, into monosaccharides through recognition and 
cleavage of the -D-galactose moiety.265 Even though -gal is able to hydrolyze fucosides and 
arabinosides, the hydrolysis efficiency is significantly lower than that for -D-galactosides. -Gal 
has a homotetrameric structure composed of four identical polypeptide chains, with each 
monomer possessing one reactive site.266 The monomers interact with each other through non-
covalent bonds (hydrophobic effects, hydrogen bonds, and electrostatic interactions). Because 
the catalytically active site of each monomer requires collaboration with other amino acids from 
the same polypeptides, as well as other polypeptides in the tetramer, splitting up of tetrameric -
gal into dimers leads to loss of its enzymatic activity.267-268 Upon substrate binding and its 
movement deeper within the active site, two sequential catalytic steps are involved in the 
hydrolysis mechanism of -gal.265  The first step, known as galactosylation, involves the substrate 
being attacked by the amino group of glutamic acid via a nucleophilic substitution reaction. The 
substitution results in -gal forming a covalent bond with galactose, thereby producing a covalent 
intermediate. In the second step (degalactosylation), the previously formed -N-glycosidic bond 
is broken by water attack, which ultimately leads to the formation of galactose. Yuan et al. found 
that when Glu-537 of -gal expressed by Escherichia coli (E. coli) was replaced by aspartic acid 
(Asp), glutamine (Gln), or valine (Val), the catalytic efficiencies of the mutants were significantly 
reduced (100-fold, 30000-60000-fold, 160000-300000-fold less for the respective Asp-, Gln-, and 
Val-mutants).269 That study indicated that Glu-537 is the amino acid responsible for acting as the 
nucleophile in the hydrolysis catabolism, which hinges on nucleophilic attack and breaking down 
of glycosidic bonds. This finding is contrary to the initial thought that Glu461 is the catalytic 
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nucleophile.270  In a similar study, by isolating and identifying the glycosyl enzyme intermediate in 
the catabolism process using high-performance liquid chromatography coupled with tandem 
mass spectrometry, McCarter et al. found that Glu-268 is the catalytic nucleophile in endogenous 
-gal in human beings.271  
1.8.2  -Galactosidase-Activatable Probes 
Due to its extensive applications as a reporter gene and enhanced upregulation in 
senescent cells and ovarian cancer cells, a great amount of effort has been made to establish 
methods to detect and measure -gal activity through the use of magnetic resonance imaging 
(MRI),272-278 positron emission tomography (PET),279-282 photoacoustic imaging,283 and optical 
imaging.152, 169, 284 A summary of the developed probes for detection of -gal is listed in Table 1.2. 
Because -gal is an exo-type hydrolase that recognizes and cleaves the end part of its substrates 
(here, -D-galactose), masking strategies are often employed to design -gal-responsive contrast 
agents.2 The key signal-generating structure is masked by the -D-galactose recognition moiety, 
resulting in an inhibited signal generation process. However, upon specific and effective cleavage 
of the masking moiety by -gal, the signal generation capability is recovered. 
Table 1.2 Summary of Probes for Detection and Measurement of -gal 
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MRI is an important clinical imaging technique, widely employed for disease diagnosis in 
hospitals.303 Unlike computed tomography (CT), MRI utilizes strong magnetic fields and radio 
waves to construct “pictures” of the organs in the human body, and X-rays are not involved in its 
imaging procedure. Therefore, MRI is believed to be a safer imaging system versus CT. It is also 
becoming a prominent scientific tool to study gene expression and enzyme activity, due to its 
potential to obtain three-dimensional images of opaque living organisms.304 Louie et al. developed 
a -gal responsive gadolinium-based MRI contrast agent, EgadMe, to visualize lacZ gene 
expressing tissues within living Xenopus laevis embryos with deep penetration and cellular 
resolution.274 EgadMe is comprised of a chelator binding to the gadolinium core with high affinity, 
and a galactose moiety that recognizes -gal with high specificity. The access of water molecules 
to the paramagnetic gadolinium core is blocked by the galactose moiety, leading to decreased 
MR signal in T1-based images. Upon the removal of the -galactose moiety by -gal, water 
molecules are allowed to interact directly with gadolinium and have shortened T1 relaxation times, 
resulting in the MR signal increase in the -gal-expressing tissues. Some other strategies were 
47 
 
also explored to manipulate MR signal by reaction of the developed probes with -gal. For 
example, Hanaoka et al. took advantage of a receptor-induced magnetization enhancement 
(RIME) phenomenon to develop a contrast agent, [Gd-5].275 RIME is related to changes of the 
proton relaxation time of water (T1 and T2) in the presence of specific acceptors. [Gd-5] is 
composed of a -galactose moiety, an albumin-binding moiety, and a gadolinium based MR 
signal-generating moiety. [Gd-5] does not exhibit the RIME phenomenon, because the albumin-
binding moiety is masked by the -galactose moiety. Upon reaction with -gal, [Gd-5] released 
the compound [Gd-8] with an exposed albumin-binding site and recovered its capability of binding 
to human serum albumin (HSA). The binding of gadolinium ion to HSA slows the molecular 
rotation of the chelating gadolinium complex and significantly increases the relaxation rate (r1) of 
its neighboring water protons.  
Paramagnetic chemical exchange saturation transfer (PARACEST) is another strategy 
exploited by Chauvin et al. to design -gal-responsive MRI contrast agents.272 A lanthanide-
chelating unit was coupled to the -D-galactose recognizing moiety with a self-cleavable linker. 
Enzymatic cleavage of -D-galactose by -gal breaks the initial carbamate bond into a free amine, 
accompanied by a change in the PARACEST properties of the lanthanide complex. All of the 
aforementioned contrast agents are employed to build 1H MRI images. One of the shared 
drawbacks is that the background signals are very high due to the prevalence of 1H nuclei in the 
human body and enhanced 1H MRI signals need to be carefully discriminated from background 
signals.  
To avoid this limitation, 19F MRI is an alternative technique used to study physiological 
events in living systems, due to the high sensitivity and endogenous absence of 19F nuclei in the 
human body. Mizukami et al. reported a 19F MRI contrast agent to detect -gal activity in vitro and 
in fixed HEK293T cells.273 Based on the design, the 19F MRI signal was quenched by the 
covalently connected paramagnetic chelated gadolinium complex. Upon enzymatic hydrolysis of 
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the contrast agent by -gal, the contrast agent was broken down into an 19F-bearing moiety and 
a gadolinium complex. Cleavage of the gadolinium quenching group leads to a great 19F MRI 
signal increase. 
PET is another important imaging modality widely utilized to monitor metabolic processes 
in the body upon the administration of radionuclide-labeled tracers. Three-dimensional images 
are constructed by detecting pairs of gamma rays emitted by the radionuclides. Due to it providing 
deep tissue penetration and high sensitivity, this technique was also exploited to monitor 
enzymatic activities.279 Bormans et al. developed a radioactive probe, -O-D-galactopyranosyl-
(1,4’)-2’-[18F]fluoro-2’-deoxy-D-glucopyranose (18FDL) through coupling 18FDG with -D-
galactose.280 18FDL was designed to investigate its usefulness in monitoring in vivo expression of 
lacZ gene. By the design, after 18FDL entered -gal-expressing cells, 18FDL was hydrolyzed by -
gal, resulting in the released 18FDG that could be trapped inside cells due to phosphorylation by 
hexokinase. Even though 18FDL exhibited effective activation by -gal in vitro, it failed to allow 
visualization of lacZ-expressing tumors in vivo. The authors attributed this observation to the 
cellular impermeability of 18FDG. Another two radiolabeled probes are 18F- and 11C-labeled 
derivatives of ortho-nitrophenyl--D-galactopyranoside, which were developed for in vivo 
visualization of lacZ gene expression.281 Both of them were demonstrated to be good substrates 
of -gal in vitro, and they exhibited good cellular permeability and faster uptake by -gal-
expressing cells (2.5 and 7.5 fold). However, the -gal cleaved products tended to leak out of the 
cells leading to significant signal loss, and thus low signal-to-background ratio.  Upon 
administration of both probes in vivo, -gal-expressing tumors were not visualized, and 
accumulation of the probes in kidneys and liver were found. Van Dort et al. reported a 125I-labeled 
probe 5-[125I]Iodoindol-3-yl--D-galactopyranoside ([125I]IBDG), designed for PET imaging of -
gal-expressing tumors.282 Based on their design, after [125I]IBDG was hydrolyzed by -gal, the 
formed [125I]iodoindoxyl aglycone compound would experience oxidative dimerization and be 
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immobilized at the active site. Even though [125I]IBDG exhibited effective hydrolysis by -gal in 
vitro and more efficient trapping of radioactive signal in -gal-expressing tumors than -gal-non-
expressing tumors with intratumoral injection, it failed to visualize both  -gal-expressing and -
gal-non-expressing tumors, likely caused by rapid renal clearance of [125I]IBDG upon intravenous 
administration. The slow oxidative dimerization rate of the produced [125I]iodoindoxyl aglycone at 
very low concentrations relative to its rate of free diffusion out of cells might be another cause of 
the unsuccessful visualization. 
Optical imaging is a well-known light-harvesting imaging technology with broad 
applications for basic research and medical science.35, 305  Compared to MRI and PET imaging 
modalities, optical imaging holds the advantages of high sensitivity, high spatiotemporal resolution 
(< m), real-time, lack of ionizing radiation, ease of use, and economic effectiveness. Many 
chromogenic,286-288 fluorescent,152, 160, 169, 284, 289, 292-296, 300-302, 306-312 and luminescent297-298, 313-314 
probes have been developed and applied to detect -gal in vitro and in vivo. X-gal is a 
conventionally and widely used chromogenic probe to report gal presence in histochemical 
samples.285-286 Hydrolysis of X-gal by -gal produces -D-galactose and 5-bromo-4-chloro-3-
hydroxyindole. The latter experiences spontaneous oxidative dimerization and forms insoluble 
blue 5,5’-dibromo-4,4’-dichloro-indigo precipitate, which is indicative of effective lacZ gene 
expression. ortho-Nitrophenyl--galactoside (ONPG) and chlorophenol red--D-
galactopyranoside (CPRG) are two other chromogenic substrates for -gal detection.287 Upon -
gal activation, colorless ONPG and yellow CPRG can be converted into compounds with 
respective yellow and red colors.  Another -gal substrate 9H-(1,3-dichloro-9,9-dimethylacridin-
2-one-7-yl) -D-galactopyranoside (DDAOG) was initially developed by Corey et al. to measure 
lacZ gene expression, with the advantages of a large absorption change, high solubility, high 
enzymatic affinity (low Km), and high catalytic efficiency (large kcat value).288 With the advancement 
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of near-infrared imaging techniques, this substrate probe was further explored by Tung et al. to 
investigate in vivo detection and imaging of lacZ-transfected tumors.289 
Fluorescence imaging is a sensitive technique to measure analytes of interest. 
Measurements based on fluorescence can be several orders of magnitude more sensitive than 
those based on absorption. The development of small-molecular fluorogenic substrate probes 
responsive to -gal will greatly expand the methods for detection and measurement of -gal. 
Fluorescent probes such as 4-methylumbelliferyl β-D-galactopyranoside (MUG),290 fluorescein di-
-galactopyranoside (FDG),315 resorufin--D-galactopyranoside (RG),291 and DDAOG289 have 
traditionally been employed to study -gal activity with their fluorescence modes. Through 
masking both sides of phenolate moieties of fluorescein with -D-galactose, the non-fluorescent 
FDG probe exists within cells in its spirocyclized structure. Upon reaction with -gal, FDG is firstly 
converted to a moderately fluorescent fluorescein derivative (one unite of -D-galactose released), 
which is subsequently converted to fully fluorescent fluorescein (two units released). Even though 
FDG is a sensitive substrate to measure -gal activity in cellular lysates, it is not suitable for 
applications in cells and living systems due to its slow activation, cellular impermeability, and low 
sensitivity to changes in -gal activities.149  
Due to its high catalytic efficiency and ease of acquisition, -gal is widely used as an 
enzyme platform to examine design strategies of fluorogenic probes. These tested strategies 
include photoinduced electron transfer (PeT),152, 284, 292 fluorescence resonance energy transfer 
(FRET),293 spirocyclization,160, 169, 295, 311 and aggregation-induced emission (AIE).296 PeT is an 
electron transfer process by which an excited electron is transferred from a donor to an acceptor. 
Fluorescence quenching as a result of the PeT process is often exploited for design of 
fluorescence-silent probes. Urano et al. found that fluorescence efficiencies of fluorescein 
derivatives can be precisely tuned by the substituted benzene moieties with different energy levels 
of the highest occupied molecular orbital (HOMO).152 A direct donor-acceptor system was 
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constructed with the benzene moieties and the xanthene scaffold. The observed tunable quantum 
yields of the fluorescein derivatives are caused by their different PeT efficiencies. Because 
masking of phenolate anion changes the molecular orbital energy levels of the xanthene structure, 
masked and unmasked fluorescein derivatives with a carefully-crafted, substituted benzene 
moiety can have significantly different fluorescence properties. Based on this design strategy, TG-
Gal was developed through appending the -D-galactose moiety with the optimized fluorescein 
derivative. TG-Gal is non-fluorescent at physiological pH due to its efficient PeT process. Its 
fluorescence is revealed by -gal, because the cleavage of -D-galactose moiety unmasks the 
phenolate ion and inhibits its PeT process. TG-Gal also has good cellular permeability to 
measure intracellular -gal enzyme, making possible live cell imaging. However, the released 
fluorescent TG product suffers from poor cellular retention, likely caused by exportation by organic 
anion transporter commonly present in metastatic cancer cells.295, 316  
To conquer the cellular retention issue, Kamiya et al. developed a fluorogenic probe, AM-
TG-Gal, by introducing an ester moiety onto the TG-Gal structure.284 The non-fluorescent AM-
TG-Gal releases the fluorescent product AM-TG upon reaction with -gal, with AM-TG 
subsequently hydrolyzed by ubiquitous intracellular esterases so as to generates a hydrophilic 
fluorescent product with high cellular retention. However, this probe cannot be applied in vivo or 
in living tissues, due to the ubiquitous presence of extracellular esterases.   
Both of these aforementioned probes generate green-emitting fluorophores, which are not 
suitable for deep tissue imaging.5 Development of fluorescent probes emitting in a different 
emission range is also beneficial for multi-color imaging. By replacing the oxygen atom on the 
xanthene ring of fluorescein with a silicon atom, Egawa et al. developed a red-emitting fluorophore, 
which was employed to craft a fluorogenic probe for detection of -gal.292 The PeT strategy was 
exploited in the design, similar to the previous two probes. The fluorogenic probe of Egawa et al. 
is non-fluorescent due to efficient electron transfer quenching, while cleavage of the -D-galactose 
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moiety by -gal alters the molecular energy level of the xanthene core, thus inhibiting the PeT 
process, allowing for the strong fluorescence of the reporter to be revealed.  
FRET describes a distance-dependent energy transfer mechanism between a donor 
fluorophore and an acceptor fluorophore. When these two fluorophores are in close proximity, the 
donor fluorophore in its electronic excited state can transfer non-radiative energy to the acceptor 
fluorophore, resulting in emitting light from the acceptor fluorophore.  Both OFF/ON and 
ratiometric probes can be designed based on the FRET strategy, depending on the fluorescence 
properties of the acceptor fluorophore. Komatsu et al. developed a ratiometric probe with 7-
hydroxycoumarin as the donor, and fluorescein as the acceptor, for detection of -gal.293 The 
probe exhibited strong emission at 515 nm, corresponding to the fluorescence of fluorescein in 
its initial state. Upon reaction with -gal, the probe had its emission switched to 460 nm, 
corresponding to the fluorescence of 7-hydroxycoumarin. Its capability to detect -gal in living 
cells was further demonstrated with lacZ-transfected cellular imaging experiments. However, the 
disadvantages of this detection system are obvious. It can be inferred that the probe is not able 
to pass through the cellular membrane, considering its large molecular weight and negative 
charges. Microinjection of the probe into cells had to be performed to detect intracellular -gal. 
This is also evidenced by similar work using cellular impermeable fluorescein.221 Another obvious 
disadvantage of FRET-based ratiometric probes is that their energy transfer efficiency is greatly 
impacted by environmental factors, such as viscosity, polarity, and protein binding.  
Intramolecular spirocyclization is another widely used strategy for the design of fluorogenic 
probes. Spirocyclization breaks the conjugated structure of xanthene dyes, resulting in 
fluorescence loss of carefully designed molecules. FDG is an example of this strategy. Both sides 
of the phenolate anion are masked by -D-galactose, which leads to the formation of its non-
fluorescent spirocyclized structure. To decloak the strong fluorescence, masking groups on both 
sides must be cleaved by -gal, which slows the activation rate and leads to low sensitivity for 
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detection of -gal. Kamiya et al. developed a fluorogenic probe, HMDER-Gal, with an 
intramolecular spirocyclized rhodol structure.169 The highly fluorescent HMDER fluorophore with 
an open form was constructed by the unmasking of one -D-galactose moiety. HMDER-Gal was 
employed to detect and visualize -gal in cells and in Drosophila melanogaster tissues. However, 
released HMDER tends to leak out of cells, resulting in fluorescence loss over time. Doura et al. 
modified HMDER-Gal by integrating it with a protein-reactive quinone methide moiety.294 Its 
released intermediate, upon -gal activation, further reacts with intracellular proteins, and thus 
anchors the fluorescent product inside cells for a prolonged time. Single-cell resolution was 
achieved by this improvement. One of the shared disadvantages of these two probes is that their 
pKcycl value is 6.9. That means, at pH 7.4, 25% of the probe exists in its open form, causing a very 
large background signal. By replacing the two ethyl groups on the xanthene ring with electron-
withdrawing groups, Asanuma et al. developed the fluorogenic probe HMRef-Gal, having pKcycl 
of 4.5.295 HMRef-Gal exhibited minimum background signal and a significant fluorescence 
increase upon reaction with -gal; it was successfully employed to visualize disseminated 
metastases with small sizes (1 mm) in a xenograft mouse model. However, all the aforementioned 
fluorophores suffer from pH dependence, which limits their applications in pH-sensitive situations, 
thereby making them unattractive for quantitative analysis. Besides these three strategies for the 
design of fluorogenic probes, intramolecular charge transfer (ICT) and AIE were also explored to 
design fluorogenic probes.296  
Luminescence imaging is another technique to visualize -gal activity, but it requires the 
use of newly crafted molecules. In contrast to fluorescence imaging, no illumination is required, 
which makes this technique free from phototoxicity, photobleaching, scattered light interference, 
and autofluorescence problems. Wehrman et al. developed a bioluminescent probe 1-O-
galactopyranosyl-luciferin through direct coupling of galactopyranoside to luciferin.297 Upon 
intraperitoneal administration, this probe was successfully utilized to track -gal expression in the 
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lacZ- and luc-transfected tumor in xenograft mouse models. One drawback of the bioluminescent 
system is the necessity of luc-transfection, which limits its broad application for detection of 
endogenous analytes of interest in wild-type tissues. Chemiluminescent probes hold the 
advantages of measuring enzymatic activities without the need of gene transfection. Liu et al. 
applied a commercially available chemiluminescent probe Galacto-Light PlusTM with 1,2-
dioxetane structure in xenograft models.298 With intravenous administration of Galacto-Light 
PlusTM, significantly higher luminescence signal was observed in lacZ-transfected MCF7 tumors 
than wild-type MCF7 tumors. However, it can be posited that its short luminescence wavelength 
and low luminescence efficiency will cause issues in its further applications. Chemiluminescent 
probes targeting -gal but with NIR wavelength and high luminescence efficiency will benefit this 
area. Besides these applications, gal was also utilized as a biomarker to develop prodrugs,317-
318 photoacoustic,283 and photodynamic agents.299 
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A NEAR-INFRARED, WAVELENGTH-SHIFTABLE, TURN-ON FLUORESCENT PROBE FOR 
THE DETECTION AND IMAGING OF CANCER TUMOR CELLS 
 
2.1  Introduction 
Hypoxia is one of the hallmarks of solid tumors, caused by ineffective oxygen 
transportation into the avascular regions of solid tumors.1-2 Low oxygen distribution is proposed 
to be the main cause of chemoresistance and radioresistance, which leads to ineffective cancer 
therapies.1-2 On the other hand, hypoxic tumor cells often have elevated levels of reductases, 
such as human NAD(P)H:quinone oxidoreductase type I (hNQO1), NADPH-cytochrome P450 
reductase (CYP450), nitroreductase,  azoreductase, etc. in comparison to normal cells as a 
response to oxidative stress caused by the accumulation of reactive oxygen species (ROS).3 The 
overexpressed reductases have been selected as specific targets in the development of 
bioreductive anticancer drugs (e.g., mitomycin C4 and -lapachone5-6) to achieve selective 
elimination of tumor tissue with minimal effect on healthy tissue. Meanwhile, rapid, selective, and 
accurate signaling of cancer-associated species, events, and real-time determination of borders 
between cancerous tissues and normal tissues during surgery poses a great challenge to 
conventional analytical techniques. Development of new strategies for selective and sensitive 
reporting of overexpressed reductases in solid tumors would be useful in understanding 
tumorigenesis and could assist in diagnosis and personalized cancer treatments.  
Optical imaging, especially fluorescent molecular imaging, has attracted attention 
because it is a time and cost-effective, and is a sensitive technique for reporting enzymatic 
processes of interest with the aid of enzyme-specific fluorescent agents.7-9 In this method, 
fluorophores are incorporated with enzyme-targeting ligands or enzyme-specific triggers to form  
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always-on fluorescent or non-fluorescent turn-on imaging probes. Compared to always on probes, 
turn-on probes have their fluorescence revealed from their native non-fluorescent state by specific 
enzymes, offering an enhanced signal-to-background ratio (SBR).10 The various intensities of light 
emitted from the enzyme-liberated reporters can provide information on enzyme concentration 
and activity in different areas of the cellular microenvironment (e.g., cytosol).11 These turn-on 
probes can be also utilized to assist surgeons in identifying the border between diseased and 
healthy tissue, based on abnormal enzyme activities of different tissue areas.12 With that in mind, 
cancer-associated reductases such as hNQO113-17 and nitroreductases18-22 have been used as 
targets for developing turn-on/activatable fluorescent probes. 
hNQO1 is a cytosolic, 2-electron reductase whose expression is regulated by the 
Keap1/Nrf2/ARE pathway like many other cytoprotective reductases.23 In normal physiology, the 
Keap1 protein binds to the Nrf2 transcription factor and promotes degradation of Nrf2 through 
ubiquitination and a proteasomal degradation process. However, in response to increased 
oxidative stress, Keap1 loses its ability to target and degrade the Nrf2 transcription factor because 
of the oxidation of the reactive cysteine sites of the Keap1 protein. The stabilized Nrf2 transcription 
factor accumulates in the nucleus where it binds to an ARE DNA sequence and triggers the 
transcription of hNQO1.24-26 The expression of hNQO1 is typically low in normal cells but is 
overexpressed in many types of cancer cells including the pancreas, colon, breast ovarian, and 
non-small cell lung carcinoma.27 Moreover, hNQO1 overexpression is reportedly associated with 
tumorigenesis, as hNQO1 maintains redox homeostasis in response to the generation of large 
oxidative stress.27 Therefore, development of hNQO1-activatable profluorogenic probes that 
target the elevated hNQO1 found in solid tumors is useful for understanding enzymatic processes 
at the molecular level and developing tools to determine borders between diseased and healthy 
tissue during fluorescence-assisted surgery.  
Although fluorescent probes emitting the visible light are useful tools for some specific 
applications, they are not suitable for in vivo imaging applications because the visible light 
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overlaps with tissue autofluorescence.13-17 The visible light (< 650 nm) is highly absorbed by 
endogenous molecules (e.g., oxy- and deoxy-hemoglobin). Infrared light (> 900 nm) is absorbed 
by water and lipids. Near-infrared light (NIR, 650–900 nm) is less absorbed by tissues, resulting 
in its deeper penetration. Therefore, imaging probes emitting light in the optimal “NIR window” are 
desired for the detection and imaging of hNQO1 in living animals. 
Moreover, most of the probe/reporter pairs have the same absorption and emission 
profiles. This not only produces large background signal, but also increases uncertainty in 
differentiating the emission signal of the reporter from the background signal. I posit that a NIR 
and wavelength-shiftable probe will overcome the drawbacks of previously reported probes.  
Herein, I designed, synthesized, and evaluated an NIR fluorescent small-molecular probe 
Q3STCy targeting to hNQO1.  Fluorescence efficiency of Q3STCy was greatly decreased through 
a photo-induced electron transfer (PeT) quenching mechanism, evidenced by their respective 
redox potentials. Rapid fluorescence turn-on (193-fold) of Q3STCy was achieved by the addition 
of hNQO1 under physiological conditions. Effective enzymatic kinetic experiments (high enzyme 
affinity Km = 1.09 ± 0.471 M, and high catalytic efficiency Kcat/Km = 1.49 × 105 ± 0.682 × 105 M–
1s–1) indicated that Q3STCy was a good substrate for hNQO1. Its ability to detect endogenous 
hNQO1 was validated through fluorescence imaging of cells with varied hNQO1 activities (HT29, 
H596 (+), SHIN3, and H596). The strong fluorescence from hNQO1 gene transfected H596 cells 
clearly indicated that Q3STCy was activated by hNQO1 in a highly selective fashion. 
Colocalization experiments showed that the produced TCy reporter mainly accumulated in 
lysosomes pointing to enhanced cellular retention of TCy. Its capability in imaging colorectal 
multicellular spheroids (1 mm diameter) with spatially heterogeneous hNQO1 activities and 
detecting human ovarian cancer-derived metastases (0.5 mm dimension) in xenograft mouse 





2.2  Experimental Section 
2.2.1  Synthetic Materials and Methods 
All chemicals used in syntheses were purchased from Sigma-Aldrich or Fisher Scientific 
and used without further purification. Aluminum-backed 60 F254 silica plates used to perform thin-
layer chromatography were purchased from EMD Chemicals. A Biotage FlashMaster Personal 
column system, with 50-g, 25-g, or 10-g silica columns from Biotage, were used to perform 
separations. 1H and 13C NMR spectra were recorded in CDCl3 or methanol-d6 on Bruker AVIII-
400 or Bruker AVIII-500 spectrometers at 25 ºC. All chemical shifts are reported in the standard 
 notation of parts per million, with calibration achieved using residual protio-solvent of CDCl3 
Scheme 2.1 Synthetic route for the hNQO1-activatable probe, Q3STCy, and the electronically 
similar analogue, iBuTCy. 
Reagents and conditions: (a) 2 M methylamine in methanol, DMF, 85 °C, 95%; (b) 
carbonyldiimidazole, 2-mercaptoethanol, DCM/DMF/toluene, −10 °C, 40%; (c) i: phosgene, 
THF; ii: sodium hydride, THF, 85%; (d) isobutyl chloroformate, DIPEA, DCM, 90%. 
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(7.26 for 1H and 77.16 for 13C) and methanol-d6 (3.31 for 1H and 49.00 for 13C). Absorption bands 
in NMR spectra are listed as singlet (s), doublet (d), triplet (t), or multiplet (m), and coupling 
constants (J) are reported in hertz (Hz). 
2.2.2  Synthesis 
 The general approach for synthesis of the Q3STCy probe is outlined in Scheme 2.1.  The 
starting materials, quinone propionic acid (Q3PA), 1-ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide 
and 2-chloro-3-(hydroxymethylene)-1-cyclohexene-carboxaldehyde were synthesized through 
reported procedures.19, 28 
 Synthesis of Cy7-Cl. A mixture of 1-ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide (3.65 g, 
11.6 mmol), 2-chloro-3-(hydroxymethylene)-1-cyclohexene-carboxaldehyde (1.0 g, 5.8 mmol), 
and sodium acetate (1.9 g, 23.2 mmol) were dissolved in 15 mL acetic anhydride in a 50-mL 
round-bottom flask under nitrogen atmosphere. The solution was heated to 130 ºC for 1 h, during 
which the solution color changed from red to dark green, and then the resulting mixture was 
cooled to room temperature and filtered. The dark green product Cy7-Cl (3.5 g, 95%) was 
obtained after washing the precipitate with diethyl ether and aqueous potassium iodide solution. 
1H NMR (500 MHz, MeOD)  8.46 (d, J = 14.2 Hz, 2H), 7.53 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.4 
Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.30 (d, J = 14.1 Hz, 2H), 4.23 (q, J = 
7.2 Hz, 4H), 2.75 (t, J = 6.1 Hz, 4H), 2.01–1.93 (m, 2H), 1.74 (s, 12H), 1.42 (t, J = 7.2 Hz, 6H). 
13C NMR (126 MHz, MeOD)  173.93, 151.21, 145.70, 143.18, 142.78, 129.93, 127.95, 126.57, 
123.56, 112.04, 101.94, 50.68, 40.38, 28.24, 27.38, 22.14, 12.47. ESI-HRMS: for [C34H40ClN2]+: 




Synthesis of TCy. Cy7-Cl (256 mg, 0.40 mmol) was dissolved in 20 mL anhydrous DMF 
in a 50-mL round bottom flask under nitrogen environment, followed by the addition of 2 M 
methylamine in methanol (0.8 mL, 1.6 mmol) using a syringe. The solution was heated to 85 ºC 
for 3 h, during which the color changed from green to blue. The solvent was removed under 
reduced pressure. The crude product was dissolved in DCM and purified by silica gel 
chromatography with methanol/DCM (1:99 to 3:97) as eluent to afford product TCy (228 mg, 90%) 
as a blue solid. 1H NMR (500 MHz, MeOD)  7.68 (d, J = 12.8 Hz, 2H), 7.34 (d, J = 7.4 Hz, 2H), 
7.29 (t, J = 7.7 Hz, 2H), 7.11–6.97 (m, 4H), 5.75 (d, J = 12.7 Hz, 2H), 3.96 (q, J = 6.9 Hz, 4H), 
3.45 (s, 3H), 2.57 (t, J = 6.3 Hz, 4H), 1.88–1.79 (m, 2H), 1.64 (s, 12H), 1.31 (t, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, MeOD)   171.75, 167.75, 144.06, 141.31, 138.40, 129.34, 123.61, 123.03, 
120.81, 109.51, 94.53, 68.84, 38.67, 37.66, 29.01, 26.90, 22.54, 11.61. ESI-HRMS: for 
[C35H44N3]+: expected m/z = 506.3535 [M]+; found m/z = 506.3537 [M]+; 0.4 ppm error.  
 
Synthesis of Q3PA-S.  Q3PA (250 mg, 1.0 mmol) was dissolved in 2 mL anhydrous DCM 
in a 25-mL round bottom flask under nitrogen environment, followed by the addition of 1,1’-
carbonyldiimidazole (211 mg, 1.3 mmol). The solution was stirred for 30 min at room temperature, 
then diluted by toluene (4 mL) and DMF (0.3 mL) and cooled to −10 ºC. To the cooled solution 
was added slowly 2-mercaptoethanol (0.075 mL, 1.1 mmol) diluted with DCM (1 mL). After stirring 
at −10 ºC for 2 h, the solvent was removed under reduced pressure. The residue was purified by 
silica gel chromatography with 1:2 ethyl acetate/hexane (RF = 0.2) as eluent to afford the Q3PA-
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S product as a yellow oil (124 mg, 40%). 1H NMR (400 MHz, MeOD)  
  3.56 (t, J = 6.6 Hz, 2H), 3.29 (s, 2H), 2.95 (t, J = 6.6 Hz, 2H), 2.13 (s, 3H), 1.98 (s, 6H), 1.45 (s, 
6H). 13C NMR (101 MHz, MeOD)  200.00, 191.93, 188.55, 153.88, 144.42, 139.59, 139.32, 61.79, 
57.55, 40.11, 32.20, 29.13, 14.39, 12.67, 12.03. ESI-HRMS: for C16H22O4S: expected m/z = 
311.1317 [M + H]+; found m/z = 311.1306 [M + H]+; 3.5 ppm error. 
 Synthesis of iBuTCy. TCy (43 mg, 0.068 mmol) was dissolved in 10 mL anhydrous DCM 
under nitrogen environment. Isobutyl chloroformate (93 mg, 0.68 mmol) and N,N-
diisopropylethylamine (DIPEA, 0.4 mL) were added using a syringe at room temperature. The 
solution was stirred for 2 h, during which the color changed from blue to green. The solvent was 
removed under reduced pressure. The residue was dissolved in DCM and purified using silica gel 
chromatography with methanol/DCM (1:99 to 5:95) as eluent to afford a solid green product 
iBuTCy (45 mg, 90%). 1H NMR (500 MHz, CDCl3) (rotamers)  7.62 (d, J = 14.0 Hz, 2H), 7.37 (m, 
4H), 7.23 (t, J = 7.4 Hz, 2H), 7.16 (d, J = 7.9 Hz, 2H), 6.20 (d, J = 14.1 Hz, 2H), 4.25 (m, 4H), 4.01 
(d, J = 6.5 Hz, 0.35H), 3.79 (d, J = 6.5 Hz, 1.65H), 3.28 (s, 3H), 2.80–2.58 (m, 4H), 2.05–1.87 (m, 
2H), 1.77 (m, 1H), 1.66 (s, 6H), 1.59 (s, 6H), 1.44 (t, J = 7.2 Hz, 6H), 1.08 (d, J = 6.7 Hz, 1.15H), 
0.73 (d, J = 6.7 Hz, 4.85H). 13C NMR (126 MHz, CDCl3) (mixture of rotamers)  171.18, 156.03, 
155.97, 141.93, 141.61, 141.40, 141.13, 129.01, 127.77, 125.31, 122.33, 110.79, 101.11, 72.38, 
49.22, 40.20, 40.10, 38.63, 38.24, 28.47, 28.35, 28.26, 27.94, 25.18, 24.93, 20.88, 20.76, 19.37, 
18.98, 12.58, 12.53. ESI-HRMS: for [C40H52N3O2]+: expected m/z = 606.4060 [M]+; found m/z = 




Synthesis of Q3STCy. Phosgene (caution: highly toxic) in toluene (3 mL, 15% w/w, 4.2 
mmol) was added to a solution of Q3PA-S (93 mg, 0.3 mmol) in anhydrous THF (12 mL) under 
nitrogen environment. The solution was stirred for 12 h at room temperature. The solvent was 
removed under reduced pressure, with any remaining phosgene deactivated with 2 M aqueous 
NaOH solution in a vacuum trap. The resulting crude product was used for the next step without 
further purification.  
To the solution of TCy (35 mg, 0.055 mmol) in dry THF (10 mL) under nitrogen 
environment, sodium hydride (2 mg, 0.083 mmol) was added. The solution was stirred for 20 min 
at room temperature, during which the color changed from dark blue to orange. The crude product 
from the previous step was dissolved in THF (2 mL) and then slowly added to the orange solution, 
followed by the addition of DIPEA (0.06 mL, 0.34 mmol). The solution was stirred overnight, during 
which the solution became green. The solvent was removed under reduced pressure, and the 
residue was purified using silica gel chromatography with methanol/DCM (1:99 to 5:95) as eluent. 
The Q3STCy product was afforded as a green solid (45 mg, 85%).  1H NMR (500 MHz, CDCl3) 
(rotamers)  7.58 (d, J = 14.2 Hz, 2H), 7.43–7.31 (m, 4H), 7.24 (t, J = 7.4 Hz, 2H), 7.16 (d, J = 7.9 
Hz, 2H), 6.20 (d, J = 14.1 Hz, 2H), 4.33–4.22 (m, 4H), 4.17 (m, 0.4 H), 4.04 (t, J = 6.7 Hz, 1.6H), 
3.37 (s, 0.4H), 3.26 (s, 3H), 3.20 (t, J = 6.5 Hz, 0.4H), 3.15 (s, 1.6H), 2.90 (t, J = 6.7 Hz, 1.6H), 
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2.80–2.58 (m, 4H), 2.15 (s, 0.6H), 2.04 (s, 2.4H), 2.03–1.97 (m, 1H), 1.91 (m, 4.6H), 1.82 (s, 
2.4H), 1.67 (s, 6H), 1.57 (s, 6H), 1.45 (m, 7.2H), 1.32 (s, 4.8H). 13C NMR (126 MHz, CDCl3) 
(rotamers)  197.92, 190.59, 187.46, 171.14, 155.46, 155.30, 151.78, 142.92, 141.95, 141.39, 
141.13, 138.96, 138.63, 129.03, 127.79, 127.54, 125.36, 122.35, 110.82, 101.40, 101.30, 64.42, 
57.03, 56.75, 49.22, 40.29, 40.17, 39.25, 39.15, 38.79, 38.46, 29.11, 28.98, 28.52, 28.38, 28.30, 
27.92, 25.22, 24.97, 20.78, 14.45, 14.32, 12.84, 12.69, 12.67, 12.56, 12.28. ESI-HRMS: for 
[C52H64N3O5S]+: expected m/z = 842.4567 [M]+; found m/z = 842.4565 [M]+; 0.2 ppm error. 
2.2.3  Demonstration of Purity of the Q3STCy Probe by HPLC with UV Absorption and Mass 
Spectrometry Detection  
High-performance liquid chromatography (HPLC) analysis with ultraviolet-visible (UV-Vis) 
absorption detection was performed to analyze the purity of the compound Q3STCy. The 
instruments were composed of a Waters 616 pump, Waters 2707 Autosampler, an Agilent Zorbax 
300Extend-C18 column (5 m, 150 x 4.6 mm), and 996 Photodiode Array Detector, which were 
controlled by Waters Empower 2 software. The separation was performed on the Agilent Zorbax 
 
 
































300Extend-C18 reverse phase column by a gradient elution resulting from mixing eluents A (0.1% 
trifluoroacetic acid in water) and B (0.1% trifluoroacetic acid in acetonitrile). The gradient started 
with 20% B and was changed to 80% B over a 40-min period. The flow rate was 1.0 mL min−1.  
Detection was achieved using wavelengths of 254 nm and 786 nm, respectively, Figure 2.1. 
HPLC-mass spectrometry. The separation was performed on an Agilent Zorbax SB-C18 (3.5 m, 
30 x 2.1 mm) using a gradient resulting from mixing eluents A (0.1% formic acid in water) and B 
(0.1% formic acid in acetonitrile). Detection was achieved by ESI-TOF mass spectrometry (150 V 
ionization voltage). Separation and verification data of Q3STCy is shown in Figure 2.2. 
2.2.4  Demonstration of both Q3STCy and iBuTCy Existing as Their Respective Rotamers 
 The 1d selective chemical-exchange experiment was performed with Bruker AVIII-500 
spectrometers. An appropriate amount of Q3STCy and iBuTCy was dissolved in CDCl3 to acquire 
their respective 1H NMR spectrum. The residual protic peak of CDCl3 ( = 7.26) was used as the 
standard calibration peak. Based on calibrated NMR spectra, peaks of interest were selected to 
be excited. The desired 1D gradient NOE spectra were further obtained with the employment of 
a 100 ms Gaussian pulse and a 1.0 s mixing time with a standard 1D gradient NOE pulse.29-30 
2.2.5  Spectroscopic Measurement Methods  
UV-visible absorption spectra were recorded in a 10-mm path length quartz cuvette on a 
Varian Cary-50 spectrophotometer. Fluorescence spectra were recorded in a 10 mm × 10 mm 
quartz cuvette on a PerkinElmer LS55 spectrofluorometer or a PTI QuantaMaster4/2006SE 
spectrofluorometer. Water (> 18 MΩ cm) from a Barnstead NANOpure Diamond Water System 
       
Figure 2.2 HPLC data of Q3STCy (left) and its respective mass spectrum (right). 
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was used to prepare pH = 7.4, 0.1 M phosphate-buffered saline/0.1 M KCl (PBS). Stock solutions 
of Q3STCy, iBuTCy, and TCy (1 mM in DMSO) were used to prepare corresponding diluted PBS 
sample solutions.  
2.2.6  Quantum Yields and Molar Extinction Coefficients for Q3STCy, iBuTCy, and TCy  
The fluorescence standard ICG was purchased from Sigma-Aldrich, and the HPDITCP 
cyanine dye was synthesized by the reported procedure.31 Relative quantum yields () of Q3STCy 
and iBuTCy in 2% DMSO/PBS solution (pH = 7.4) were calculated relative to ICG ( = 0.012 in 
water)32 and that of TCy relative to HPDITCP ( = 0.161 in ethanol)33 using the following equation: 








Where the subscripts st and x stand for standard and test sample, respectively. is the quantum 
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance. Absorbance at the excitation wavelength was maintained 
between 0.02–0.10 to minimize reabsorption effects and maximize illumination homogeneity. 
Emission spectra were recorded with the same parameters. Both absorption and emission spectra 
at one specific concentration were measured three times. 
 Molar extinction coefficients () were determined by the plot of absorbance vs 
concentration at the maximum absorption wavelength using the Beer-Lambert law. Each sample 
at one specific concentration was prepared and measured three times. 
2.2.7 Reaction of Q3STCy Probe with hNQO1 Demonstrated by HPLC with Mass Spectrometry 
HPLC analysis was carried out as above. Q3STCy (60 M, 5 mL) was incubated with 2-3 g mL−1 
hNQO1 in 100 M NADH in PBS for 1 h in a 37 °C water bath. The solution was kept in a 
refrigerator at 24 °C until execution of the experiment. 
2.2.8  Cyclic Voltammetry Measurements 
Cyclic voltammetry (CV) experiments were performed using a Princeton Applied Research 
Potentiostat/Galvanostat Model 273A with Power Suite-2.53 software. A glassy carbon working 
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electrode, platinum wire counter electrode, and silver wire pseudo-reference electrode (Ag/Ag+) 
were used in a 20-mL cell, with anhydrous acetonitrile (15 mL) and tetrabutylammonium 
fluoroborate (0.1 M) as a solvent and supporting electrolyte. The solution was purged for 15 min 
using nitrogen gas, at which point a nitrogen atmosphere was maintained above the solution 
through the voltammetric measurements. Pretreatment of the working electrode was performed 
by applying a +1.5 V potential for 10 min, which to activate the working electrode surface. 
Ferrocene (1 mM) was used as an internal reference. Voltammograms were obtained for Q3PA 
(1 mM) and iBuTCy (1 mM) by applying cyclic potentials (+1.8 V to –1.8 V, then back to +1.8 V 
vs Ag/Ag+) and (0 V to +1.8 V, then back to 0 V vs Ag/Ag+), respectively, at a scan rate of 0.1 V 
s−1. The resulting E1/2 values were used to calculate the thermodynamic feasibility of PeT 
processes via the Rehm-Weller equation:  
GPeT = Eox  − Ered − G00 − wp 
Where Eox is the donor oxidation potential corresponding to the cyanine group attached to a stable 
carbamate (iBuTCy) linkage; Ered is the Q3PA acceptor reduction potential; G00 is the first excited 
singlet state energy of the fluorophore corresponding to that of iBuTCy; and wp is the Coulombic 
attraction energy of the ion pair, which is 0.06 eV in acetonitrile. 
2.2.9  Measurements of Enzymatic Kinetics Parameters  
hNQO1 kinetic experiments with Q3STCy as substrate were performed using a 
PerkinElmer LS55 spectrofluorometer at 37 ºC.  Solutions of 0.1 M PBS/0.1 M KCl (pH = 7.4) 
containing 100 M NADH and 0.007% BSA were prepared freshly and were used to make 0.5–5 
M final concentration Q3STCy sample solutions. 1.5 mL of a given Q3STCy sample solution in a 
2.0-mL cuvette was equilibrated at 37 ºC for 3 min, and then 3 L of a 0.25 mg mL−1 hNQO1 
solution was added to yield a resulting in 0.5 g mL−1 hNQO1 concentration (250 U mL−1) that 
initiated the assay. Fluorescence at the TCy reporter energy (ex = 600 nm, em = 755 nm) was 
collected every 2 s over a 5-min time period (each assay was performed three times). Released 
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TCy reporter concentration was obtained by converting the fluorescence signal with a calibration 
curve of TCy in the same buffer system. By fitting the TCy reporter release velocities versus 
Q3STCy concentrations with nonlinear least-squared analysis, the apparent kinetic parameters 
Km and Vmax were obtained. 
2.2.10  Monolayer Cell Culture.  
HT-29 (human colorectal adenocarcinoma), and H596 (human nonsmall cell 
adenosquamous lung carcinoma) were all purchased from American Type Culture Collection 
(ATCC; Manassas, VA). The gene-transfected H596 cell line was provided by Dr. Molly Silvers 
and Professor David Boothman at the Simmons Cancer Center of the UT Southwest Medical 
Center.34 SHIN3-DsRed cells contain a red fluorescent protein (RFP DsRed2)-expressing plasmid 
(Clontech Laboratories, Mountain View, CA, USA) that was stably transfected into SHIN3 cells, 
as previously described.35 The SHIN3-DsRed cells serve as the standard of reference for cancer 
location for in vivo optical imaging of peritoneal ovarian cancer metastases.36  Unless stated 
otherwise, cell culture media, fetal bovine serum albumin (BSA), and other supplements were 
also purchased from ATCC. HT-29 cells were cultured in McCoy’s 5A medium, while H596 (+), 
H596, SHIN3, and SHIN3-DsRed2 cells were cultured in RPMI-1640 medium, with all 
supplemented with 10% fetal bovine serum, 10 IU mL−1 penicillin, and 10 g mL−1 streptomycin 
(Life Technologies). Cells were incubated in 75 cm2 treated tissue culture flasks in the dark at 
37 °C under 5% CO2/95% air in a humidified incubator. 
2.2.11  3-Dimensional Cell Culture 
Multicellular tumor spheroids (MCTSs) were cultured as previously described using the 
liquid overlay method.37  HT-29 cells (20,000) in 100 L culture medium were pipetted into well of 
a 96-well plate coated with agarose. MCTSs were cultured at 37 ºC under 5% CO2 in a humidified 





2.2.12  Western Blot and hNQO1 Activities 
 This work was performed by Bijeta Prasai and Milcah S. Jackson in the McCarley research 
group. HT-29, H596 (+), SHIN3, and H596 cells were cultured in six-well culture dishes in for 1 
day. The 24-h-old cells (0.2 million) were added with 1 mM phenylmethylsulfonyl fluoride in radio 
immunoprecipitation buffer and the protease inhibitor cocktail. The cells were then placed in an 
ice-water bath for 35 min with periodic agitation. The resulted solution with lysed cells was 
centrifuged at 18,000 × g for 20 min. The supernatant was collected, aliquoted, and stored at – 
80 °C until the following western blot assay and hNQO1 activity assay. Protein concentration in 
the previous supernatant was measured using the BCA assay.38  
 Western blot experiments were performed by following the Bio-Rad recommended 
protocol. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate and measure hNQO1. The previously acquired cellular lysate containing 25 g protein 
was loaded into the wells on the polyacrylamide gel, along with 10 L molecular weight marker 
(Bio-Rad). The gel was run for 5 min at 50 V, then for 70 min at 100 V. After the separation, the 
proteins on the gel were transferred onto the membrane in transfer buffer (25 mM Tris, 192 mM 
glycine, and 20% (v/v) methanol; pH = 8.3). The blotted membrane was blocked by 5% non-fat 
dry milk for 1 h, and incubated overnight in the solution of NQO1 monoclonal primary antibody 
(A180, Thermo Fisher) at 4 °C. The membrane was further incubated with -actin monoclonal 
primary antibody overnight at 4 °C. After the membrane was washed with Tris buffer (three times), 
horseradish peroxidase (HRP) conjugated secondary antibodies were added and incubated with 
the membrane for 1 h. The membrane was washed to remove the secondary antibody and put in 
the working solution of the Pierce ECL substrate for 1 min. The resulting membrane was imaged. 
 The hNQO1-specific activities of different cellular lysates were measured using UV-vis 
spectrometer. Dichlorophenolindophenol (DCPIP) is a substrate of hNQO1, and dicoumarol is a 
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competitive inhibitor of hNQO1.39 Cellular lysates containing 5 g proteins was added to 0.75 mL 
Tris buffer solution (25 mM, pH = 7.4) containing 200 M NADH and 0.014% BSA with or without 
dicoumarol (20 M). 80 M DCPIP in 0.75 mL Tris buffer solution was mixed with the previous 
solution with or without dicoumarol to start the reaction. Absorption decrease of DCPIP at 600 nm 
was recorded for a 6-min time period using UV-vis spectrometer. The absorption decrease rate 
at 600 nm was divided by the extinction coefficient of dicoumarol and the cuvette diameter, which 
gave the reduction rate of dicoumarol. hNQO1-specific activities were further calculated by 
subtracting the acquired reduction rate of the assay with dicoumarol from that of the assay without 
dicoumarol. 
2.2.13  Fluorescence Imaging of Monolayer Cells Using Confocal and Wide-field Microscopy 
HT-29, H596 (+), SHIN3, and H596 cells (0.5 million each) were separated and cultured 
overnight in dark at 37 ºC on 22 × 22 mm (no. 1-1/2; Corning) sterile glass coverslips before 
treatment with Q3STCy probe. After replacement with fresh respective medium (2 mL), the cells 
were treated by the addition of 10 L Q3STCy (1 mM in DMSO) to give a final probe concentration 
5 × 10-6 M, with subsequent incubation at 37 ºC for 30 min. Then the cells were washed with PBS 
(pH 7.3, Dulbecco) twice and fixed in 4% paraformaldehyde (PFA) for 15 min with shaking at room 
temperature in the dark.  After the PFA solution was removed, the fixed cells were covered using 
coverslips coated with Immu-Mount. These slides were left in the dark overnight at room 
temperature to allow the mounting medium to dry. Then the slides were used for confocal 
microscopy and wide-field microscopy imaging experiments. For confocal microscopy, a Leica 
TCS SP2 spectral laser-scanning confocal microscope was utilized to capture the cellular images. 
A 40× oil immersion objective with numerical aperture 1.25 and a beam splitter TD 488/543/633 
was utilized. The prepared cellular samples were excited with a 633-nm laser line of a helium-
neon laser (laser intensity = 45%), and the emitted photons in the range of 660–820 nm 
wavelengths were collected with a photomultiplier detector (PMT, voltage = 718 V) with the 
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pinhole setting as 1.0 Airy unit (AU, 82 m). The resulting images were zoomed 3.3 fold and 
captured with frame and line averaged 4 times. For wide-field microscopy, a Leica DM6 wide-field 
microscope with a 40x/1.30 NA oil objective and an ORCA-Flash 4.0 Hamamatsu Digital CMOS 
camera. The filter sets Cy5 (excitation: BP 590–650 nm, dichroic mirror: 660 nm; and emission: 
BP 662–738 nm) and 50 ms exposure time were applied. Image analysis and statistical evaluation 
of cytosolic intensities were accomplished with Fiji/ImageJ software. 
2.2.14  Colocalization Study 
For the live-cell colocalization studies, HT-29 cells (0.5 million) were cultured overnight on 
35-mm glass-bottomed Mat Tek dishes. In fresh media, cells were incubated with 5 M Q3STCy 
and corresponding organelle tracker (30 nM lysotracker for lysosome or 100 nM mitotracker for 
mitochondria) for 30 min. The cells were washed with PBS, and the fresh warm phenol-free RPMI-
1640 medium was added, with subsequent imaging using a Leica TCS SP2 spectral laser-
scanning confocal microscope. A 63× objective with numerical aperture 1.4 was utilized. The 
samples were excited with a 633-nm helium-neon laser line and their emitted light was collected 
in the range of 660–785 nm wavelengths to construct cellular images of the activated probe. 
Similarly, cellular images of lysosomes or mitochondria were built through collecting 500–600 nm 
light with a 488-nm argon laser line as the excitation wavelength. Different laser intensities and 
PMT voltages were applied for different images.  Images of one sample spot were captured 
sequentially to build probe and organelle images with the respective settings, and they were 
utilized for colocalization analysis. Image analysis and statistical evaluation of colocalization 
degree were accomplished using Fiji/ImageJ software with the coloc 2 plugin.  
2.2.15  Wide-field Fluorescence Microscopy Imaging of 3-dimensional Cell Cultures   
23-day old MCTSs were used for wide-field imaging.  Q3STCy (5 M) solution was made 
in phenol red-free RPMI-1640, and then MCTSs were incubated in the solution for 0, 30, 60, 90, 
120, 150, and 180 min.  Images were collected for all above mentioned time intervals using a 
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Leica DM6 wide-field microscope with 10x/0.4 NA objective and ORCA-Flash 4.0 
Hamamatsu Digital CMOS camera. Leica Application Suite X (LAS X) software was used to 
capture the images. The filter sets Cy5 (excitation: BP 590–650 nm, dichroic mirror: 660 nm; and 
emission: BP 662–738 nm) and Cy7 (excitation: BP 672–748 nm, dichroic mirror: 760 nm; and 
emission: BP 765–855 nm) were used, with 500 ms and 50 ms exposure times, respectively.  
Fiji/ImageJ software was used to perform image analysis.  
2.2.16  Animal Model 
The examination of Q3STCy with animal models and its ex vivo imaging evaluation were 
a collaboration work with Dr. Hisataka Kobayashi of National Institutes of Health (NIH). All 
procedures were performed in compliance with the Guide for the Care and Use of Laboratory 
Animals10 and approved by the National Cancer Institute Animal Care and Use Committee.  Six- 
to eight-week-old female homozygote athymic nude mice were purchased from Charles River 
(National Cancer Institute, Frederick, MD, USA).  In order to generate the animal model, 
intraperitoneal xenografts were established by intraperitoneal (i.p.) injection of 2 × 106 SHIN3-
DsRed cells suspended in 200–300 L of pH 7.4 phosphate-buffered saline (PBS) into the 
peritoneal cavity of nude mice.  Imaging was performed at 14–21 days after injection of the cells. 
2.2.17  Ex vivo Imaging 
To examine the sensitivity and specificity of Q3STCy for imaging peritoneal disseminated 
cancer foci, Q3STCy (300 L of 100 M in pH 7.4 PBS) was injected into the peritoneal cavities 
of RFP-transfected SHIN3 tumor-bearing mice.  Mice were euthanized with carbon dioxide 1 h 
after i.p. injection of probe.  After euthanasia, the abdominal walls were removed, and the small 
bowel mesenteries were extracted and spread out on a non-fluorescent plate.  Spectral 
fluorescence images were acquired using the Maestro In-Vivo Imaging System (CRi, Woburn, 
MA, USA). The following conditions were used for imaging RFP: band-pass excitation from 503 
to 555 nm; long-pass emission above 645 nm.  For experiments involving the Q3STCy probe, the 
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following were used: band-pass excitation from 710 to 760 nm; long-pass emission above 800 
nm).  The tunable filter was automatically stepped in 10-nm increments from 600 to 800 nm for 
RFP or 700 to 900 nm for Q3STCy, while the camera sequentially captured images at each 
wavelength interval.  The spectral fluorescence images consisting of autofluorescence, RFP, and 
probe spectra were then unmixed, based on their spectral patterns, using the Maestro software. 
2.3  Results and Discussion 
2.3.1  Design Considerations of hNQO1-targeted Probes  
To design a successful profluorogenic hNQO1-specific probe for practical applications in 
living systems, many factors are required to be carefully considered. hNQO1 is an intracellular 
enzyme present mainly within the cytosol. Its location can provide an advantage of in situ 
activation of developed hNQO1-specific probes within targeted cells, and the step of enzyme-
generated reporter transportation into targeted cells is avoided. In situ activation of hNQO1-
specific probes and retention of hNQO1-generated reporters offer discrimination of targeted tumor 
cells from non-targeted normal cells or the ability to provide quantitative information on cellular 
enzymatic activity levels. These properties are of great importance in the field of fluorescence-
assisted cytoreductive removal of cancerous tissues that requires sustained and time-invariant 
target-to-background ratios (TBRs).10 They are also beneficial for correlation of prodrug efficacy 
and their hNQO1-based activation in cellular assays.40 In contrast, for extracellular or cellular 
membrane-located enzymes fluorescent reporters generated by them are required to be 
internalized into targeted cells to emit signal.41 Their ineffective internalization of reporters into 
targeted cells and rapid reporters’ diffusion out cause significant signal attenuation resulting in 
low TBRs. However, a big challenge for the design of hNQO1-specific probes is that the probes 
are required to have appropriate lipophilicity to pass through cellular membranes and encounter 
the targeted enzyme. In addition, effective cellular retention of the released reporter is essential 
for a long-lasting and increasing fluorescence signal.  
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To achieve an effective reporting of cellular hNQO1 activity, the probes must be 
recognized and activated selectively by hNQO1 without interferences from competing reducing 
agents (e.g., bio-thiols and reductases) present in the complex physiological environment. To 
achieve a remarkable TBR values and be capable of distinguishing reporters’ emission signal 
from background, the probe and the reporter should have distinctive photophysical properties 
(quantum efficiency, absorption and emission wavelength, and Stokes shift). As such, the reporter 
will have high photostability, independent of pHs and viscosity, high brightness (×) and large 
Stokes shift (abs vs em). In contrast, the unactivated probe must possess a low quantum 
efficiency, significantly different absorption and emission profiles from the reporter, and good 
environmental stability.  
Because NIR light has the advantages of high tissue penetration depth, low 
autofluorescence from excited biological samples, low tissue absorption, and low phototoxicity, it 
is the optimal emission range for in vivo applications.42-43 Therefore, the developed probes are 
desired to have reporting signatures in the NIR range.  
With these criteria in mind, the tricarbocyanine fluorophore (TCy) was selected as the 
reporter because of its NIR emission wavelength, large Stokes shift, high quantum efficiency, and 
photostability, Scheme 2.2.44-45 Importantly, the methylamine group in its meso position provides 
a synthetic handle that can be functionalized with an hNQO1-specific trigger (Q3PA). Small 
changes in the electronic properties of substituents at meso position can induce large changes in 
photophysical properties of the TCy fluorophore due to the alteration of its -electron density 
distribution.31, 46 Introduction of an electron-withdrawing carbamate bond at the meso position 
decreases the energy level of the lowest occupied molecular orbitals (LUMO) of the molecular 
backbone structure, thereby causing a dramatic bathochromatic shift of absorption/emission 
wavelength of the TCy reporter. The trimethyl-locked quinone propionic acid (Q3PA), a highly 
selective hNQO1 substrate, is capable of being reduced by hNQO1 to hydroquinone effectively 
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with NAD(P)H cofactor.47 Q3PA has been successfully applied in the design of bioreductive 
prodrugs,48-51 nanomaterials,52-53 drug delivery systems,28 and imaging probes.13-17 Due to its 
electron deficient nature, Q3PA acts not only as an hNQO1-specific trigger, but also a 
photoinduced electron transfer (PeT) quenching moiety to cloak the fluorescence of certain 
fluorophores in close proximity. A flexible self-eliminating linker, 2-mercaptoethanol, is also 
inserted between the Q3PA trigger and the bulky TCy reporter to enhance the enzyme affinity of 
the probe.47 Based on these considerations, I designed an hNQO1-targeted profluorogenic small-
molecular substrate probe Q3STCy with absorption/emission wavelength-shiftable characteristics 
and an NIR reporting signature. 
2.3.2  Synthesis of the hNQO1-Activatable Fluorogenic Probe Q3STCy 
The synthetic route of Q3STCy is outlined in Scheme 2.1. Briefly, the tricarbocyanine TCy 
reporter was synthesized by nucleophilic substitution of the chlorine of the cyanine dye Cy7-Cl 
precursor with methylamine under DMF refluxing conditions. The self-eliminating linker, 2-
mercaptoethanol, was incorporated to Q3PA using 1,1’-carbonyldiimidazole as a coupling agent, 
affording the thiol ester compound Q3PA-S. Q3STCy was eventually obtained through coupling 
Q3PA-S to TCy through a carbamate bond using phosgene under basic conditions. To explain the 
unique spectroscopic properties of Q3STCy and investigate the influence of Q3PA on the 
photophysical properties of Q3STCy, an electronically similar structural analogue of Q3STCy, 
namely iBuTCy without the Q3PA moiety, was also prepared. All compounds were characterized 
with 1H-NMR, 13C-NMR, and ESI-HRMS. 
  




2.3.3  Demonstration of Q3STCy and iBuTCy Existing as their Respective Rotamers Using 1D 
Gradient Chemical-Exchange NMR Experiment 
An interesting observation in the 1H NMR spectra of iBuTCy and Q3STCy was that the 
peaks belonging to the same type of protons close to the carbamate bond were split into two sets 
of peaks. For instance, in the 1H NMR spectrum of iBuTCy, it was observed that there are two 
sets of doublet peaks at 0.73 and 1.08 ppm with the same J coupling constant 7.0 Hz that 
appertain to the six equivalent protons labeled HA on the iBuTCy structure, Figure 2.3. Even 
though a similar NMR spectrum of the TCy having a carbamate bond was also observed by 
another research group, no possible assignment had been proposed.54  I sought to study the 
cause of the NMR peak splitting. I first eliminated the possibility that impurity is the probable cause 
of splitting with HPLC and HPLC-mass spectrometry. As described in Figure 2.1 and Figure 2.2, 
the synthesized Q3STCy probe was demonstrated to be a pure compound showing only one 
signal peak with HPLC separation. Considering its large molecular weight and the existence of a 
carbamate bond of Q3STCy or iBuTCy, I hypothesized that the observed peak splitting of each 
molecule was caused by the existence of rotamers. The relatively slow rotation rate of the 
carbamate bond resulted in the same type of equilibrating protons having different transient 
chemical environments, which ultimately led to the splitting of NMR peaks.  
The existence of molecular rotamers is mostly studied by variable-temperature (VT) NMR, 
solvent switching,55-56 or the introduction of a complexing agent.57-59  However, these techniques 
are inconvenient when the examined samples are precious and need to be recovered. A simple 
alternative technique is chemical-exchange NMR experiments. In my experiment, I employed 1D 
selective chemical exchange NMR experiments to demonstrate that Q3STCy and iBuTCy existed 
as their respective rotamers in solutions.29-30 As an illustration, if two sets of peaks in a compound 
are attributed to equivalent protons, one set of peaks will behave the same spectroscopically as 
the other set of irradiated peaks considering the chemical exchange nature of rotamers in a 
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neutral chloroform solution. I first examined the six equivalent protons HA belonging to the two 
terminal methyl groups of iBuTCy, Figure 2.3. When a selective pulse at 1.08 ppm was applied to 
irradiate iBuTCy in deuterated chloroform, two peaks having the same phase at 1.08 and 0.73 
ppm were created concomitantly, and vice versa. Peaks of the same phase were generated in 
this case, which is different from that caused by normal nuclear overhauser effect (NOE). Normal 
NOE-generated peaks will appear with opposite phase in response to an irradiated pulsed peak, 
indicating two different types of protons in close proximity. The two sets of peaks are separated 
from each other in a manner much larger than the NMR resolution. Observed peaks of the same 
phase were not caused by the broadness of the irradiation window. The statement became clearer 
when there is a third peak located between the two sets of peaks. For example, two sets of triplet 
peaks at 2.93 ppm and 3.22 ppm with the same J coupling constant of 6.75 Hz belonging to the 
two HB protons of the methylene group next to sulfur atom in Q3STCy, Figure 2.4. When the peak 
at 2.93 ppm was irradiated, both peaks at 2.93 ppm and 3.22 ppm appeared. However, the singlet 
peak in between did not appear on the spectrum. Therefore, appearance of peaks having the 
same phase is not caused by the broadness of the irradiation pulse.  This study showed that the 
protons responsible for the split peaks behaved the same spectroscopically, indicating that 








       
      
Figure 2.3 (A) 1H NMR spectrum of iBuTCy in CDCl3; (B) 1D gradient chemical exchange 
spectrum of iBuTCy with an initial selective pulse irradiation at 1.08 ppm creating two peaks at 
1.08 ppm and at 0.73 ppm; (C) irradiation at 0.73 ppm creating two peaks at 1.08 ppm and at 0.73 
ppm; (D) irradiation at 4.01 ppm creating two peaks at 4.01 ppm and at 3.79 ppm; (E) irradiation 
at 3.79 ppm creating two peaks at 4.01 ppm and at 3.79 ppm. All the newly created peaks are on 
the same phase. 
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Figure 2.4 (A) 1H NMR spectrum of Q3STCy in CDCl3 ; (B) 1D gradient chemical exchange 
spectrum of Q3STCy with an initial selective pulse irradiation at 2.93 ppm creating two peaks at 
2.93 ppm and at 3.22 ppm;(C) irradiation at 4.04 ppm creating two peaks at 2.93 ppm and at 4.21 
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2.3.4  Spectroscopic Characterization of Q3STCy and TCy 
As shown in Figure 2.5, the spectral behaviors of the Q3STCy probe and the TCy reporter 
were measured in aqueous phosphate buffered saline solution (PBS, pH=7.4). Q3STCy has its 
absorption maximum at 𝜆abs
probe
 = 786 nm and its emission maximum at 𝜆em
probe
 = 798 nm. In 
contrast, TCy has hypsochromic shifts in both absorption and emission maxima (𝜆abs
reporter
 = 606 
nm and 𝜆em
reporter
 = 755 nm) and entirely different spectral profiles from the Q3STCy probe. This 
wavelength-shiftable nature of the probe/reporter system is advantageous because the emission 
signature the reporter can be easily differentiated from that of the probe even in a complex 
biological environment. In cellular imaging applications, an illumination wavelength can be 
selected to only excite the reporter rather than the probe, resulting in a smaller background 
fluorescence signal. When irradiated at 600 nm, TCy had a 240-fold higher emission intensity at 
765 nm than Q3STCy, which was partially caused by the absorption/emission wavelength-
shiftable characteristics of the probe/reporter pair. Additionally, the TCy reporter has a remarkably 
large Stokes shift (149 nm) due to its strong ICT effect.44 A fluorophore with a large Stokes shift 
is beneficial as a reporter, because it can avoid self-quenching and provide minimal background 
scattering issues from illumination light.  































































Figure 2.5 (A) Absorption spectra and (B) emission spectra of TCy (2 M, red), Q3STCy (2 
M, black) and iBuTCy (2 M, dashed grey) in 1% DMSO 0.1 M PBS/0.1 M KCl solution (pH 
= 7.4). Emission spectra were measured at ex = 600 nm. T = 25 °C. 
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Another observation is that Q3STCy and iBuTCy have similar absorption spectra (𝜆abs
probe
 = 
786 nm vs 𝜆abs
iBuTCy
 = 783 nm) and similar emission spectra (𝜆em
probe
 = 798 nm vs 𝜆em
iBuTCy
 = 798 nm). 
It can be argued that their similar fluorophore skeletal structures with an electron-withdrawing 
carbamate bond at the meso position give them equivalent electron density distribution, resulting 
in similar HOMO and LUMO energy levels. 
2.3.5  Molecular Orbital Calculations  
The striking difference in spectral properties between Q3STCy and TCy was proposed to 
be caused by the introduction of the carbamate bond at the meso position.31 I was motivated to 
further investigate how the carbamate bond affects the HOMO and LUMO energy levels of the 
Q3STCy probe. iBuTCy, an analogue of Q3STCy, is structurally similar to the Q3STCy probe, but 
iBuTCy is more facile to study with computational methods. To gain a better understanding of the 
phenomenon, the electron distribution and HOMO/LUMO energy levels of TCy and iBuTCy were 
calculated using density functional theory (DFT) with the B3LYP functional and the 6-31G basis 
set in Gaussian 09, Figure 2.6. For the HOMO orbital of the TCy reporter, electron distribution is 
localized on the entire fluorophore excluding the carbon and nitrogen atoms at the meso position. 
In fact, the electron density is almost zero on the meso carbon. In contrast, electron distribution 
of the LUMO orbital is predominantly localized on the heptamethine chain including the meso 
carbon and nitrogen atoms. Therefore, introduction of an electron-withdrawing group mainly 
stabilizes the HOMO orbital. This was clearly observed on the calculated HOMO/LUMO of the 
probe analogue iBuTCy. The HOMO of iBuTCy has a similar electron distribution and energy level 
as that of TCy. However, the LUMO of iBuTCy has a stabilized electron distribution and a lowered 
energy level. This electron redistribution due to the introduced carbamate bond, which led to a 
decreased energy HOMO/LUMO gap of iBuTCy (1.35 eV) in comparison with that of TCy (1.63 





Figure 2.6 HOMO/LUMO Frontier Molecular Orbitals of TCy and iBuTCy. 
2.3.6  Quantum Yield Measurement 
Quantum yields of Q3STCy and iBuTCy were measured in aqueous solution (2% DMSO: 
98% 0.1 M PBS, pH = 7.4) using indocyanine green (ICG) in water ( = 0.012) as a standard,32, 
60 while TCy was measured using an in-house synthesized 1,1’,3,3,3’,3’-hexamethyl-3,5-
propylene-4-(dimethylamino)-2,2’-indotricarbocyanine perchlorate (HPDITCP) in ethanol ( = 
0.161) as a standard.33 ICG and HPDITCP were selected as the standards because their 
absorption and emission profiles match well to their respective samples. This absorption/emission 
match can avoid the variance of detection efficiency of the detector at different wavelengths, 
resulting in more accurate measurement. The quantum yields of Q3STCy, iBuTCy, and TCy were 
determined as 0.0046, 0.024, and 0.063, respectively, Table 2.1. A lower quantum efficiency for 
Q3STCy was observed than that for iBuTCy (5-fold lower), and for TCy (14-fold lower). 
Considering that the Q3PA moiety has a low electron density and is in close proximity with the 
heptamethine fluorophore, photoinduced electron transfer from the excited fluorophore donor to 
the Q3PA acceptor (d-PeT) was proposed as the cause of the low fluorescence efficiency of 
Q3STCy, Figure 2.7. 
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Table 2.1 Photophysical data for iBuTCy, Q3STCy, and TCy 
Compounds Solvent abs (nm) em (nm) M−1cm−1) 
iBuTCy PBS 783 798 111100 0.024a 
Q3STCy PBS 786 798 60600 0.0046a 
TCy PBS 606 755 36800 0.063b 
aICG ( = 0.012 in water) with ex  = 725 nm; bHPDITCP ( = 0.161 in ethanol) with ex = 633 nm. 
 
Figure 2.7 Schematic illustration of d-PeT process of the probe, Q3STCy. 
2.3.7  Thermodynamic Feasibility of PeT Process 
The proposed d-PeT process was further studied and demonstrated as the cause of the 
fluorescence quenching of Q3STCy. As shown in Figure 2.7, in the d-PeT process, the 
heptamethine fluorophore is the donor, and the electron-deficient quinone is the acceptor. After 
the electron on the HOMO orbital of the fluorophore donor was excited to the LUMO orbital, it was 
transferred to the LUMO orbital of the quinone acceptor, resulting in the fluorescence quenching 
of the fluorophore.  Because the carbamate bond greatly changed the HOMO/LUMO orbitals of 
TCy, the fluorophore iBuTCy with a carbamate bond instead of TCy was an optimal representative 
of the donor in the d-PeT system of Q3STCy. To demonstrate that the d-PeT process is 
spontaneous, I measured the electrochemical and spectroscopic characteristics of the donor 
iBuTCy and the acceptor Q3PA. The first excited singlet state energy (G00) of iBuTCy was 
calculated to be 1.56 eV by converting the cross over wavelength for the absorption and emission 




Figure 2.8 Normalized absorption and emission spectra of iBuTCy in acetonitrile, showing the first 
excited state at 795 nm (1.56 eV). T = 25 °C
 
Figure 2.9 Cyclic voltammograms of 1 mM solutions of iBuTCy (A) and Q3PA (B) in anhydrous 
acetonitrile with 0.1 M tetrabutylammonium perchlorate as supporting electrolyte; scan rate = 0.1 
V/s; iBuTCy: Epa = 0.46 eV, Epc = 0.38 eV; Q3PA: Epc1 = -1.16 eV, Epc2 = – 1.53 eV, Epa1 = – 0.46 
eV, Epa2 = – 1.43 eV; T = 25 °C. 
Cyclic voltammetry measurements showed that the oxidation potential of iBuTCy (Eox) was 0.42 
V vs Fc/Fc+ and the reduction potential of Q3PA (Ered) was - 0.81 V vs Fc/Fc+, Figure 2.9. By 
applying these outcomes in the Rehm-Weller equation 
GPeT = Eox  − Ered − G00 − wp 
The Gibbs free energy change (GPeT) was determined to be – 0.39 eV, indicating that electron 
transfer of Q3STCy is a thermodynamically feasible process. These measurements corroborated 
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that Q3PA is an effective quenching group to significantly decrease the fluorescence efficiency of 
Q3STCy. 
2.3.8  Spectral Rsponse of Q3STCy Toward hNQO1 
I next examined the efficacy of Q3STCy activation by hNQO1 under physiological 
conditions (at 37 ºC in 0.1 M pH 7.4 PBS buffer). The absorption spectra of Q3STCy were first 
recorded over time after the addition of 688 U mL–1 hNQO1 in the presence of NADH cofactor 
(100 M), Figure 2.10. 1 U of hNQO1 will reduce 1 nmol of cytocytochrome c min−1 in the presence 
of menadione substrate at 37 ºC.61 The absorption band of Q3STCy at 786 nm rapidly decreased 
(50% decrease in 3 min, 90% decrease in 10 min),  while a new band centered at 606 nm 
increased concomitantly. The new band was presumably caused by the formation of TCy. An 
isosbestic point at 665 nm was also observed. The solution color changed from green to blue 
within 20 min, Figure 2.10 inset.  
 
Figure 2.10 Time-dependent absorption spectral changes of 2 M Q3STCy in 0.1 M PBS/0.1 M 
KCl solution (pH = 7.4) with 100 M NADH cofactor and 0.007% BSA initiated by the addition of 
hNQO1 (688 U mL–1, U = nmol of cytochrome c reduced min−1). Inset is the solution color change 
before and after treatment with hNQO1. T = 37 °C. 
Under identical conditions, the emission spectral changes of Q3STCy were also recorded, Figure 
2.11. Upon addition of hNQO1 to the Q3STCy solution, the fluorescence experienced an 
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immediate increase at 798 nm, then gradually shifted to 755 nm, accompanied by a 193-fold 
fluorescence increase at 755 nm within 20 min. The immediate fluorescence increase at 798 nm 
was hypothesized to be the result of rapid formation of the fluorescent intermediate STCy, 
Scheme 2.2. STCy has an intact carbamate bond, which has spectral properties similar to iBuTCy. 
A subsequent fluorescence shift and increase at the emission maximum of TCy (755 nm) was 
attributed to the ultimate release of TCy upon intramolecular cyclizative cleavage of the five-
membered ring compound 1,3-oxathiolan-2-one, Scheme 2.2. 









































Figure 2.11 Time-dependent emission spectral changes of 4 M Q3STCy in 0.1 M PBS/0.1 M KCl 
solution (pH = 7.4) with 100 M NADH cofactor and 0.007% BSA initiated by the addition of 
hNQO1 (688 U mL–1, U = nmol of cytochrome c reduced min−1). Excitation slit width: 5.0; emission 
slit width: 7.5; T = 37 °C. 
2.3.9  Confirmation of the Enzymatic Activation Mechanism of Q3STCy 
 To further investigate whether the hNQO1-induced fluorescence turn on was indeed 
caused by the release of TCy via the proposed mechanism, HPLC-mass spectrometry experiment 
was further performed, Figure 2.12. Q3STCy (30 M) in aqueous solution (pH = 7.4) was treated 
with 688 U mL−1 hNQO1 and 100 M NADH at 37 °C for 20 min. The resultant mixtures were 
analyzed with HPLC coupled ESI-TOF mass spectrometry, Figure 2.12. Four products were 
successfully separated and identified, having m/z values of 235.1356 [HQ3-L + H]+, error = 11.5 
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ppm; 610.3458 [STCy]+, error = 1.4 ppm; 506.3539 [TCy]+, error = 0.8 ppm; and 842.4639 
[Q3STCy]+, error = 8.6 ppm. The cleaved lactone product HQ3-L, the formed intermediate STCy, 
the released TCy reporter, and the unreacted Q3STCy probe were identified as expected, which 
confirmed my proposed enzymatic activation mechanism for Q3STCy. H2Q3STCy was not 
observed, probably due to its rapid intramolecular lactonization rate (~ 1 min). The linker 
cyclization product, 1,3-oxathiolan-2-one, was not observed, either because it eluted out in the 
beginning 1–2 min elution of solvent or its ionization efficiency was too low in comparison with 
other molecules’. 
 
    
  
Figure 2.12 Upper: High-performance liquid chromatogram for separation of mixture resulted 
from 30 M Q3STCy probe treated with 688 U mL−1 hNQO1 and 100 M NADH at 37 °C for 20 
min.  Lower: Mass spectra of corresponding peaks in the chromatogram. 
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2.3.10  Enzymatic Kinetic Parameters for Q3STCy    
As previously described in the design of an effective probe/reporter system, unactivated 
probe is non-fluorescent until it react with a targeted enzyme, which rapidly convert the probe to 
the highly fluorescent reporter. Simultaneously, the fluorescence of the released reporter should 
last as long as possible to allow effective and efficient detection. Two aqueous solutions of 
Q3STCy (4 M) containing NADH (100 M) and BSA (0.007%) were treated with or without 
hNQO1 (688 U mL–1). The release rate of TCy was monitored by measuring the fluorescence at 
755 nm with an excitation wavelength 605 nm, Figure 2.13. TCy release was not observed during 
the 150-min examined time period in the untreated Q3STCy sample, indicating the stability of 
Q3STCy in aqueous solution. In contrast, the Q3STCy solution, treated with hNQO1 at the 20-min 
time point, exhibited rapid fluorescence increase, with the fluorescence reaching a plateau at 
around 30 min. The fluorescence caused by the release of TCy was constant over a 90-min time 
course, indicating no sacrificed reporting capability of the probe/reporter system. 
To evaluate the hNQO1 efficacy in activating Q3STCy, the apparent kinetic parameters 
were obtained by measuring the release rate of TCy with various Q3STCy substrate 




















































Figure 2.13 The fluorescence intensity at 755 nm of 4 M Q3STCy solution (ex = 605 nm) was 
recorded with (red line) or without (black line) the addition of hNQO1 (688 U mL–1) at the 20-
min time point. T = 37 °C.  
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concentrations (0.5–5 M), Figure 2.14. The released TCy concentrations were first converted 
from the measured fluorescence intensity with a linear calibration curve. The calibration curve 
was established with TCy under identical measurement conditions. The obtained TCy 
concentrations were used to calculate TCy production rate. Upon fitting the TCy production rate 
to the Michaelis-Menten kinetic equation, the apparent Michaelis constant (Km = 1.1 ± 0.5 M) and 
maximum velocity (Vmax = 0.31 ± 0.05 mol min–1 mg hNQO1–1) were determined. Based on these 
acquired values, the catalytic constant or turnover number (kcat = 0.16 ± 0.02 s–1) and the catalytic 
efficiency (Kcat/Km = 1.5 ± 0.7 × 105 M–1s–1) were calculated. The small Km value indicated strong 
binding interactions between hNQO1 enzyme and Q3STCy probe. It was reasoned that the 
hNQO1-recognizing quinone moiety was separated by the flexible 2-mercaptoethanol linker away 
from the bulky moiety TCy, allowing its deep penetration into the active site of hNQO1.47 The 
catalytic efficiency was also higher than all the previously developed probes in the McCarley lab 
or others.  
 
Figure 2.14 Kinetic plot of hNQO1 (0.5 × 10–6 g mL–1, 250 U mL–1) with Q3STCy as a substrate 
in aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA. T = 
37 °C. Values shown are the average of three trials with errors bars being ±1 standard 




2.3.11  Physiological Stability of the Probe/Reporter System 
pH fluctuations can occur in many cellular miroenvironments. For example, extracellular 
fluids in tumor areas can yield an acidic pH.62 Cellular compartments, such as lysosomes and 
endosomes, also have a low pH value (4.5–5.0) to facilitate their functions.63 To assure that the 
probe/reporter pair can measure hNQO1 activity accurately, the fluorescence of Q3STCy and TCy 
should not be influenced by pH fluctuations. As shown in Figure 2.15, the fluorescence signal of 
Q3STCy and TCy at various pH values (4.5–9.5) was examined. The fluorescence intensity at 798 
nm of Q3STCy was invariant across the pH range. Although the TCy structure has an amino group, 
pH values in the range of 4.5–9.5 did not have a pronounced effect on TCy fluorescence. This 
was must likely due to its low pKa value (less than 4.5), resulting from efficient conjugation of the 
amino group with the heptamethine structure. Therefore, the developed probe/reporter system 
provides signal response that are pH independent from pH 4.5 to 9.5, and it should function well 
in cellular microenvironments.  
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Figure 2.15 (A) Plot of fluorescence intensity at 755 nm for TCy (2 M, ex = 600 nm) and at 
803 nm for Q3STCy (2 M, ex = 600 nm and 725 nm) in 0.1 M PBS/0.1 M KCl with 1% DMSO 
at various pH values (4.5–9.5). T = 25 °C. 
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Considering the abundance of reducing species in cells (e.g., thiols and NADH), a 
significant concern for the probe/reporter system was whether the fluorescence of the released 
reporter is stable in the presence of the aforementioned reducing species. To achieve non-
interfering fluorescence is even more challenging for fluorophores that emit in the NIR range. 
Because the NIR fluorophore often possesses a large -conjugated structure, the latter may be 
easily attacked by biological nucleophiles. Interferent-induced quenching and redox reactions 
may also pose a big threat to its reporting ability.61 The fluorescence intensity of TCy upon 120-
min incubation with high concentrations (1 mM) of various reducing species was compared with 
that of the initial TCy solution, Figure 2.16. Less than 10% fluorescence decrease was found, 
indicating that the reporting capability of TCy was not sacrificed by the presence of biological 
reducing species. 
2.3.12  Selectivity of Q3STCy Toward hNQO1 Over Other Reducing Species in Cells  
Another requirement for the probe/reporter system is high selectivity of Q3STCy toward 





































Figure 2.16 Fluorescence intensity at 755 nm (ex = 600 nm) of 4 M TCy in 0.1 M PBS/0.1 M 
KCl (pH = 7.4) with 1 mM corresponding reducing agent. Green bars indicates the initial 
fluorescence intensity and red bar indicates the fluorescence intensity after 120 min incubation 
with corresponding reducing agent. T = 25 °C. 
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reductases are commonly present in mammalian cells, which would presumably to be the main 
potential interferents.64 Glutathione (GSH), ascorbic acid (AA), L-cysteine (Cys), L-homocysteine 
(Hcy), dithiothreitol (DTT), NRH:quinone oxidoreductase 2 (QR2), and cytochrome P450 
reductase (CPR) were selected to investigate their effects on possible fluorescence turn-on of 
Q3STCy, Figure 2.17. Q3STCy solutions (4 M) were treated with high concentrated thiols (1 mM) 
for 20 min at 37 ºC. No significant fluorescence increase was observed. The reductases QR2 and 
CPR have the potential to reduce certain quinone species in the presence of their respective 
cofactors, NRH and NADPH;13-14 their ability to activate Q3STCy was also investigated. The sole 
presence of NRH (100 M) or NADPH (100 M) did not produce any fluorescence increase. QR2 
(617 U mL–1) in the presence of NRH (100 M) produced a small fluorescence increase, that is 
about 20% of that for the hNQO1 (688 U mL–1). However, the QR2 activity used is 275 times 































































Figure 2.17 Normalized fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 μM) in 
0.1 M PBS/0.1 M KCl solution (pH = 7.4) after incubation with a given reducing agent for 20 
min at 37 ºC. Reducing agent concentrations: 1 mM for ascorbic acid (AA) and thiols; 100 M 
for NRH cofactor of NRH:quinone oxidoreductase 2 (QR2); and 100 M for NADH and 
NADPH. The reductases were present at 688 U mL−1 for hNQO1, 617 U mL−1 for QR2, and 




tumor-derived cell lines such a prostate carcinoma (PC-3) and glioblastoma multiforme (U373-
MG and U87-MG), QR2 activity is merely 0.2% of hNQO1 activity. Moreover, the QR2 cofactor 
NRH is unstable in aqueous and cellular environments, and its fleeting concentration in cells is 
not enough to cause QR2 activation of quinone substrates.65 CPR (14.1 U mL–1) in the presence 
of its cofactor NADPH (100 M) produced a signal 10% that of hNQO1. CPR activity used here 
is roughly the same as that found in lung cancer cells, and is 4% of the hNQO1 activity in colorectal 
cancer xenografts.66-67 In summary, Q3STCy exhibited low activation by the previously discussed 
biological reducing species.  
 Considering the electron deficient nature of the quinone and heptamethine moieties, and 
the strong nucleophilicity of thiols, the question came about: was it possible that the low thiols-
induced activation of Q3STCy was caused by the degradation of Q3STCy? To rule out this 
possibility, the various thiol-treated Q3STCy solutions were subsequently treated by hNQO1 
enzyme, thereby resulting in pronounced fluorescence increases, Figure 2.18. This data showed 
that the thiol-treated Q3STCy solutions maintained their ability to be activated by hNQO1. The 
Cys-treated Q3STCy solution showed the lowest fluorescence increase than the untreated 
Q3STCy, indicating that Cys might cause the biggest interference for the detection of hNQO1 with 
the Q3STCy probe through possible reaction with either Q3STCy or the released TCy. This 
observation is most likely because Cys has the highest nucleophilicity among the tested thiols. 
However, it is worth noting that the concentration of Cys used here was 1 mM, much larger than 
its actual presence in biological environments. For example, in human blood plasma, unbound 
Cys is around 10–20 M.68 Its intracellular concentration in human cells is also in M levels. 
Another concern was that Q3STCy can bind to hNQO1 enzyme leading to its fluorescence 




2.3.13  hNQO1 Expression and Activity in Tumor-derived Cancer Cell Lines 
After demonstrating that Q3STCy can detect hNQO1 in an effective and selective manner 
in vitro, I sought to investigate its capability to measure endogenous hNQO1 in cells. Three wild-
type cell lines and a gene-transfected cell line were examined. Wild-type cell lines include a 
colorectal carcinoma cell line (HT-29), an ovarian cancer cell line (SHIN3), and a non-small cell 
lung carcinoma cell line (H596). HT-29 was established as an hNQO1-expressing cell line with 
high hNQO1 activity.69 H596 was reported to have undetectable hNQO1 activity, resulted from a 
gene point mutation.70 HT-29 and H596 were previously employed as representive hNQO1-
positive and -negative cell lines in the McCarley group. An hNQO1 gene-transfected H596 cell 
line (H596 (+)) was also exploited as an hNQO1-positive control model. H596 (+) should possess 





















































Figure 2.18 Fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 μM) in 0.1 M 
PBS/0.1 M KCl solution (pH = 7.4). Black bars: the solution was incubated with respective 
reducing agents for a 20-min time period at 37 ºC. Red Bars: the treated solution was further 
followed by the addition of 700 U mL–1 hNQO1 and incubated for a second 20-min time period 
at 37 ºC. Reducing agent concentrations: 100 M for NADH, and 1 mM for DTT, AA, GSH, 
Cys, and HCy. 
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used for the first time in the McCarley lab or others in order to investigate whether the developed 
Q3STCy probe was appropriate to visualize SHIN3-derived metastases. 
The hNQO1 expression level in these four cell lines was studied with conventional 
Western blot assay, Figure 2.19. hNQO1 presence was clearly visualized in HT-29, H596 (+), and 
SHIN3 cell lines. In contrast, no hNQO1 presence was observed in the H596 cell line. Their 
hNQO1-specific activities were also measured, Figure 2.20. 24-h-old plated cells were used for 
the measurement. The cells were first lysed and centrifuged to acquire their lysates. 
Dichlorophenolindophenol (DCPIP) was selected as the hNQO1 substrate to examine the 
reduction capability of the acquired lysates.39 Dicoumarol-inhibited reduction capability was 
                   
Figure 2.19. Western blots of protein extracts (20–21 g each) from H596, H596 (+), HT-29, 
and SHIN3 cells.  -Actin was used as a standard. 

























Figure 2.20 hNQO1-specific activities of protein extracts from H596, H596 (+), HT-29, and 
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calculated to indicate the hNQO1-specific activity. HT-29 was validated to have a high hNQO1 
activity, 488 ± 10 nmol of DCPIP min−1 mg protein−1. SHIN3 and H596 (+) had moderate hNQO1 
activities, 55 ± 3 and 179 ± 7 nmol of DCPIP min−1 mg protein−1, respectively. H596 had 
undetectable hNQO1 activity. In the following cellular imaging experiment, HT-29, H596 (+), and 
SHIN3 were used as hNQO1-positive cell lines, while H596 was used as a hNQO1-negative cell 
line. 
2.3.14  Visualization of Endogenous hNQO1 in Monolayer Cancer Cell Lines with Fluorescence 
Microscopy 
Wide-field fluorescence microscopy and laser-scanning confocal fluorescence microscopy 
were employed to capture the images of Q3STCy-exposed cells, Figure 2.21 and Figure 2.22. In 
the following acquired cellular images, only emission signal from the TCy reporter was detected 
by customizing the microscopic imaging conditions (e.g., filter switch and excitation/emission 
wavelength tune). This was attributed to the large differences in the spectroscopic properties of 
the Q3STCy probe and the TCy reporter.  
All four cancer cell lines were incubated with 5 M Q3STCy for 30 min under monolayer 
cell culture conditions at 37 °C, and then washed with DPBS (pH = 7.3) twice and fixed with 4% 
PFA for 15 min. Confocal microscopic images were further captured under the same imaging 
conditions. As noted in Figure 2.21, strong cytosolic fluorescence in the near-infrared region (660–
820 nm) was found for the hNQO1-positive HT-29, H596 (+), and SHIN3 cell lines. These 
observations indicate the Q3STCy probe is cell membrane permeable, in agreement with its high 
log octanol-water partition coefficient of 7.9 at pH 7.4;71 the probe is readily activated by 
intracellular hNQO1. In contrast, virtually undetectable fluorescence in this energy range was 
emitted in the hNQO1-negative H596 cell line under the same imaging conditions. To offer a more 
quantitative approach for distinguishing target cells (positive) from non-target (negative) cells, I 
calculated their target-to-background ratios (TBR) based on the acquired cellular images. The 
TBR is a significant index for predicting the potency of optical imaging agents in real-time 
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cytoreductive surgery for cell/tissue differentiation.72 The TBR is defined as the signal from the 
hNQO1-positive (HT-29, OVCAR-3, and SHIN3) cells compared to that from hNQO1-negative 
H596 cells. TBR values reported at the 95% confidence interval are 5.4 ± 0.4 for HT-29 (53 
cells)/H596 (38 cells), 3.1 ± 0.3 for H596 (+) (45 cells)/H596 (33 cells), and 2.2 ± 0.2 for SHIN3 
(32 cells)/H596 (32 cells). All TBR values are sufficiently large to identify targeted regions during 
fluorescence-guided surgery, as well as to evaluate hNQO1-related drug efficacy.40, 72 Similarly, 
strong cytosolic fluorescence was found in the wide-field microscopic images of HT-29 cells, 
Figure 2.22. The acquired HT-29 (20 cells)/H596 (22 cells) TBR value is 29.4 ± 6.8. All the cells 
were washed twice with PBS solution (pH = 7.4); the TBR values were still high suggesting that 
there is effective cellular retention of the intracellularly produced TCy reporter from the Q3STCy 
probe. This property of high cellular retention was not achieved by other enzyme-activated probes 
using fluorescein derivatives as reporters;73-75 they underwent significant fluorescence loss after 
a washing process. 
 
Figure 2.21 Fluorescence and differential interference contrast (DIC) images of H596 
(negative), SHIN3 (positive), H596 (+) (positive), and HT-29 (positive) cells using confocal 
microscopy. Cells were incubated with 5 M Q3STCy for 30 min at 37 °C under humidified, 5% 
CO2 conditions and fixed with 4% PFA. Fluorescence images were captured using 633-nm 
excitation and 660–820 nm emission. Scale bar = 20 m. 
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It came to my attention that the TBR value of HT-29/H596 was relatively smaller than 
expected. A possible cause was the microscope imaging setting emitted photons in the 660–820 
nm range were collected with the 633-nm illumination light. Emission from the unactivated 
Q3STCy probe was also included in the large detection range, possibly, resulting in a large 
background signal. In addition, the thioester bond on Q3STCy might be not as stable as an amide 
bond in the cellular environment. Nonspecific hydrolysis of Q3STCy, even in trivial amounts, could 
lead to an increased background signal. The relatively slow cleavage rate of 1,3-oxathiolan-2-one 
might also retard the production of TCy, resulting in a low reporting signal. All the aforementioned 
factors may contribute to the observed relatively low TBR value of HT29/H596. These 
speculations were evidenced by another crafted probe Q3NTCy. In the Q3NTCy molecule, the 2-
mercaptoethanol linker of Q3STCy was replaced by N-methyl-p-amino-benzyl alcohol. The 
formation of stable amide bond and the fast cleavage rate of the newly introduced linker made 
 
Figure 2.22 Fluorescence and DIC images of HT-29 (positive) and H596 (negative) cells using 
wide-field microscopy. Cells were incubated with 5 M Q3STCy for 30 min at 37 °C and fixed 
with PFA. Fluorescence images were captured with a Cy5 (ex = 590–650 nm, em = 662–738 
nm; 50 ms exposure time) filter. Scale bar = 20 m.                                                                       
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Q3NTCy achieve a much higher HT-29/H596 TBR value (7.6 ± 0.6). The Q3NTCy probe will be 
discussed in the next chapter of my dissertation. 
 To assess the selective detection of hNQO1 by the Q3STCy probe, HT-29 cells were 
treated with the competitive hNQO1 inhibitor dicoumarol, Figure 2.23. A significantly lower 
fluorescence (over 70%) was observed in the dicoumarol-treated cells compared to the untreated 
cells. It was an easy conclusion that the inhibited hNQO1 activity led to the observed fluorescence 
loss. However, drawbacks of enzyme selectivity assay with chemicals such as inhibitors are 
obvious. Inhibitors may perturb a cellular system (e.g., endocytosis inhibition and enzyme 
up/downregulation), and react with applied probes or produced reporters, in addition to any 
possible selectivity problems they may have. All these factors can lead to a false positive signal. 
I further examined the effect of dicoumarol on the TCy reporter. Significant fluorescence loss was 
found when an equal amount of dicoumarol (5 M) was added to the TCy solution (5 M). 
Therefore, the dicoumarol-induced fluorescence loss of TCy might also be part of the reason for 
the fluorescence decrease in the dicoumarol-treated cells. The hNQO1 gene-transfected cell line 



































Figure 2.23 (A) Fluorescence and DIC images of dicoumarol-free and dicoumarol-treated 
(hNQO1 inhibitor) HT-29 cells using confocal microscopy. Cells were preincubated 
with/without 10 M dicoumarol for 60 min, then incubated with 5 M Q3STCy for an additional 
30 min. Fluorescence images were captured using 633-nm excitation and 660–820 nm 
emission. Scale bar = 20 m; (B) Mean cytosolic fluorescence intensity of dicoumarol-free and 
dicoumarol-treated HT-29 cells. 
123 
 
H596 (+) was a better cellular model to study the enzymatic selectivity of Q3STCy. As shown in 
Figure 2.21, higher fluorescence intensity from the H596 (+) cells than that from the H596 cells 
showed the high selectivity of Q3STCy toward hNQO1. To strictly rule out the effects of all the 
other reducing species in cells, if laboratory conditions allowed, hNQO1 gene knockout 
experiment can provide a definitive answer.  
2.3.15  Colocalization Study 
To track the ultimate location of TCy produced by the hNQO1-stimulated Q3STCy within 
the cytosol, colocalization experiments were performed with Q3STCy and organelle trackers 
(mitotracker green and lysotracker green DND-26). As shown in Figure 2.24, the fluorescence 
signal from the released TCy reporter colocalized well with that from the lysotracker dye. The 
acquired images were analyzed with Fiji/ImageJ software. The Pearson correlation coefficient for 
colocalization (PCCC) was determined to be 0.77, a value indicative of excellent TCy/lysotracker 
colocalization.76 In contrast, cellular images exhibited a low colocalization level between TCy and 
 
Figure 2.24 Live cell fluorescence and DIC images of HT-29 cells using confocal microscopy. 
Cells were incubated with Q3STCy (5 μM) for 30 min (633-nm excitation and 660–785 nm 
emission) and an organelle tracker (30 nM lysotracker green DND-26, or100 nM mitotracker 




mitotracker green. A PCCC value 0.28 was calculated confirming their poor colocalization. These 
outcomes indicated that TCy released in the cytosol was accumulated mainly in lysosomes, which 
was beneficial for the enhanced intracellular retention of TCy. 
 The cell viability of Q3STCy and TCy with HT-29 cells was also evaluated, Figure 2.25. 
HT-29 cells were exposed to 1 M or 2 M Q3STCy for 3 h, and the live/dead cells were counted 
via the trypan blue staining method.77  The cell viability was calculated to be 93.4 ± 2.0% and 88.1 
± 1.0%. Similar cell viability for HT-29 cells incubated with 1 M or 2 M TCy was obtained, 84.8 
± 7.0% and 96.0 ± 4.0%. Both the Q3STCy probe and the TCy reporter exhibited low cytotoxicity 
with similar concentrations and incubation time applied in cellular imaging studies. Due to the 
absence of sulfonated groups on the heptamethine cyanine molecules, both the probe and the 
reporter are prone to accumulate inside cells.42 This property could result in cell toxicity problems 


























Figure 2.25 Cell viability of HT-29 cells treated with 1 M and 2 M Q3STCy and TCy for 3 h. 
Percentage values are the average of three independent measurements. Error Bars are ± one 
standard deviation.  
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2.3.16  Fluorescence Imaging of Multicellular Tumor Spheroids (MCTSs) 
 After the successful applications of the developed probe/reporter system in monolayer cell 
culture, I sought to examine its potential for imaging an avascular tumor model – MCTSs. MCTSs 
are laboratory-cultured multicellular aggregates, which have realistic features of in vivo avascular 
tumors, such as structure diversity and gradient distribution of nutrients, oxygen, and H+.78 Even 
though the two-dimensional cultured cell model is significant in the drug development field, it fails 
to resemble avascular tumors. It is often the case that promising preclinical outcomes derived 
from cell monolayer-based assays do not translate to the patient in the clinic.79 As a result, the 
use of MCTSs is a better drug screening model resulting in improved patient outcomes. 
Furthermore, MCTSs resemble disseminated peritoneal metastases from ovarian, colorectal, 
gastric, and pancreatic cancers.80-81 The metastases are too small to be readily identified and 
removed by surgeons during cytoreductive surgery under white-light illuminated surgical 
conditions. They also locate away from blood vessels, which causes the therapeutic drugs to be 
unable to reach and kill them. Thus, it is highly valuable to evaluate the ability of enzyme-
responsive, fluorescence-based probes to be turned on inside cells of sub-mm-sized MCTSs. 
 The developed 23-day-old colorectal cancer MCTSs were exposed to 5 M Q3STCy, and 
their fluorescence images were captured with wide-field microscopy, Figure 2.26. MCTSs with 
advanced culturing age (23 days here) have features more closely related to that of multicellular 
aggregates and avascular metastases in vivo.82-83 As shown in the DIC images, the 23-day-old 
MCTSs were composed with a ~100-m-thick viable cell layer at the periphery and a necrotic 
core (dark part) in the center. The necrotic core was formed because cells in the core had 
inefficient supply of nutrients and increased accumulation of produced waste. Because the 
Q3STCy probe, and the TCy reporter have distinct emission range, they can be measured 
simultaneously with different fluorescence channels. The fluorescence signal collected from the 
Cy5 channel (em = 662–738 nm) reflects the emission of TCy, while the signal from the Cy7 
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channel (em = 765–855 nm) is the summed fluorescence of the weakly fluorescent unreacted 
Q3TCy probe and any formed highly fluorescent STCy intermediate possibly present. Before the 
addition of Q3STCy, there was no fluorescence in either detection channel as shown in control 
images. Upon exposure of the MCTSs to Q3STCy, both fluorescence channels underwent 
immediate fluorescence increases. Relatively linear time-dependent fluorescent responses were 
observed for both emission ranges in the entire MCTS region during the 3-h experimental period, 
the longest time used, Figure 2.27.  Another observation was that the TCy reporter fluorescence 
was much brighter near periphery than in the core. This is because the hNQO1 activity in the 
viable cell layer is larger than in the necrotic core.84 All the acquired outcomes from the MCTSs 
studies indicate that Q3STCy can quickly penetrate into the three-dimensional tumor mimics, enter 
their component cells, and report the cytosolic hNQO1 activity.   
 
Figure 2.26 Fluorescence and DIC images of living HT-29 MCTSs (23 days old, 970 ± 24 m 
diameter) in a phenol-free RPMI-1640 medium using wide-field microscopy. The MCTSs were 
exposed to 5 M Q3STCy at 37 ºC for different times.  Images were captured every 30 min 
using a Leica DM6 microscope with sequential Cy7 (ex = 672–748 nm, em = 765–855 nm; 50 
ms exposure time) and Cy5 (ex = 590–650 nm, em = 662–738 nm; 500 ms exposure time) 
filters. The control images are from an MCTS without the addition of the probe. Scale bar = 
200 m.  The dark center in DIC images is the necrotic core. 
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2.3.17  Fluorescence Dequenching of Q3STCy under In Vivo Conditions 
 Before moving on to possible animal studies, I examined whether Q3STCy is stable under 
in vivo conditions. The fluorescence response of Q3STCy was measured in the presence of 50% 
fetal bovine serum (FBS), Figure 2.28. Even though the immediate fluorescence signal at 820 nm 
increased and reached a plateau in less than 10 min, this fluorescence increase profile was 
distinct from that with the treatment of hNQO1. The fluorescence wavelength shift did not appear 
in the obtained spectra, indicating that treatment with FBS was not able to initiate the production 
of TCy. I posit that the fluorescence increase around 820 nm is caused by the unfolding of the 
quenched Q3STCy probe in altered environments, not interferent-induced activation/removal of 
the quinone group of the probe. To verify this hypothesis, the FBS treated Q3STCy solution for 60 
min was inspected by mass spectrometry. Besides ions associated with proteins at m/z > 1000, 
only the mass peaks of the unactivated Q3STCy probe (m/z = 842.4534) were observed. The 
signal of the TCy reporter (m/z = 506.3535) did not appear in the spectrum, indicating there was 
no formation of TCy under these conditions. This outcome supported the conclusion that the 
Q3STCy probe is not activated by the presence of FBS, but rather its ~820-nm emission is 
increased, most likely the result of decreased PeT quenching from the fluorophore donor to the 

























































Figure 2.27 Corresponding fluorescence increase of the MCTSs in Figure 2.26. Fluorescence 




quinone acceptor. FBS is composed of a variety of proteins. The addition of FBS to the PBS 
solution greatly altered the viscosity and polarity of the resulting solution. The binding of the 
heptamethine fluorophore to the proteins probably separated the fluorophore from the quinone 
moiety, resulting in the decreased PeT quenching. The emission peak of Q3STCy shifted from 
 
 
Figure 2.28 (A) Fluorescence spectra of a 12.5 μM Q3STCy solution in PBS/FBS (50%:50%). 
25 μM Q3STCy in PBS (2 ml) was mixed with 100% FBS (2 mL), resulting in the desired 
solution, whose fluorescence was monitored for 60 min at room temperature; (B) Mass spectra 




798 nm to 820 nm is in accordance with observation stemming from the established emission 
peak of ICG in human plasma.85 The latter is well known to bind rapidly to plasma in the human 
body.86 
2.3.18  Identification of Peritoneal Ovarian Cancer Micrometastases in an In Vivo Mouse 
Xenograft Model 
Having demonstrated successful detection of upregulated hNQO1 activity within various 
cancer cell lines cultured in two and three dimensions, I wished to explore the potential of the 
Q3STCy probe for in vivo identification of tiny cancer foci in an animal model. The ability to 
visualize and surgically remove <1-mm-diameter metastatic lesions that result from 
intraperitoneal dissemination will have important ramifications in the treatment of colorectal, 
gastric, pancreatic, and ovarian cancers. For example, it has been shown that the median overall 
survival of patients is twice as great (64 months) if the surgeon is able to remove ovarian cancer 
tumors less than 1-mm in dimension versus patients with residual diseased tissue larger than 1 
mm.87  
Successful resection of such small cancers is predicated on their identification/detection, 
a feat impeded by poor differentiation of diseased and healthy tissues during traditional white light 
examination.88-89  Fluorescence-guided surgery88, 90-91 that is based on topical application of 
activatable probes holds much promise for discrimination of tissues,92-94 because such turn-on 
probes outshine their always-on fluorescent counterparts as a result of increased target-to-
background signal ratio and exceedingly rapid nature of the visualization events, often times on 
the timescale of min.89  Importantly, cell-permeable probes that are activated by cancer-
associated intracellular enzyme targets to yield cell-retained fluorescent reporters hold the 
possibility of providing diseased/healthy tissue discrimination with near cellular resolution.  To 
date, only two intracellular enzyme–probe systems have been used to detect human cancers in 
preclinical studies, namely, one based on -galactosidase73 that is overexpressed in ovarian 
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cancers and another targeting hexosaminidase, which is upregulated in colorectal cancer cells;95 
both enzymes reside in the lysosomes.  
Exposure of peritoneal xenograft tumors in living mice to  
dilute solutions of Q3STCy probe subsequently affords ready detection of ovarian cancer tumors 
as small as ~0.5 mm diameter, Figure 2.29.  Although imperceptible by white light, the tiny ovarian 
cancer tumors are clearly visible in spectral images of the excised mesentery that correspond to 
the red fluorescent protein (RFP)-transfected SHIN3 cells and their interaction with the Q3STCy 
probe.  We selected the low hNQO1-expressing SHIN3 cells in the xenograft studies so as to 
demonstrate the capabilities of the Q3STCy probe.  There was no detectable signal in control 
animals that were not exposed to Q3STCy; Figure 2.29 Control.  Importantly, spectral acquisition 
and unmixing allows for examination of the integrity of cancer foci identification by the Q3STCy 
probe, which is achieved by a side-by-side comparison of the resulting “Q3STCy image” and the 
“RFP image” produced by the genetically encoded fluorescent protein in the SHIN3-DsRed 
ovarian cancer cells.96  As seen in Figure 2.29, the fluorescence signal generated by Q3STCy 
incubation in the peritoneum of mice possessing SHIN3-DsRed tumors is mostly coincident with 
RFP-positive foci, thereby demonstrating the ability of the NIR probe to identify the presence of 
the hNQO1-overexpressing SHIN3 cells.  However, in the Q3STCy image, fluorescence signal is 
sometimes noted in areas of the small bowel adjacent to the RFP-labelled tumor nodules, 
suggesting possible non-specific activation of the probe within healthy, neighboring cells in these 
regions.  It is posited this observation is actually due to probe activation in healthy cells having a 
higher-than-normal hNQO1 activity that results from their being stimulated by-products released 
from their cancer cell neighbors.  Such a scenario is supported by reports of higher-than-normal 
hNQO1 expression within some healthy tissues in immediate proximity to cancerous tissue;97 this 
was attributed to induced hNQO1 activity in normal tissue cells by membrane-permeable 
materials released from tumor cells,98-99 with said inducing agents potentially being the cause of 
increased hNQO1 activity in cancer cells cultured at high cell density.37, 100 This observation with 
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hNQO1 may eventually lead to limitations in the resolution of surgical resections that rely upon 
hNQO1-based probes, similar to what is possible with extracellularly- activated probes whose 
reporters may enter cancerous and nearby healthy cells. 
It is of particular note that short exposure times and dilute concentrations of the Q3STCy probe in 
the peritoneum result in the effective identification of peritoneally disseminated ovarian cancer by 
fluorescence-activated imaging, in a spectral range that allows for deep penetration of light into 
tissue.  These outcomes are quite valuable, as the construction and successful use of NIR probes 
and reporters for in vivo biomedical imaging applications is exceedingly challenging.  
Development of enzyme-activatable, cell-penetrable NIR probes is complicated by the multitude 
of structure and size limitations imposed on the probe, often times making so poor the efficiency 
 
Figure 2.29 Visualization of peritoneal metastases in SHIN3 mouse model of human ovarian 
cancer via fluorescence spectral imaging of mesentery at 1 h post intraperitoneal 
administration of Q3STCy (300 L of 100 M probe in pH 7.4 PBS).  Red fluorescent protein 
(RFP) signal results from the RFP-transfected cells (SHIN3-DsRed).  Control designates 
mouse having no xenograft and treated with Q3STCy.  Scale bar = 5 mm.   
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of enzymatic activation that topical application of probe is no longer feasible.  As a result, the use 
of intravenously delivered always-on fluorescent molecules that target cell surface uptake 
receptors has been extensively investigated, but they often times yield high background 
fluorescence signals that decrease the TBR due to their being taken up by cancer tissue in non-
specific97 or inefficient101 ways.  Although synthetic elaboration of the structure of tissue-targeting 
NIR molecules can yield lower background signal,102 the time needed for them to reach the target 
site is large.  Also, due to their intravenous delivery at relatively high concentrations, they face the 
prospect of regulatory agency approval, similar to that for new drug molecules.88  Furthermore, 
systemically-introduced reporters cannot access remote diseased tissues, such as multicellular 
tumor spheroids associated with ovarian cancer metastasis and reoccurrence.80   Thus, the 
achievements with the Q3STCy NIR probe demonstrate the strength of locally applied, activatable 
molecules for fluorescence-based identification of diseased tissues, particularly those 
overexpressing reductases that are key to disease progression.    
2.4  Conclusion 
A novel NIR probe, Q3STCy, was designed, synthesized, and biologically evaluated, which 
was successfully applied in the detection and visualization of endogenous intracellular human 
NAD(P)H: quinone reductase (hNQO1) activity in two- and three-dimensional cancer cell cultures 
and an in vivo preclinical model of peritoneally disseminated ovarian cancer. The Q3STCy probe 
comprises 1) an hNQO1-specific substrate tri-methyl locked quinone propionic acid (Q3PA) trigger 
that is reduced to its hydroquinone effectively by an appropriate reducing agent, 2) a self-
eliminating linker, 2-mercaptoethanol that separates the Q3PA trigger from the bulky reporter, and 
3) a hemptamethine fluorophore TCy emitting intense NIR light for fluorescence reporting. The 
Q3STCy probe and the TCy reporter have distinctive spectroscopic characteristics (𝜆abs
probe
 = 786 
nm vs 𝜆abs
reporter
  = 606 nm and 𝜆em
probe
 = 798 nm vs 𝜆em
reporter
 = 755 nm). This stark spectral 
difference was attributed to their altered electronic molecular orbitals as evidenced by frontier 
133 
 
molecular orbital calculations.  Q3STCy exhibited a low fluorescence efficiency caused by the 
donor-excited-photoinduced electron transfer (d-PeT) quenching as verified by electrochemical 
voltammetry.  
Upon hNQO1-specific reduction, the quinone recognition substrate (Q3PA) was reduced 
to its corresponding unstable hydroquinone that was cleaved through the intramolecular formation 
of lactone. This process triggered the removal of the 2-mercaptoethanol linker through the 
formation of 1,3-oxathiolan-2-one, resulting in the release of the highly fluorescent NIR 
heptamethine TCy reporter. The detection mechanism was substantiated by the unique spectral 
response of the Q3STCy solution to the addition of hNQO1 and by the LCMS studies of the 
probe/enzyme reaction mixtures. The cloaked fluorescence of Q3STCy was revealed by hNQO1 
in aqueous solutions within a brief period course (< 30 min) with a large SBR ratio (193-fold). 
Further enzymatic kinetics evaluation exhibited that Q3STCy had a strong affinity to hNQO1 (Km 
= 1.09 ± 0.471 M) and an unprecedented high catalytic efficiency (kcat/Km = 1.49 × 105 ± 0.682 × 
105 M–1s–1).  This is probably caused by the effective separation between the hNQO1 recognition 
substrate (Q3PA) and the bulky fluorophore TCy by the flexible 2-mercaptoethanol linker allowing 
the immediate penetration of Q3STCy into the reactive site of hNQO1. Stability and selectivity of 
the probe/reporter system were examined by exposing both probe and reporter to putative 
competing reducing interferents (thiols and reductases) and various pH solutions. 
The ability of Q3STCy to differentiate cell lines with various intracellular hNQO1 activities 
(HT-29, H596 (+), SHIN3, and H596) was investigated using fluorescence microscopy. A large 
fluorescence turn-on was observed in hNQO1-expressing cell lines (HT-29, H596 (+), and SHIN3), 
but limited fluorescence was formed in hNQO1 non-expressing cell line (H596); these outcomes 
reflect the ability of Q3STCy to detect and differentiate human cancer cells possessing varied 
hNQO1 activity levels.  The high fluorescence observed for the hNQO1-gene transfected H596 
cell line, H596 (+), clearly indicated that Q3STCy was activated by hNQO1 in a highly selective 
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manner. Through the colocalization study, the ultimate location of the produced TCy reporter was 
shown to be mainly in lysosomes, thereby offering enhanced cellular retention. 
Furthermore, it was demonstrated that the developed probe/reporter system allowed facile 
detection and imaging of three-dimensional multicellular tumor spheroids (MCTSs) possessing 
spatially heterogeneous hNQO1 activities. In a mouse xenograft model, peritoneal injection of 
dilute solutions of the probe led to ready identification and visualization of human ovarian cancer 
tumors as small as 0.5-mm dimension. The specificity and sensitivity of detecting disseminated 
ovarian metastases in vivo were further studied by a collaborating group, and reported in a 
separate publications.103 It was found that Q3STCy can provide high sensitivity (96.9%) and 
moderate specificity (61.0%). Both sensitivity and specificity can be improved to 100% by 
employment of clinically relevant imaging methodologies. 
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A NEAR-INFRARED, FAST-RESPONSIVE, AND ON-ON FLUORESCENT PROBE TO 
VISUALIZE AN INTRACELLULAR CANCER-ASSOCIATED QUINONE REDUCTASE IN 
CELLS AND MULTICELLULAR TUMOR SPHEROIDS 
 
3.1  Introduction 
Smooth progression of dynamic biological processes in living subjects relies on the 
precise and deliberate actions of abundant enzymes. Abnormal enzymatic activities often indicate 
the onset and progression of some specific diseases. Sensitive, selective, and rapid detection of 
enzyme activity will unravel the roles of such an enzyme in biological processes, greatly broaden 
human understanding of physiological and pathophysiological mechanisms, and potentially 
contribute to the successful design of precision medicines.1-2 Fluorescence imaging as a sensitive 
and non-invasive technique has the potential to report the enzymatic presence in vitro and in vivo 
in conjugation with the use of enzyme-targeting fluorescent probes in real-time and high resolution. 
The development of enzyme-specific, small-molecule fluorescent probes is based on always-on 
and off-on probe design strategies.3 Highly specific always-on fluorescent probes can be 
constructed through direct conjugation of fluorophores to specific enzyme targeting groups, such 
as monoclonal antibodies (mAbs), aptamers, and enzyme-specific binding molecules with high 
affinity. However, to generate a detectable target-to-background ratio (TBR), a longer exposure 
period is required for the systemic clearance of the unbound fluorescent probe.4 Always-on probes 
do not fully exploit the catalytic feature of an enzyme, which is very important to amplify the signal 
in the targeted area to report enzyme presence.  In contrast, high TBR values can often be 
achieved with an off-on fluorescent probe due to the enzymatic amplification effect.4 However, to 
achieve rapid and sensitive detection of enzymes with activatable fluorescent probes, the 
designed probes are required to have certain characteristics such as efficacious enzyme kinetics 
and a rapid fluorescence turn-on rate. 
Reductases, which are overexpressed in tumor and other diseased cells often caused by 
the cellular accumulation of the reactive oxygen species (ROS), have been broadly investigated 
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as biomarkers to design targeted medicines.5 Among the reductase family, hNQO1 has attracted 
great attention in the scientific community due to its close relation to tumor invasiveness and 
progression, and its overexpression in a multitude of tumor cell lines.6 Optical imaging of hNQO1 
in vitro and in cellulo with the use of enzyme activatable fluorescent probes has been recently 
investigated by the McCarley group7-10 as well as the colleagues groups.11-15 However, both the 
absorbance and fluorescence of all the developed probes for hNQO1 lie within the ultraviolet (UV) 
and visible range of the electromagnetic spectrum. Short excitation and emission wavelengths 
suffer from strong autofluorescence and shallow detection depth; in addition, their use can cause 
damage to applied biological systems.16 Considering that NIR light is capable of avoiding the 
aforementioned drawbacks, I described in the previous chapter a fluorescent probe Q3STCy 
whose NIR fluorescence was selectively and effectively decloaked by hNQO1. Q3STCy was also 
successfully employed to report hNQO1 activity in hNQO1-expressing cells, multicellular tumor 
spheroids (MCTSs) with spatially heterogeneous hNQO1 expression, and ovarian cancer 
derivative metastases in mouse xenograft models.17 Despite its high enzyme kinetics, the 
relatively slow cleavage of the 2-mercaptoethanol linker curtailed the release rate of the strongly 
fluorescent reporter. The linker is flexible and thus the distance between the hNQO1 recognition 
substrate, Q3, and the fluorophore, TCy, can become short in aqueous solutions due to its folding 
structure. The short distance greatly enhanced the photoinduced electron transfer (PeT) efficiency 
and quenched the fluorescence of Q3STCy, thus making Q3STCy an ideal off-on probe. Hence, if 
the 2-mercaptoethanol linker were to be substituted by a rigid and fast-eliminating linker, a 
fluorescent probe could be crafted with improved imaging capability, such as faster reporter 
release and on-on fluorescence in an energetically distinct wavelength range. The linker N-
methyl-p-aminobenzyl alcohol (NMPABA) has a fast cleavage rate (within minutes) and the 
methyl group can inhibit the formation of a spirolactam with quinone.18-20 Therefore, NMPABA was 
selected as the linker to construct a new fluorescent probe, dubbed Q3NTCy. 
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Herein, a fast-responsive NIR fluorescent probe, Q3NTCy, was designed, which is capable 
of sensitive and selective detection of hNQO1 in both off-on and on-on imaging modes. It was 
successfully employed for imaging hNQO1-expressing cells and multicellular tumor mimics with 
spatially heterogeneous hNQO1 expression. Q3NTCy had a tripartite structure: 1) the Q3 
recognition substrate, which can be selectively reduced by hNQO1 in the presence of its cofactor 
NADH; 2) the rigid and fast-eliminating linker N-methyl-p-aminobenzyl alcohol (NMPABA), 
predicted for effectively separating efficiently the Q3 substrate and the fluorophore TCy; 3) the 
bright fluorophore TCy, acting as a reporter emitting NIR light.  The cleavage mechanism was 
proposed as in Scheme 3.1. Upon the reduction by hNQO1, the Q3 motif was rapidly reduced and 
cleaved off in the form of lactone, followed by the cleavage of the self-eliminating linker NMPABA 
and the production of the strongly fluorescent TCy reporter.  
 
Scheme 3.1 Proposed activation mechanism of Q3NTCy by hNQO1. 
3.2  Experimental Section 
3.2.1  Synthetic Materials and Methods  
All the chemicals and solvents in the synthesis were purchased from Sigma-Aldrich or 
Fisher Scientific, unless otherwise stated, and used without further purification. Thin-layer 
chromatography (TLC) separation was performed on Aluminum-backed 60 F254 silica plates 
purchased from EMD Chemicals. Preparative separation and purification of crude products were 
performed on a FlashMaster Personal (Biotage) with Biotage SNAP KP-Sil flash cartridges (50-g, 
25-g, or 10-g size). 1H and 13C NMR spectra were measured in deuterated chloroform (CDCl3) on 
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a Bruker AVIII-500 nuclear magnetic resonance (NMR) spectrometer at 25 ºC. Chemical shifts in 
the NMR spectra were reported in the standard  notation of parts per million, and calibrated by 
the residual protio-solvent of CDCl3 (7.26 for 1H and 77.16 for 13C). Absorption bands in the NMR 
spectra were listed as singlet (s), doublet (d), triplet (t), or multiplet (m), and coupling constants 
(J) are reported in hertz (Hz). Mass spectra were measured with an Agilent 6210 ESI-TOF high 
resolution mass spectrometer. 
 
Scheme 3.2. Synthetic scheme of Q3NTCy. 
3.2.2  Synthesis  
The starting materials quinone propionic acid (Q3PA), and tricarbocyanine compound 
(TCy) were obtained as described in Chapter 2. 4-(tert-butyldimethylsilyloxy)-N-methylamino) 
benzyl alcohol was synthesized by following the reported procedures with necessary 




Synthesis of compound 2. Q3PA (250 mg, 1 mmol) was dissolved in 18 mL anhydrous 
DCM in a 25 mL round-bottom flask under nitrogen conditions. The solution was cooled to – 50 
ºC in an acetone/dry ice cooling bath, followed by the injection of N-methylmorpholine (330 L, 3 
mmol) and isobutyl chloroformate (145 L, 1.1 mmol). The reaction was allowed to proceed for 
15 minutes, then 4-(tert-butyldimethylsilyloxy)-N-methylamino) benzyl alcohol (276 mg, 1.1 mmol) 
in 2 mL anhydrous DCM was injected into the solution slowly. After 6 h, the solution was washed 
with water and brine, then dried by magnesium sulfate, which was removed through filtration. 
After removing the organic solvent in a rotary evaporator, the crude product was purified with a 
silica gel column using hexane/ETHYL ACETATE (6/1) as the eluent yielding a pale yellow oil 
product (391 mg, 81%). 1H NMR (500 MHz, CDCl3)  7.38 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 
2H), 4.77 (s, 2H), 3.13 (s, 3H), 2.73 (s, 2H), 2.08 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.28 (s, 6H), 
0.95 (s, 9H), 0.12 (s, 6H). 13C NMR (126 MHz, CDCl3)  191.33, 187.80, 172.26, 154.98, 143.76, 
142.77, 141.30, 137.80, 136.25, 127.41, 127.36, 64.52, 47.63, 38.17, 37.21, 28.52, 26.06, 18.54, 
14.16, 12.85, 12.22, -5.15. ESI-HRMS: for C28H41NO4Si: expected m/z = 484.2878 [M + H]+; found 
m/z = 484.2891 [M + H]+; 2.7 ppm error. 
 
Synthesis of 3-(3ʹ,6ʹ-dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic 
acid 4-(N-methylamino) benzyl alcohol amide (4). Compound 2 (95 mg, 0.2 mmol) was dissolved 
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in 5 mL anhydrous THF solvent in a 20 mL round-bottom flask under nitrogen. The solution was 
then cooled to 0 ºC in an ice-water bath. 1 M TBAF in THF (220 L, 0.22 mmol) was diluted further 
by 0.8 mL THF, which was injected to the previous solution slowly. After 10 minutes, the reaction 
was quenched by saturated ammonium chloride solution. The quenched reaction solution was 
put in a rotary evaporator to remove THF, followed by extraction with DCM. The combined organic 
phase was then washed with water and brine, and then dried with MgSO4. The crude product was 
then purified using a silica gel column with hexane/ethyl acetate (1/1) as the eluent, yielding a 
pale yellow solid product 3 (53 mg, 72%). 1H NMR (500 MHz, CDCl3)  7.43 (d, J = 8.0 Hz, 2H), 
7.18 (d, J = 8.0 Hz, 2H), 4.74 (s, 2H), 3.14 (s, 3H), 2.73 (s, 2H), 2.08 (s, 3H), 1.99 (s, 3H), 1.94 
(s, 3H), 1.28 (s, 6H). 13C NMR (126 MHz, CDCl3)  191.36, 187.83, 172.24, 154.89, 143.73, 
143.34, 140.73, 137.89, 136.36, 128.41, 127.64, 64.68, 47.71, 38.19, 37.24, 28.56, 14.19, 12.86, 
12.23. ESI-HRMS: for C22H27NO4: expected m/z = 370.2013 [M + H]+; found m/z = 370.2023 [M 
+ H]+; 2.7 ppm error. 
 
Synthesis of Q3NTCy. Compound 3 (30 mg, 0.081 mmol) in 5 mL anhydrous THF solvent 
was cooled to 0 ºC in an ice-water bath in a sealed 20 mL vial, followed by the injection of 15% 
phosgene (caution: toxic) in toluene (0.6 mL, 0.84 mmol). After 2 h, the solvent was removed in 
a rotary evaporator with aqueous NaOH solution (1 M) in the trap to neutralize the extra phosgene. 
The afforded residue was then dissolved in 1 mL anhydrous DCM, and this was then injected to 
TCy (10 mg, 0.016 mmol) in an anhydrous DCM solution with N,N-diisopropylethylamine (DIPEA, 
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0.1 mL) under nitrogen. The solution was allowed to stir for 6 h at room temperature, during which, 
a change of the solution color from blue to green was observed. After removing the solvent in a 
rotary evaporator, the crude product was purified using a silica gel column with methanol/DCM 
(1:99 to 5:95) as the eluent to yield a green product Q3NTCy (14 mg, 85%). 1H NMR (500 MHz, 
CDCl3) (rotamers)  7.63 (d, J = 14.0 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 
7.29 (d, J = 8.0 Hz, 2H), 7.22 (t, J = 7.5 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 
6.23 (d, J = 14.0 Hz, 2H), 5.24 (s, 2H), 4.26 (q, J = 7.5 Hz, 4H), 3.35 (s, 3H), 3.05 (s, 3H), 2.84–
2.7 (m, 4H), 2.59 (s, 2H), 2.15–1.80 (m, 11H), 1.66 (s, 6H), 1.50–1.36 (m, 12H), 1.20 (s, 6H). 13C 
NMR (126 MHz, CDCl3) (rotamers)  191.17, 187.63, 171.85, 171.08, 155.66, 155.19, 154.50, 
143.53, 143.41, 141.81, 141.41, 141.13, 141.00, 137.84, 136.31, 136.13, 128.92, 128.74, 127.80, 
127.45, 125.26, 122.34, 122.23, 110.66, 101.35, 101.15, 66.66, 49.08, 47.66, 39.97, 39.85, 38.52, 
37.91, 36.95, 28.47, 28.36, 28.06, 25.06, 24.78, 20.84, 14.06, 12.71, 12.56, 12.44, 12.11. ESI-
HRMS: for C58H69N4O5: expected m/z = 901.5262 [M]+; found m/z = 901.5259 [M]+; 0.3 ppm error. 
3.2.3  Spectroscopic Measurement Methods  
Q3NTCy and TCy were dissolved in DMSO to make their respective stock solutions (1 mM) 
and stored in a refrigerator (– 20 °C) until use. The stock solutions were used to prepare their 
corresponding diluted sample solutions. Spectroscopic measurements were performed in 0.1 M 
phosphate-buffered saline/0.1 M KCl (PBS, pH = 7.4). The PBS buffer was prepared with water 
(> 18 MΩcm) from a Barnstead NANOpure Diamond water System. UV-visible absorption 
spectra and fluorescence spectra were recorded in a 10-mm path length quartz cuvette on a 
Varian Cary-50 spectrophotometer and a PerkinElmer LS55 spectrofluorometer.  
3.2.4  Quantum Yield Measurement for Q3NTCy and TCy  
The measurement of quantum yield of TCy was described in Chapter 2.  The quantum 
yield of Q3NTCy in 2% DMSO/PBS solution (pH = 7.4) was measured with indocyanine green 
(ICG,  = 0.012 in water) as a standard.21 The quantum yields of Q3NTCy, Q3NNTCy, Q3STCy, 
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iBuTCy in acetonitrile were measured with ICG ( = 0.13 in DMSO) as a standard.21 ICG was 
purchased from Sigma-Aldrich. Relative quantum yields () of respective compounds in PBS or 
acetonitrile were calculated relative to ICG using the following equation: 








where the subscripts st and x stand for standard and test sample, respectively. is the quantum 
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance.  
Stock solution of Q3NTCy (1 mM in DMSO) was diluted by 0.1 M PBS solution, resulting 
in 0.8, 1.4, 1.8, and 2.2 M Q3NTCy solution with 2% DMSO as a co-solvent.  The absorbance at 
725 nm was maintained between 0.02–0.10 to minimize reabsorption effects. The Q3NTCy 
solutions of various concentrations were excited at 725 nm and their corresponding emission 
spectra were collected. Both absorption and emission spectra of each solution were collected 
three times. Similarly, the absorption and emission spectra of ICG solutions with various 
concentrations were collected. The gradients of Q3NTCy and ICG were plotted and obtained, with 
them being used in the previous equation to calculate the quantum yield of Q3NTCy. The quantum 
yield of Q3NTCy was determined to be 0.012. 
3.2.5  Enzyme Kinetics 
The hNQO1 enzyme (500,000 U mg–1, 1 U = 1 nmol of cytochrome C reduced min–1) was 
purchased from Sigma-Aldrich. hNQO1 was dissolved in 0.1 M PBS to prepare the hNQO1 stock 
solution (0.5 mg mL–1). Reduced -nicotinamide adenine dinucleotide (NADH, Sigma Aldrich) and 
bovine serum albumin (BSA, Sigma Aldrich) were dissolved in 0.1 M PBS (pH = 7.4) to yield a 
solution containing 100 M NADH and 0.007% BSA; this solution was prepared freshly and used 
for the following tests. Q3NTCy sample solutions with 0.5–12 M final concentration were 
prepared using the previously prepared stock solution. 1.5 mL of a given Q3NTCy sample solution 
was added with 3 L of the hNQO1 stock solution (0.5 mg mL–1), resulting in a 1 g mL–1 hNQO1 
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concentration (500 U mL–1). After the hNQO1 was added, fluorescence at the TCy reporter energy 
(ex = 600 nm, em = 755 nm) was immediately collected every 2 s over a 5-min time period using 
a PerkinElmer LS55 spectrofluorometer at 25 °C. Each solution was measured three times. 
Released TCy reporter concentration was obtained by converting the fluorescence signal with a 
calibration curve of TCy in the same buffer system. By fitting the TCy reporter release velocities 
versus Q3NTCy concentrations via nonlinear least-squared analysis, the apparent kinetic 
parameters Km and Vmax were obtained.  
3.2.6  Cell Culture  
HT-29 (human colorectal adenocarcinoma), A549 (non-small cell lung cancer cells), and 
H596 (human nonsmall cell adenosquamous lung carcinoma) were all purchased from American 
Type Culture Collection (ATCC; Manassas, VA). SHIN3 cells were provided by Dr. Hisataka 
Kobayashi at National Cancer Institute of U.S. National Institutes of Health.  Unless stated 
otherwise, cell culture media, fetal bovine serum albumin (BSA), and other supplements were 
also purchased from ATCC. HT-29 cells were cultured in McCoy’s 5A medium, while A549, SHIN3, 
and H596 were cultured in RPMI-1640 medium. All the media were supplemented with 10% fetal 
bovine serum, 10 IU mL−1 penicillin, and 10 g mL−1 streptomycin (Life Technologies). Cells were 
incubated in 75 cm2 treated tissue culture flasks in the dark at 37 °C under 5% CO2/95% air in a 
humidified incubator. 
3.2.7  Cellular Fluorescence Imaging Using Confocal and Wide-field Microscopy  
HT-29, A549, SHIN3, and H596 cells (0.3 million each) were cultured overnight in the dark 
at 37 ºC on 22 × 22 mm sterile glass coverslips (no. 1-1/2; Corning). After the old medium was 
replaced and the cells were washed with PBS once, the cells were cultured with 5 × 10-6 M 
Q3NTCy in the phenol red and L-glutamine free RPMI-1640 medium at 37 ºC for 20 min. The 
medium was then removed, and the cells were washed with PBS (pH 7.3, Dulbecco) twice.  4% 
paraformaldehyde (PFA) was used to fix the cells for 15 min with shaking at room temperature in 
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the dark.  After the PFA solution was removed, the fixed cells were bonded to microscope glass 
slides with a mounting medium (Immu-Mount, Fisher Scientific). These prepared slides were left 
in the dark overnight at room temperature to allow the mounting medium to dry. Then the slides 
were used for confocal microscopy and wide-field microscopy imaging experiments.  
Confocal cell images were captured with a Leica TCS SP2 spectral laser-scanning 
confocal microscope. The microscope was used with a 40× oil immersion objective (NA: 1.25) 
and a beam splitter (TD 488/543/633). The pinhole was set as 1.0 airy unit (AU, 82 m). The 
prepared cell slides were excited at 633 nm with a helium-neon laser (laser intensity = 25%), and 
the emitted photons in the range of 670–750 nm wavelengths were collected with a photomultiplier 
detector (PMT, voltage = 533 V). Cellular images were zoomed 3.2 fold and captured after being 
frame and line averaged 4 times.  
Conventional (wide-field) fluorescence images were captured with a Leica DM6 wide-field 
microscope equipped with an ORCA-Flash 4.0 Hamamatsu Digital CMOS camera. A 40x oil 
immersion objective (1.30 NA) was used. A Cy5 filter (excitation: BP 590–650 nm, dichroic mirror: 
660 nm; and emission: BP 662–738 nm) was selected to capture the fluorescence images from 
the TCy reporter, with 500 ms exposure time. The Cy7 filter (excitation: BP 672–748 nm, dichroic 
mirror: 760 nm; and emission: BP 765–855 nm) were selected to capture the fluorescence images 
from the Q3NTCy probe with 50 ms exposure time. Image analysis and statistical evaluation of 
cytosolic intensities from both confocal and conventional fluorescence microscopes were 
accomplished with Fiji/ImageJ software. 
3.3  Results and Discussion 
3.3.1  Spectroscopic Properties of the Probe/Reporter Pair 
Q3NTCy was prepared efficiently in a facile synthetic route (Figure 3.2). All the obtained 
compounds were characterized and their structures were determined by 1H, 13C-NMR, and HRMS. 
With the synthesized Q3NTCy probe in hand, its spectroscopic characteristics in an aqueous 
solution (0.1 M PBS, pH = 7.4) was firstly measured.  As shown in Figure 3.1, the absorption and 
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emission peaks of the Q3NTCy probe (𝜆𝑎𝑏𝑠
𝑝𝑟𝑜𝑏𝑒
 = 786 nm and 𝜆𝑒𝑚
𝑝𝑟𝑜𝑏𝑒
 = 798 nm) had bathochromic 
shifts of 180 nm and 43 nm respectively compared to that of the TCy reporter (𝜆𝑎𝑏𝑠
𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑟
 = 606 nm 
and 𝜆𝑒𝑚
𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑟
 = 755 nm). This prominent difference in their spectroscopic properties was attributed 
to the change of electronic energy levels of Q3NTCy and TCy. The introduction of the electron-
withdrawing carbamate bond into the meso positon of the tricarbocyanine fluorophore decreased 

































































































Figure 3.1 Absorption and emission spectra of 2 × 10–6 M Q3NTCy (A) and 3 × 10–6 M TCy (B)  




the HOMO-LUMO energy gap of Q3NTCy, resulting in its longer absorption/emission 
wavelength.22-23 The quantum yield of Q3NTCy in aqueous solution (2% DMSO: 98% PBS, pH = 
7.4) were measured as 0.012 relative to indocyanine green (ICG). Q3NTCy had a similar 
fluorescence efficiency as ICG, which was three-fold higher and two-fold lower than the probe 
Q3STCy ( = 0.0046) and the fluorophore analogue iBuTCy ( = 0.024), without the Q3PA moiety, 
described in Chapter 2. Considering the rigid linker NMPABA of Q3NTCy separated the 
fluorophore and the quinone moieties more efficiently that the flexible linker 2-mercaptoethanol of 
Q3STCy, the degree of photoinduced electron transfer (PeT) of Q3NTCy from the fluorophore 
donor to the quinone acceptor was lower than for Q3STCy. The quantum yield of TCy in the same 
solution was determined to be 0.063.23  Both the Q3NTCy probe and the TCy reporter had high 
fluorescence efficiencies and their absorption/emission wavelengths were located in energetically 
distinct wavelength regions, which made the probe/reporter pair suitable to act as an on-on 
fluorescence reporting system.  
3.3.2  hNQO1-initiated Spectral Response of Q3NTCy  
The hNQO1-initiated absorption/emission spectral response was next examined in an 
aqueous solution (0.1 M PBS, pH = 7.4) in the presence of the hNQO1 cofactor NADH (NADH) 
at room temperature. A solution of Q3NTCy (4 M) was treated with hNQO1 (1000 U mL–1, U = 1 
nmol of cytochrome c reduced min–1), it was observed in the absorption spectra of Q3NTCy that 
an immediate slight increase and then a decrease at 786 nm accompanied by an increase at 606 
nm with an isosbestic point at 655 nm, Figure 3.2. The 786 nm and 606 nm absorption bands 
were in agreement with that of the Q3NTCy probe and the TCy reporter, respectively. The spectral 
changes were caused by the hNQO1-induced consumption of Q3NTCy and concomitant 
production of TCy. HPLC-mass spectrometry data also corroborated TCy release. 
155 
 

























Figure 3.2 Time-dependent absorption spectra of Q3NTCy (4 M) in 0.1 M PBS solution (pH = 
7.4) containing NADH (100 M) and BSA (0.007%) initiated by the addition of hNQO1 (2 g mL–
1, 1000 U mL–1). The spectra were measured every 4 min. T = 25 ºC. 
The prominent photophysical properties of Q3NTCy and TCy (the distinct 
absorption/emission profiles and high fluorescence efficiencies) motivated me to investigate the 
possibility of the probe/reporter pair to be a ratiometric system. A solution of Q3NTCy (4 M) upon 
the addition of hNQO1 (1000 U mL–1) was excited at its isosbestic point 655 nm, and emission 
spectra were collected every 2 min, Figure 3.3. An immediate fluorescence increase at 798 nm 
was observed, and the peak gradually moved to 755 nm. The initial cleavage of the quinone 
moiety by hNQO1 was most likely the cause of the fluorescence increase at 798 nm. The 
corresponding ratio of fluorescence intensity at 755 nm to that at 798 nm was plotted, Figure 3.3. 
As time increased, the ratio showed a decrease at the onset of the experiment, then a steady 
linear increase occured, followed by a plateau. These outcomes indicated that the ratio 
interpretation was affected by the slight fluorescence quenching of Q3NTCy in the PBS solution.  
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Figure 3.3 (A) Time-dependent emission spectra of Q3NTCy (4 M, ex = 655 nm) in 0.1 M PBS 
solution (pH = 7.4) containing NADH (100 M) and BSA (0.007%) initiated by the addition of 
hNQO1 (2 g mL–1, 1000 U mL–1). The spectra were collected every 2 min. (B) The corresponding 
fluorescence intensity ratio (F765/F798) change. T = 25 ºC. 


















































Figure 3.4 (A) Time-dependent emission spectra of Q3NTCy (2 M, ex = 655 nm) in FBS/PBS 
(20%:80%, v/v) containing NADH (100 M) and BSA (0.007%) initiated by the addition of hNQO1 
(1 g mL–1, 500 U mL–1). The spectra were collected every 3 min. (B) The corresponding 
fluorescence intensity ratio (F745/F810) change. T = 25 ºC. 
The cytosol is rich in proteins, and its viscosity and polarity are different from the PBS 
solutions.24 I next sought to examine the fluorescence response of Q3NTCy towards hNQO1 
under cytosol-mimicking conditions. A 20% with fetal bovine serum (FBS) in 0.1 M PBS (pH = 7.4) 
solution was employed to mimic the protein-rich conditions. Upon the addition of hNQO1 (500 U 
mL–1) to the solution of Q3NTCy (2 M), a slight decrease in fluorescence intensity of Q3NTCy at 
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808 nm and a simultaneous fluorescence increase at 750 nm were observed during the 90-min 
time period, Figure 3.4. The corresponding ratio of fluorescence intensity at 745 nm to that at 810 
nm exhibited a steady increase. These results showed that Q3NTCy could act as a ratiometric 
probe under cellular conditions that mimic those inside cells. 
3.3.3  Stability of Q3NTCy 
 
 
Figure 3.5 (A) Fluorescence spectra of a 25 M Q3NTCy solution (ex = 660 nm) in PBS (20 mM, 
pH = 7.4) or PBS/FBS (50%:50%). The fluorescence spectra of 25 μM Q3NTCy in PBS/FBS 
(50%:50%) were collected every 3 min for 30 min at room temperature; (B) Mass spectra of 25 
M Q3NTCy upon exposure to the solution of PBS/FBS (50%:50%) for 60 min. 
 The stability of Q3NTCy in the presence of FBS was further evaluated to investigate 
whether there are concerns with its non-specific activation. The fluorescence response of Q3NTCy 
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was measured in the presence of 50% fetal bovine serum (FBS), Figure 3.5. Similar to Q3STCy, 
fluorescence intensity at 820 nm increased two-fold and reached a plateau in less than 10 min, 
and the fluorescence intensity at 755 nm did not increase. The binding of the heptamethine 
fluorophore to the proteins probably inhibited the PeT quenching and rigidified its structure, 
resulting in the observed fluorescence increase at 820 nm. The behavior of the emission peak at 
820 nm is in agreement with the established emission peak of ICG in the human plasma.25 The 
FBS-treated Q3NTCy solution at 60 min was investigated with mass spectrometry. The mass peak 
of the unactivated Q3NTCy probe (m/z = 901.5268) was observed, while that of the TCy reporter 
(m/z = 506.3535) did not appear in the mass spectra. This result further demonstrated that the 
Q3NTCy probe was chemically stable in the presence of FBS, and the two-fold fluorescence 
increase at 820 nm was caused by the inhibited PeT quenching of the fluorophore donor to the 
quinone acceptor.  
3.3.4  Enzymatic Kinetics of hNQO1 with Q3NTCy as a Substrate 
To investigate whether the purportedly fast-eliminating linker NMPABA resulted in a rapid 
production of TCy, the reporter release rates of Q3NTCy and Q3STCy (Chapter 2) under the same 
conditions was measured. As shown in Figure 3.6, the half-time (t1/2) of Q3NTCy to achieve its 
maximum TCy release was 15 minutes, a value much faster than that of Q3STCy. To quantitatively 
evaluate Q3STCy and Q3NTCy activation by hNQO1, the kinetics of hNQO1 activation of Q3STCy 
and Q3NTCy as substrates were measured at room temperature. The apparent parameters were 
acquired by plotting the TCy release rate initiated by hNQO1 (1 g mL–1, 500 U mL–1) with various 
concentrations of Q3STCy (0.5–12 M) and Q3NTCy (0.5–12 M). For Q3STCy, the enzyme 
affinity (Km) was 2.9 ± 0.8 mol, maximum velocity (Vmax) was 0.031 ± 0.004 mol min–1 mg 
hNQO1–1, catalytic constant (kcat) was 0.016 ± 0.002 s–1, and catalytic efficiency (kcat/Km) was 5.5 
± 1.7 × 103 M–1s–1). In contrast, for Q3NTCy, the enzyme affinity (Km) was 4.5 ± 0.5 mol, maximum 
velocity (Vmax) was 0.22 ± 0.01 mol min–1 mg hNQO1–1, catalytic constant (kcat) was 0.12 ± 0.01 
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s–1, and catalytic efficiency (kcat/Km) was 2.6 ± 0.3 × 104 M–1s–1). Q3NTCy has a slightly lower 
enzyme affinity than Q3STCy, which is evidenced by the larger Km value of Q3NTCy. However, 
the catalytic efficiency of Q3NTCy is 5 times larger than that of Q3STCy. Moreover, all the acquired 
values for Q3NTCy were comparable to our previous reported probes constructed by directly 
coupling the Q3PA recognition substrate to the fluorophores without a linker.7, 10, 26 This further 










 5 M Q
3
NTCy + 1 g/mL hNQO1
 5 M Q
3
NTCy + No hNQO1
 5 M Q
3
STCy + 1 g/mL hNQO1
 5 M Q
3

























Figure 3.6 The fluorescence intensity at 755 nm of 5 M Q3NTCy and 5 M Q3STCy (ex = 600 
nm) in aqueous solutions (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA 
was recorded with and without the addition of hNQO1 at the 5-min time point. T = 25 ºC. 

































































Figure 3.7 Kinetic plot of hNQO1 (1 g mL–1, 500 U mL–1) with Q3STCy (A) and Q3NTCy (B) 
as substrates in the aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and 
0.007% BSA. T = 25 ºC. Error bars indicate the standard deviation from three trials; line is best 
fit to data (2 = 0.000001 and 0.00002 for Q3STCy and Q3NTCy, respectively).  
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proved that the NMPABA linker can be automatically cleaved off rapidly. In contrast, the probe 
with a naphthalimide reporter had much lower enzymatic kinetic behavior.20 Considering that the 
naphthalimide compound is more hydrophobic than the cyanine compound, the quinone 
recognizing moiety folding with the naphthalimide group might block its interaction with hNQO1, 
thus leading to a non-efficient enzymatic activation. 
3.3.5  Cellular Imaging with Q3NTCy as an off-on Fluorescent Probe 
Assured by the effective and efficient activation of Q3NTCy by hNQO1 in vitro, I next 
sought to examine the capability of Q3NTCy to detect hNQO1 activities in cells. Four cancer cell 
lines with various hNQO1 activities were utilized to examine the imaging potential of Q3NTCy. HT-
29 (colorectal carcinoma cells, hNQO1-expressing), A549 (non-small cell lung cancer cells, 
hNQO1-expressing), SHIN3 (ovarian cancer cells, hNQO1-expressing), and H596 (non-small cell 
lung cancer cells, hNQO1 non-expressing) cell lines were included as hNQO1-positive and 
hNQO1-negative cell lines. 
I first utilized Q3NTCy as an off-on probe to examine the intracellular production of the TCy 
reporter in the hNQO1-positive cell lines (HT-29, A549, and SHIN3).  All four types of cells were 
incubated with 5 M Q3NTCy for 20 min under the humidified cell culture conditions with 5% CO2 
at 37 °C. Cellular fluorescence images were captured using a Leica TCS SP2 spectral laser-
scanning confocal microscope. The prepared cellular samples were excited at 633 nm, and their 
emission in the range of 660–750 nm was collected. The excitation/emission settings matched 
perfectly with the excitation/emission spectra of TCy, while they did not match with that of Q3NTCy. 
The minimally excited Q3NTCy emitted light in a longer wavelength range, which would not 
interfere the detection signal of TCy-coating cells. Therefore, the settings promised that only the 
emission from the hNQO1-induced production of TCy in cells was detected, making Q3NTCy an 
off-on probe. As shown in Figure 3.8, strong cytosolic fluorescence was observed in hNQO1-
positive cells (HT-29, A549, and SHIN3), while almost no detectable fluorescence was observed 
in hNQO1-negative cells (H596) under the same imaging conditions. These outcomes indicated 
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that Q3NTCy was cell membrane permeable, and it can be rapidly converted to the TCy reporter 
by the intracellularly present hNQO1 enzyme. The target-to-background ratios (TBR) of the 
acquired cellular images were also determined. The TBR was defined as the emission signal from 
the hNQO1-positive cells (HT-29, A549, and SHIN3) compared to that from the hNQO1-negative 
cells (H596).  It was found that the TBR values of HT-29 (33 cells)/H596 (28 cells), A549 (21 
cells)/H596 (28 cells), and SHIN3 (31 cells)/H596 (27 cells) were 7.6 ± 0.6, 6.5 ± 1.0, and 9.8 ± 
0.7 (95% confidence) respectively. It was noticed that the obtained TBR values of Q3NTCy were 
much higher than that of Q3STCy; the TBR values for Q3STCy treated cells are 5.4 ± 0.4 for HT-
29 (53 cells)/H596 (38 cells) and 2.2 ± 0.2 for SHIN3 (32 cells)/H596 (32 cells). As discussed in 
the Chapter 2, probable causes were the higher chemical stability of Q3NTCy than that of Q3STCy, 
resulting in smaller non-specific activation of Q3NTCy and thus low background signal, and the 
fast cleavage rate of the NMPABA allowing more effective production of TCy. 
 
Figure 3.8 Confocal and differential interference contrast (DIC) images of H596, A549, and HT-
29 cell lines. All the cells were incubated with 5 M Q3NTCy for 20 min under 5% CO2, humidified 
conditions at 37 ºC. Fluorescence images were captured in the 670–750 nm emission range upon 




















3.3.6  Cellular Imaging with Q3NTCy as an on-on Fluorescent Probe 
After verifying the effective production of TCy inside hNQO1-positive cells, I next 
examined the applicability of Q3NTCy to work as an on-on fluorescent probe. An on-on fluorescent 
probe is defined as one where both the probe and the reporter are highly fluorescent but their 
emitted light is located in different energetic ranges of the electromagnetic spectrum. In contrast 
to an off-on probe, an on-on probe has the advantages of being able to monitor the presence of 
both the unactivated probe and the produced reporter, which allows for the avoidance of false 
negative signals. Probes of this type also allow for gaining information about probe entry into cells. 
Q3NTCy treated cellular samples were imaged using a Leica DM6 wide-field microscope. Cy5 
and Cy7 filter sets were applied. The Cy5 filter sets (excitation: 590–650 nm, dichroic mirror: 660 
nm, and emission: 662–738 nm) have different excitation/emission wavelength range from the 
Cy7 filter sets (excitation: 672–748 nm, dichroic mirror: 760 nm, and emission: 765–855 nm). The 
 
Figure 3.9 Wide-field and DIC images of HT-29, A549, and H596 cells. All the cells were 
incubated with 5 M Q3NTCy for 20 min under 5% CO2, humidified conditions at 37 ºC. 
Fluorescence images were captured with Cy7 (765–855 nm; 50 ms exposure) and Cy5 (662–



































Cy5 filter sets were utilized to collect emission signal from the TCy reporter, while the Cy7 filter 
sets to collect that from the Q3NTCy probe. As shown in Figure 3.9, in the hNQO1-positive cells 
(HT-29 and A549), strong fluorescence signal in the 662–738 nm range and dim fluorescence 
signal in the 765–855 nm range were observed; the latter comes from the unreacted probe. These 
results indicated that Q3NTCy was converted to TCy by hNQO1, which was in agreement with the 
previous cellular imaging data of Q3NTCy as an off-on probe. In contrast, for hNQO1-negative 
cells (H596), strong fluorescence in the 765–855 nm range, while limited fluorescence in the 662–
738 nm range were observed. This observation proved that Q3NTCy entered H596 cells when it 
emitted fluorescence in its original probe state due to the lack of hNQO1 activity in the hNQO1-
negative cell line. This demonstration clearly showed that an on-on probe has advantages over 
an off-on probe that a false negative signal attributed to cellular impermeability of a probe can be 
avoided. These cellular imaging experiments indicated that the developed Q3NTCy/TCy pair can 
act as both off-on and on-on systems to detect and imaging hNQO1 in cells. 
3.3.7  Fluorescence Imaging of Three-Dimensional Tumor Mimic Sections 
 
Figure 3.10 Immunohistochemistry of 5-day-old and 30-day-old MCTS sections. The hNQO1 
enzyme was treated with primary mouse anti-hNQO1 monoclonal antibody and biotinylated 
secondary antibody conjugated with horseradish peroxidase (HRP). The treated sections were 
further stained with ImmPACT novared HRP substrate. Red color indicates the presence of 
hNQO1. Scale bar = 100 m. 27 
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Although monolayer cell culture is a powerful tool for testing drugs and small molecules, 
it fails to resemble tissue microenvironments.28 For example, in vivo avascular tumors have 
features of structural diversity and nutrient/waste gradients, leading to varying levels of cell 
proliferation in cell collections or tumors. To overcome the drawbacks of a two-dimensional cell 
culture model, a 3-dimensional multicellular aggregate model was developed as an easy and 
simple laboratory-cultured model to mimic the realistic in vivo features. In this research, hNQO1-
positive HT-29 cells were utilized to construct multicellular tumor spheroids (MCTSs). As shown 
in Figure 3.10,27 the immunohistochemistry images of 5-day-old and 30-day-old MCTSs sections 
exhibited spatially heterogeneous hNQO1 expression. The 5-day-old MCTS had apparently 
equivalent hNQO1 expression across the spheroid region. In contrast, the 30-day-old MCTS 
formed a necrotic core, and it had uneven hNQO1 distribution. Its inner necrotic core had 
significantly less hNQO1 expression than the peripheral layer.  
 
Figure 3.11 Fluorescence images of 5-day-old and 30-day-old MCTS sections. The 20-m-thick 
MCTS sections were incubated with 5 M Q3NTCy for 10 min. Fluorescence images were 
captured in 670–750 nm emission range upon excitation by a 633-nm laser. Scale bar = 100 m. 
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To examine the ability of Q3NTCy to detect hNQO1 activity in the solid tumor mimics, living 
MCTS sections were treated with 5 M Q3NTCy for 10 min and then imaged with confocal 
microscopy, Figure 3.11. In accord with the hNQO1 expression data, an even fluorescence signal 
was observed across the microregions of the young MCTSs. In contrast, a weaker fluorescence 
in the interior region than the peripheral layer was observed in the aged MCTS with a necrotic 
core. These observations demonstrated that Q3NTCy was capable of being specifically activated 
by hNQO1 in the solid tumor mimic model, and it provides a new route to  in enzyme activity levels 
in tumor mimics.  
3.4  Conclusion and Outlook 
In this chapter, a new hNQO1-targeting fluorescent probe/reporter pair was presented, 
which is capable of reporting the activity of human NAD(P)H:quinone oxidoreductase isozyme I 
(hNQO1) in a rapid, selective, and sensitive manner. Both the Q3NTCy probe and the TCy reporter 
emit strong near-infrared (NIR) light; however, the emitted light for the probe and the reporter 
occurs in different energetic ranges of the electromagnetic spectrum. The effective reduction of 
Q3NTCy by hNQO1 initiated a chain reaction, which rapidly produced the TCy reporter. In 
comparison with the previous Q3STCy probe, Q3NTCy had a rigid and rapid-eliminating linker, 
thus making it have high fluorescence efficiency ( = 0.012) and rapid fluorescence turn-on (t1/2 
= 15 min). Due to the unique photophysical properties of the probe/reporter pair, Q3NTCy can act 
as an off-on, on-on, and potentially ratiometric fluorescent probe under protein-rich cellular 
conditions.  The enzymatic kinetic experiment showed that Q3NTCy was an excellent substrate 
of the hNQO1 enzyme. The acquired parameters (enzyme affinity and catalytic efficiency) was so 
effective that they were comparable to that of the hNQO1-specific probes without a linker.  
Cellular imaging experiments showed that hNQO1-positive (HT-29, A549, and SHIN3) and 
hNQO1-negative cells (H596) could be differentiated by the developed probe/reporter system with 
high integrity and large TBR values. Both hNQO1-positive and hNQO1-negative cells can be 
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visualized at the same time in different fluorescence energy range, thus making the system able 
to avoid false negative signals. Q3NTCy was further investigated for imaging three-dimensional 
colorectal tumor mimics. The fluorescence response was in agreement with the spatially 
heterogeneous hNQO1 expression demonstrated by immunohistochemistry. In sum, Q3NTCy 
was a highly selective probe to measure hNQO1 activity in biological samples. 
Although the Q3NTCy/TCy system was demonstrated to be useful as off-on and on-on 
systems to detect hNQO1 activities in cells and tumor mimics, the initial proposal was to develop 
a ratiometric reporting system that would offer potential route to quantify the hNQO1 enzyme in 
biological milieu. The PeT-based fluorescence quenching of Q3NTCy in aqueous solution, even 
to a lower degree than that of Q3STCy, still occurred upon the introduction of the rigid linker. This 
was evidenced by their respective quantum yields in aqueous solution, Table 3.1. Therefore, only 
under specific conditions such as high protein concentration, can Q3NTCy act as a ratiometric 
probe.    
Table 3.1 Photophysical data for iBuTCy, Q3STCy, and Q3NTCy in aqueous solution 
Compounds abs (nm) em (nm) a (M–1cm–1) 
iBuTCy 783 798 0.0243 111100 
Q3STCy 786 798 0.0046 60600 
Q3NTCy 785 798 0.0122 63500 
aICG ( = 0.012 in water) was used as a fluorescence standard;21 the quantum yields of 
compounds were measured in 0.1 M PBS solution (pH = 7.4) with 2% DMSO as a co-solvent with 
ex  = 725 nm 
To craft an ideal ratiometric fluorescent probe, the structure of Q3NTCy was modified. 
Because PeT is a distance-dependent process, increase of the distance between the donor and 
the acceptor can significantly decrease the PeT quenching efficiency.29 A compound, Q3NNTCy, 
with two rigid NMPABA linkers was synthesized in order to separating the quinone moiety further 
from the TCy fluorophore, Scheme 3.3. Unexpectedly, Q3NNTCy did not exhibit improved 
fluorescence efficiency compared to Q3NTCy in aqueous solutions. As shown in Table 3.2, the 
quantum yields of iBuTCy, Q3NTCy, and Q3NNTCy were similar in acetonitrile pointing out that 
the fluorescence of both Q3NTCy and Q3NNTCy was not compromised by the PeT quenching. 
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That means, in unfolded molecules, the distance between the donor and the acceptor separated 
by one linker was long enough to inhibit the PeT process. The probable cause of the low 
fluorescence of Q3NNTCy was that introduction of the second linker increased its hydrophobicity, 
thus making it exist in a folded state in aqueous solution. Upon incubation with hNQO1, Q3NNTCy 
exhibited a slow release of TCy (t1/2 > 60 min) showing that TCy production required elimination 
of two linkers. I posit that if Q3NTCy could exist in the unfolded structure in solution, it would 
exhibit a ratiometric response towards hNQO1. Improving the water solubility of Q3NTCy may be 
an effective way to construct a ratiometric probe like Q3NTCy-O in Figure 3.12. 
 
Figure 3.12 Molecular structures of Q3NNTCy and Q3NTCy-O 
Table 3.2 Photophysical data for iBuTCy, Q3STCy, Q3NTCy, and Q3NNTCy in ACN 
Compound abs (nm) em (nm) a (M–1cm–1) 
iBuTCy 785 803 0.193 193400 
Q3STCy 785 803 0.134 178600 
Q3NTCy 785 803 0.202 170400 
Q3NNTCy 785 803 0.193 178900 
aICG ( = 0.13 in DMSO) was used as a fluorescence standard;21 the quantum yields of 
compounds were measured in acetonitrile (ACN) with ex  = 725 nm. 
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A RATIOMETRIC FLUORESCENT PROBE FOR THE DETECTION AND IMAGING OF 
ENDOGENOUS BETA-GALACTOSIDASE IN OVARIAN CANCER CELLS 
 
4.1  Introduction 
-Galactosidase (-D-galactohydrolase, EC 3.2.1.23, -gal), encoded by lacZ gene, is a 
glycoside hydrolase enzyme. Its function is to catalyze the hydrolysis of terminal linkages of 
-D-galactosides, such as the disaccharide lactose, into monosaccharides through recognition 
and cleavage of the -D-galactose moiety.1 -Gal has been exploited in many applications 
including food science,2-3 genetics,4-10 and molecular biology.11-15 There are two major applications 
of -gal in the food industry: the hydrolysis of lactose from dairy products to yield galactose and 
glucose, and the production of galactosylated products.2 To improve sweetness, solubility, and 
flavor of dairy products, or meet the consumption requirements of lactose intolerant individuals, 
immobilized -gal is often used to hydrolyze and convert the lactose present in foods into the 
easy-digesting galactose and glucose. -gal can act as a reporter gene to measure gene 
transfection efficency.7-8 Genetically engineered sensing systems employ a reporter genes fused 
with another regulatory sequence of interest to study biological processes (e.g., cellular 
metabolism and gene transcription). The commonly used reporter genes include the lacZ, cat, lux, 
luc, bla, gfp, and dsRed genes, which encode -gal, chloramphenicol acetyltransferase, bacterial 
luciferase, firefly luciferase, -lactamase, green fluorescent protein, and red fluorescent protein, 
respectively. Reporter genes, fused with the genes of interest, can be inserted into cells or living 
organisms in the form of circular plasmids, and, if expressed, will produce a detectable signal.10 
Escherichia coli (E. coli) -gal, one of the extensively exploited members of the reporter gene 
family, is often utilized to examine the transcription efficiencies of cloned genomic sequences or 
genes of interest in molecular biology due to its high catalytic efficiency, high sensitivity, high 
stability, excellent specificity, low endogenous expression, and availability of versatile detection 
methods. The exogenous chromogenic substrate molecule 5-bromo-4-chloro-3-indolyl--D-
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galactopyranoside (X-gal) has been conventionally employed to stain -gal-expressing tissues.8, 
16 Upon reacting with -gal, soluble and colorless X-gal is converted into 5-bromo-4-chloro-3-
hydroxyindole, which subsequently forms the blue precipitate 5,5’-dibromo-4,4’-dichloro-indigo. 
The blue color is used to indicate the presence of gal in a histochemical tissue sample.  
Aside from its applications in food science and reporter genes, -gal is also involved in 
cellular replicative senescence processes where it serves as one of the most utilized cell 
senescence biomarkers in some types of human cells.12, 17 After a number of cellular divisions, 
normal cells cease to proliferate and enter an irreversible cellular stage, known as replicative 
senescence, which is believed to be a tumor-suppressive process and an underlying cause of 
aging. Characteristics of senescent cells include permanent growth arrest, shortening of 
chromosomal telomeres, enlarged and flattened cellular morphology, and increased levels of 
intracellular reactive oxigen species (ROS). Further studies suggested that the high catalytic 
activity of -gal in senescent cells is caused by the overexpression of the GLB1 gene, resulting in 
the accumulation of -gal in lysosomes.12, 18  
-Gal was also reported to be overexpressed in cancerous ovaries when compared to 
normal ovaries, indicating it can serve as an ovarian cancer-associated biomarker.15 Primary 
ovarian cancer is a type of peritoneal carcinoma that seriously affects female individuals.19-20 Early 
diagnosis is very difficult for ovarian cancer due to lack of obvious symptoms in its early stages, 
which is one of the causes of low patient survival rate.21 Cytoreductive removal of cancer tumors 
followed by chemotherapy is one of the most effective treatments for ovarian cancer. By exploiting 
the nature of -gal upregulation in ovarian cancer, Asanuma et al. developed fluorogenic small-
molecular substrate probes to detect small-sized ovarian metastases in the peritoneum of mouse 
xenograft models.22 Cellular lysate studies showed that all the seven investigated ovarian cancer 
cell lines (SHIN3, SKOV3, OVCAR3, OVCAR4, OVCAR5, OVCAR8, and OVK18) exhibited 
higher -gal activities than the normal human umbilical vein endothelial cells (HUVEC), and all 
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the ovarian cancer metastases models derived from the seven ovarian cancer cell lines were 
successfully visualized with the developed fluorogenic probe, HMRef-Gal. That study 
corroborated that -gal is a promising biomarker that can be exploited to develop prodrugs and 
imaging agents that targets ovarian cancer.22  
As reviewed in Chapter 1, a large amount of effort has been made to establish methods 
to visualize its activity, which includes magnetic resonance imaging (MRI),23-25 positron emission 
tomography (PET),26 and optical imaging.  Compared to MRI and PET, most of the research is in 
the development of optical imaging due to its high sensitivity.  Many chromogenic, bioluminescent, 
and fluorescent probes have been developed and applied to detect -gal in vitro and in vivo.   
My interest to investigate the ovarian cancer-associated -gal enzyme motivated me to design a 
novel ratiometric probe with distinct characteristics (high cellular impermeability, pH 
independency, and ratiometric fluorescence response) that may allow its use in providing 
quantitative information on -gal activity. Different from turn-on/off fluorescent probes, ratiometric 
fluorescent probes exhibit shifts in their fluorescence energy upon probe reaction with analytes of 
interest to yield a reporter. The reporter/probe ratio, instead of fluorescence increase/decrease, 
is utilized to build a relationship with the concentrations of analytes of interest, an approach more 
suitable for quantification applications because this measurement is independent of probe 
concentrations (cellular size and probe penetration rate), illumination intensity, and probe 
bleaching.27-28 Therefore, a cell-permeable and ratiometric probe will be beneficial for the 
detection and quantification of -gal in vitro and in cellulo. To date, several fluorogenic probes are 
available to detect -gal. However, most of them suffer from cellular impermeability, reporter 
leakage out of cells, and pH dependency, all which limit exciting more applications in biological 
milieu.  Moreover, most of the probes operate via a turn-on response mode, which makes them 
vulnerable to environmental variables, such as pH and viscosity, fluctuations in illumination power, 
and variations in detector efficiency.  More recently, two ratiometric probes were developed by 
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modifying 6-(benzo[d]thiazol-2’-yl)-2-(methylamino)-naphthalene29 and 4-hydroxyl-N-butyl-1,8-
naphthalimide fluorophores30 to report senescence-associated and LacZ gene encoded -gal, 
respectively.  However, the 4-hydroxyl-N-butyl-1, 8-naphthalimide reporter suffers from low 
quantum efficiency ( = 0.06) and pH dependency (ca. pKa = 5.8). Its fluorescence efficiency can 
be affected by acidic biological environments such as that in lysosomes and tumor 
microenvironment. Its possible expulsion from cancerous cells by endogenous organic anion 
transporters may occur, due to its intrinsic negative charge at physiological pH, similar to 
fluorescein dyes.31  Moreover, none of the reported enzyme-activatable ratiometric fluorescent 
probes provide the theoretical correlation between fluorescence ratios and concentration of 
enzyme. 
 Described herein is the design, synthesis, and evaluation of a previously unreported 
ratiometric fluorescent probe, GalNap, used to track endogenous -gal upregulation in ovarian 
cancer cells in both off-on and ratiometric fluorescence modes. The green-emitting fluorophore 
4-amino-9-(n-butyl)-1,8-naphthalimide (Nap) was connected to the -D-galactose recognizing 
moiety through a self-cleavable 4-hydroxylbenzyl alcohol linker to construct the blue-emitting 
probe, GalNap (Figure 4.1). Nap is a “push-pull” ICT fluorophore with characteristics of high 
brightness, high stability, and pH independency.32 The introduction of an electron-withdrawing 
carbamate bond on its amino donor makes the naphthalimide backbone electron-deficient, 
resulting in an increased HOMO-LUMO gap that provides a hypsochromic shift of the Nap 
absorption and emission spectra. Both GalNap and Nap have high quantum efficiencies (GalNap: 
0.32 and Nap: 0.19) in aqueous solutions. When excited at the absorption maximum of the 
reporter, GalNap showed a rapid fluorescence increase upon reaction with -gal, indicating its 
ability to be effectively and rapidly hydrolyzed by -gal. By plotting the release rate of different 
concentrations of GalNap treated with -gal, the enzyme kinetic parameters were acquired; these 
values demonstrated that GalNap is a good substrate for -gal.  When excited at the isobestic 
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point, GalNap exhibited an immediate spectral profile shift from the blue emission range to the 
green emission range.  Its ratiometic response towards -gal activity was plotted, agreeing with 
my proposed theoretical equation.-Gal-expressing ovarian cancer cell lines (OVCAR3 and 
SHIN3) and -gal-non-expressing cell line (HEp2) were further applied to examine its imaging 
capability. Confocal cellular imaging experiments showed that GalNap can penetrate the cellular 
membrane, thus allowing endogenous -gal activity to be monitored in both off-on and ratiometric 
fluorescence imaging modes. 
  
Figure 4.1 Design concept of the -gal responsive ratiometric fluorescent probe GalNap. 
4.2  Experimental Section 
4.2.1  Materials and General Methods   
Unless otherwise stated, all chemicals and materials were purchased from Sigma-Aldrich 
or Fisher Scientific, and they were used without further purification. Column purification was 
performed on a Biotage Flashmaster Personal with SNAP KP-Sil cartridges (50 g, 25 g, or 10 g).  
1H and 13C NMR spectra were collected using Bruker AV-400 or AV-500 spectrometers at 25 ºC.  
All chemical shifts are reported in ppm (parts per million) using residual protio-solvent of CDCl3 
(7.26 for 1H and 77.16 for 13C) and DMSO-d6 (2.50 for 1H and 39.52 for 13C) as a calibration 
standard.  ESI-MS spectra were acquired on an Agilent 6210 electrospray ionization time-of-flight 








4.2.2  Synthesis  
The synthetic procedure of the designed probe GalNap is outlined in Scheme 4.1. Nap 
and 4-hydroxymethylphenyl (2, 3, 4, 6-tetra-O-acetyl--D-galactopyranoside) (3) were 
synthesized through reported procedures with necessary modifications.33-34 The compound 
MeNap was prepared as an electronically similar analogue to act as a control probe for GalNap. 
  
Scheme 4.1 Synthetic route for GalNap probe and the electronically similar analogue MeNap. 
 
Synthesis of AcGalNap. To a solution of Nap (54 mg, 0.2 mmol) and 4-
dimethylaminopyridine (50 mg, 0.41 mmol) in 18 mL DCM, 15% phosgene (caution: toxic) in 
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toluene (0.9 mL, 1.26 mmol) was added slowly at – 10 ºC, under nitrogen. After stirring for 3 h, 
the excess phosgene was removed by bubbling the solution with nitrogen gas in the hood with a 
base trap. Compound 3 (100 mg, 0.22 mmol) in 4 mL DCM was added to the previous solution. 
The reaction was stirred overnight at 0 ºC. Upon removal of the organic solvent with a rotary 
evaporator, the crude product was purified using a silica gel column with DCM/ethyl acetate (1/1) 
as elute to afford the pale yellow solid product, AcGalNap (170 mg, 94%). 1H NMR (400 MHz, 
CDCl3)  8.56 (d, J = 7.3 Hz, 1H), 8.52 (d, J = 8.3 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 
8.6 Hz, 1H), 7.71–7.67 (m, 2H), 7.36 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 5.52–5.42 (m, 
2H), 5.21 (s, 2H), 5.11 (dd, J = 10.4, 3.4 Hz, 1H), 5.05 (d, J = 7.9 Hz, 1H), 4.26–4.02 (m, 5H), 
2.16 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.73–1.61 (m, 2H), 1.43–1.37 (m, 2H), 0.94 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  170.45, 170.30, 170.19, 169.47, 164.17, 163.68, 
157.21, 153.21, 139.04, 132.46, 131.28, 130.43, 130.40, 128.93, 126.62, 126.14, 123.45, 123.07, 
117.97, 117.11, 116.97, 99.53, 71.14, 70.83, 68.68, 67.44, 66.92, 61.38, 40.29, 30.26, 20.80, 
20.74, 20.72, 20.66, 20.44, 13.92. ESI-HRMS: for [C38H40N2O14]: expected m/z = 749.2552 [M + 
H]+; found 749.2555 [M + H]+; 0.4 ppm error.  
 
Synthesis of GalNap. To a solution of AcGalNap (75 mg, 0.1 mmol) in 20 mL anhydrous 
MeOH, NaOMe in MeOH (25% wt, 92 L, 0.4 mmol) was added at 0 ºC under nitrogen. After 
stirring for 3 h, the reaction was quenched with saturated NH4Cl solution. Upon removing the 
solvent, the crude product was directly loaded on a silica gel column and purified with DCM/MeOH 
(10/1). The desired pale yellow solid product, GalNap (35 mg, 60%) was obtained. 1H NMR (400 
MHz, DMSO)  10.35 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 7.2 Hz, 1H), 8.49 (d, J = 8.4 
Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.83 (dd, J = 8.4, 7.2 Hz, 1H), 7.44 (d, J = 8.6 Hz, 2H), 7.07 (d, 
J = 8.6 Hz, 2H), 5.22 (s, 2H), 5.16 (d, J = 5.1 Hz, 1H), 4.86 (d, J = 1.7 Hz, 1H), 4.84 (s, 1H), 4.60–
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4.64 (m, 1H), 4.50 (d, J = 4.6 Hz, 1H), 4.05 (t, J = 7.4 Hz, 2H), 3.76–3.40 (m, 6H), 1.68–1.55 (m, 
2H), 1.33–1.39 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, DMSO)  163.48, 162.93, 
157.50, 154.00, 140.76, 131.71, 130.90, 130.05, 129.28, 128.33, 127.69, 126.37, 123.80, 122.22, 
118.08, 117.01, 116.25, 115.94, 100.86, 75.53, 73.32, 70.27, 68.15, 66.42, 60.39, 29.69, 19.82, 
13.74. ESI-HRMS: for [C30H32N2O10]: expected m/z = 581.2130 [M + H]+; found 581.2147 [M + H]+; 
2.9 ppm error.  
 
Synthesis of MeNap. To a solution of Nap (28 mg, 0.1 mmol) and DMAP (24 mg, 0.2 mmol) 
in 6 mL anhydrous DCM solution, phosgene (caution: toxic) in toluene (15% wt, 0.6 mL, 0.84 
mmol) was added at –10 ºC. After stirring for 3 h, the extra phosgene was removed with nitrogen 
bubbling, and 2 mL MeOH was added to the solution. The reaction was allowed to stir overnight. 
Upon removing solvent under reduced pressure, the residue was further eluted using a 
hexane/ethyl acetate (1/1) solvent with a silica gel column. The pale yellow solid product MeNap 
(30 mg, 92%) was obtained. 1H NMR (400 MHz, CDCl3) 8.61 (dd, J = 7.4, 0.8 Hz, 1H), 8.58 (d, 
J = 8.2 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.17 (dd, J = 8.4, 0.8 Hz, 1 H), 7.75 (dd, J = 8.4, 7.4 Hz, 
1H), 7.47 (s, 1H), 4.16 (t, J = 7.5 Hz, 2H), 3.89 (s, 3H), 1.76–1.65 (m, 2H), 1.50–1.37 (m, 2H), 
0.97 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  164.28, 163.78, 153.82, 139.00, 132.62, 
131.35, 129.05, 126.76, 125.93, 123.64, 123.09, 118.09, 116.97, 53.23, 40.37, 30.35, 20.52, 
13.98. ESI-HRMS: for [C18H18N2O4]: expected m/z = 327.1339 [M + H]+; found 327.1348; 2.8 ppm 
error. 
4.2.3  Spectroscopic Measurement Methods  
Absorption and fluorescence spectra were recorded in a 10 mm × 10 mm quartz cuvette 
on a Varian Cary-50 UV-Visible spectrophotometer and a PerkinElmer LS55 spectrofluorometer, 
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respectively.  Water (> 18 MΩ cm) from a Barnstead NANOpure Diamond Water System was 
used to prepare phosphate-buffered saline (PBS) and all relevant aqueous solutions.  Stock 
solutions of GalNap and MeNap in DMSO were stored at low temperature (– 20 ºC) in the dark.  
Fresh sample solutions prepared with stock solution were used for all experiments.  
4.2.4  Quantum Yield Measurements of GalNap and Nap 
The quantum yield of Nap ( = 0.19) was obtained from previously reported data from our 
group.34 The fluorescence quantum yield of GalNap was determined in reference to quinine 
sulfate in 1 N sulfuric acid solution ( = 0.51).35  A stock solution of GalNap (1 mM in DMSO) was 
diluted in 0.1 M PBS solution (pH = 7.4) to yield an absorbance at 360 nm between 0.02–0.10 to 
minimize reabsorption effects and maximize illumination homogeneity. Co-solvent DMSO was 
maintained at 1%. Samples with four different concentrations (2, 4, 6, and 8 M) were prepared, 
and each sample was measured three times. Similarly, quinine sulfate was dissolved in 1 N 
sulfuric acid solution to yield an absorbance at 360 nm between 0.02–0.10. Samples with four 
different concentrations (4, 8, 12, and 16 M) were prepared, and each sample was measured 
three times. Fluorescence spectra of all the prepared samples were obtained with the same 
excitation wavelength 360 nm. The quantum yield of GalNap was calculated using the following 
equation 4.1: 






2 )                                       Equation 4.1 
where the subscripts st and x stand for standard and test sample, respectively.36 is the quantum 
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance. The calculated quantum yield of GalNap was determined 
to be 0.32. 
4.2.4  Enzyme Kinetics Measurements 
-Gal from Escherichia coli (Sigma-Aldrich) was stored as 1000 U mL–1 (1.35 mg mL–1) in 
PBS solution. The enzymatic reactions in 1.5 mL GalNap solutions with varing concentrations (2–
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60 M) were initiated by the addition of 4.5 L -galactosidase stock solution resulting in 3 U mL–
1 (4 g mL–1) enzyme per assay. Fluorescence due to release of the fluorophore Nap (ex = 450 
nm, emis = 550 nm) was recorded at an interval of 5 s for 10 min at 25 ºC.  Each sample of a 
given concentration was measured three times.  The concentration of Nap released per unit time 
was calculated by converting the fluorescence signal using the Nap calibration curve, which was 
acquired under identical measurement conditions. The apparent kinetic parameters (Vmax and Km) 
were obtained by plotting the Nap release rate vs GalNap concentrations using nonlinear least-
squares analysis of Origin software.  
4.2.5  Cell Culture  
The OVCAR3 (human ovarian adenocarcinoma) cell line was purchased from American 
Type Culture Collection (ATCC).  The SHIN3 (human ovarian carcinoma) cell line was a gift from 
Professor Hisataka Kobayashi at the Center for Cancer Research (National Institutes of Health). 
The HEp2 (human Hela contaminant carcinoma) cell line was a gift from Professor Graca 
Vincente at Louisiana State University.  All cell lines were grown in RPMI-1640 medium (ATCC) 
supplemented with 10% fetal bovine serum (FBS, ATCC), 10 IU mL–1 penicillin, and 10 g mL–1 
streptomycin (Life Technologies).  All cell lines were maintained in 75 cm2 treated tissue culture 
flasks (Corning) at 37 ºC in 5% CO2 under humidified conditions. 
4.2.6  Cellular Imaging via Laser Scanning Confocal Microscopy  
Cells (3 × 105) were seeded on sterile six-well glass culture plates (Fisher Scientific) with 
the RPMI-1640 medium containing 10% FBS, and cultured for a day at 37 ºC in 5% CO2 under 
humidified conditions.  After that, the medium was removed and washed once with warm phenol 
red- and serum-free RPMI-1640 medium. Cells were incubated with 10 M GalNap or MeNap in 
phenol red- and serum-free RPMI-1640 medium (2 mL) for 1 h. The medium was then removed, 
and the cells were washed with DPBS (2 mL) twice. After washing, cells were treated with 4% 
paraformaldehyde for 15 min at room temperature to fix the cells. Differential interference contrast 
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(DIC) and fluorescence images were acquired using a Leica TCS SP5 spectral laser-scanning 
confocal microscope with oil objectives (20×, numerical aperture: 0.70) or (40×, numerical 
aperture: 1.25). The airy pinhole was set to 1.0 (60.6 m). A 405-nm laser (30% output) was 
employed with the same HyD detector gain (100.0) in both 430–495 nm and 535–600 nm 
emission regions for ratiometic fluorescence images of cells exposed to GalNap. Likewise, the 
same laser line with 20% output was employed with the same HyD detector gain (100.0) in both 
regions for that of MeNap. Image and statistical analysis were performed using Fiji/ImageJ 
software following reported procedures.37 
4.3  Results and Discussion 
4.3.1  Design of the -gal Responsive Ratiometric Probe GalNap   
The fluorophore 4-amino-9-(n-butyl)-1,8-naphthalimide (Nap) was selected to design a -
Gal responsive ratiometric probe, because of its high fluorescence quantum efficiency, stability, 
pH insensitivity, and excellent push-pull internal charge transfer (ICT) characteristics.32  Moreover, 
its 4-amino group provides a handle to install moieties that are capable of recognizing 
endogenous species; such incorporation further delivers an alteration on the spectroscopic 
properties due to a change in electron distribution on its backbone. Introduction of an electron-
withdrawing carbamate bond on the 4-amino position decreases its push-pull effect, hence 
hypsochromically shifting both absorption and emission profiles of the reporter. A direct 
connection between the -gal-recognizing unit (the galactopyranoside moiety) and the 
fluorophore, Nap, to build a -gal responsive probe would hinder the breakage of the so formed 
N-glycoside bond by -gal.  Therefore, the self-cleavable 4-hydroxyl benzyl alcohol linker was 
inserted between the galactopyranoside trigger and the Nap fluorophore reporter.  As a result, 
the probe GalNap with a tripartite structure was designed, which can undergo a spontaneous 
linker cleavage followed by release of the bathochromically-shifted fluorophore Nap upon its -
gal hydrolysis, Figure 4.2. Ratiometric probes based on an ICT fluorophore have advantages over 
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those designed using FRET strategies.  FRET strategies require two fluorophores, one as an 
energy donor and the other as an energy acceptor; in the intact probe, the excited donor transfers 
energy to the acceptor, resulting in emission from the acceptor. Breaking apart the two 
fluorophores will block the FRET effect and cause emission from the donor. The fluorescence 
ratio is utilized to indicate the amounts of analytes. However, environmental variations can also 
change the fluorescence ratio by affecting the distance between the two fluorophores in the FRET 
probe. 
4.3.2  Spectroscopic Characterization of GalNap/Nap System 
The GalNap probe and the control MeNap probe were synthesized through conventional 
synthetic procedures, as described in Scheme 4.1.  With the GalNap probe in hand, the 
spectroscopic properties of GalNap and Nap were first measured in aqueous phosphate buffer at 








368 nm and 𝜆𝑒𝑚
𝐺𝑎𝑙𝑁𝑎𝑝
 = 470 nm) are hypsochromically shifted roughly 64 nm for absorption and 78 
nm for emission in comparison with that of Nap (𝜆𝑎𝑏𝑠
𝑁𝑎𝑝
 = 432 nm and 𝜆𝑒𝑚
𝑁𝑎𝑝
 = 548 nm), which is in 
agreement with previously observed spectral changes upon the introduction of electron-deficient 
group to the ICT fluorophore Nap. The Stokes shift of GalNap is 102 nm, which is smaller than 
that of Nap (116 nm). The smaller Stokes shift of GalNap is caused by its decreased ICT effect. 
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Figure 4.3 Absorption and emission spectra of 5 × 10–6 M GalNap (A)  and Nap (B)  in 0.1 M 
PBS solution (pH = 7.4) with 1% DMSO as co-solvent. T = 25 ºC.  
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Both GalNap and Nap have high quantum efficiencies in aqueous phosphate buffer (GalNap = 
0.32 and Nap = 0.19). All these properties of GalNap and Nap make them an excellent 
probe/reporter pair to potentially act as a ratiometric system. The ratio of fluorescence of the green 
energy range (F535–600) and the blue energy range (F430–495) were calculated to be 0.19 and 29 for 
GalNap and Nap respectively, thus exhibiting a broad dynamic range (153-fold). In comparison, 
the control compound MeNap has similar spectroscopic properties (𝜆𝑎𝑏𝑠
𝑀𝑒𝑁𝑎𝑝
 = 368 nm, 𝜆𝑒𝑚
𝑀𝑒𝑁𝑎𝑝
 = 
470 nm, F535–600/F430–495 = 0.20) to GalNap, thus making it an excellent negative control compound 
(Figure 4.4).  














































Figure 4.4 Absorption and emission spectra of 2 × 10–6 M MeNap in PBS buffer (pH = 7.4) with 
1% DMSO as co-solvent. T = 25 ºC. 
4.3.3  Spectroscopic Response of GalNap to gal 
I next examined the spectral change of GalNap upon the reaction with -gal in aqueous 
buffer solution (pH = 7.4), Figure 4.5.  After the addition 3 U mL–1 -gal to GalNap solution for 1 
h, the maximum absorption peak was shifted from its initial 368 nm value to 432 nm, and the 
maximum emission peak moved from 432 nm to 548 nm, thereby exhibiting a ratiometric 
fluorescence response change.  Both the resulting absorption and emission profiles of GalNap 









change in emission spectra with various excitation wavelengths is also shown in Figure 4.6. 
GalNap and Nap can be excited for different degrees by use of different excitation wavelengths, 
thus making the GalNap/Nap pair suitable as an on-off, off-on, or ratiometric system. To further 
demonstrate that the release of Nap caused its spectroscopic response, HPLC-Mass 
spectrometry was employed to analyze the products released after -gal treatment.  The lack of 
the GalNap m/z peak and appearance of the new Nap m/z peak clearly demonstrated release of 
Nap. 



















































Figure 4.5. Absorption (A, 5 M GalNap) and emission (B, 2 M GalNap, ex = 415 nm) spectra 




4.3.4  Stability and Enzymatic Activity of GalNap 
High chemical and photochemical stability and rapid activation of developed 
probe/reporter systems in biological systems are principle factors that greatly affect their detection 
efficiency. Thus, GalNap in the presence and absence of -gal in aqueous solution was recorded 
using fluorescence spectrometry, Figure 4.7. The excitation and emission wavelengths (ex = 450 
  
Figure 4.6. Fluorescence spectral changes of GalNap (2 M) triggered by -gal (3 U mL–1) in 
1% DMSO 0.1 M PBS (pH = 7.4) solution with different excitation wavelengths: (A) 380 nm, 
(B) 400 nm, (C) 410 nm, (D) 415 nm, and (E) 430 nm. Spectra were recorded every 3 min. T 
= 25 ºC. 






















































































































ex = 380 nm ex = 400 nm
ex = 410 nm ex = 415 nm







nm, em = 500 nm) were selected to ensure that only the signal from the Nap reporter was 
monitored. When GalNap was not exposed to -gal in aqueous solutions, the fluorescence 
increase was not observed in the time course of 60 min, Figure 4.7 (blue line). This result showed 
that the non-specific activation of GalNap in aqueous solution is low. In contrast, when GalNap 
was exposed to 3 U mL–1 -gal, an immediate fluorescence increase was observed with a short 
half-time (t1/2 = 10 min) to achieve its plateau signal, Figure 4.7 (red line). The plateau signal was 
invariant over 20 min, indicating that the released reporter is stable in the presence of -gal under 
physiological conditions. This experiment showed that GalNap can be effectively activated by -
gal through the breakage of the glycosidic bond, which subsequently initiates the rapid cleavage 
of the self-immolative linker 4-hydroxyl benzyl alcohol, ultimately leading to the release of Nap, 
Figure 4.2.     
To obtain quantitative information about the ability of -gal to activate GalNap, the 
apparent kinetic parameters were acquired by fitting the Nap production rate from various 
concentrations of GalNap catalyzed by -gal to the Michaelis-Menten equation, Figure 4.8.  From 
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Figure 4.7. Fluorescence response (ex = 450 nm, em = 500 nm) of GalNap (5 M) to the 
addition of -gal (3 U mL–1) at 4 min in 0.1 M PBS buffer (pH = 7.4).  T = 25 ºC. 
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this were obtained the Michaelis constant (Km) = 12.0 M, maximum velocity (Vmax) = 0.12 ± 0.01 
mol/min/mg protein, catalytic constant (kcat) = 0.24 ± 0.01 s–1, and catalytic efficiency (kcat/Km) = 
2.02 ± 0.35 × 104 M–1s–1, indicating that GalNap is an effective substrate of -gal. Also, enzyme 
inhibition was not observed when the enzyme was treated with high concentrations (up to 60 M) 
of GalNap. The kinetics values demonstrated that GalNap is an effective substrate to reach the 
catalytic sites of -gal where it is rapidly hydrolyzed, resulting in the rapid formation of Nap. 





















Figure 4.8 Kinetic plot of -gal (4 × 10–6 g mL–1, 3 U mL–1) with GalNap as substrate in 0.1 M PBS 
buffer (pH = 7.4).  Values shown are average of three trials with error bars (± standard deviation). 
T = 25 ºC. Line is best fit to data (2 = 0.00003).  
4.3.5  Theory Development for the Ratiometric Properties of GalNap   
After establishing that GalNap was an effective substrate of -gal, which yielded a 
ratiometric fluorescence response for measurement of -gal activity, I sought to study the 
relationship between the fluorescence ratio and -gal activity. As depicted in Figures 4.5 and 4.9, 
the fluorescence signal at 470 nm that corresponds to the fluorescence maximum of GalNap is 
composed of signal only from GalNap, while the fluorescence signal at 548 nm (corresponding to 
the maximum of Nap) is made up of signal from both GalNap and Nap.  
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To further investigate the theoretical quantitative relationship between the fluorescence 
ratio and -gal concentrations, a descriptive figure was drawn, Figure 4.10. The solid blue line 
represents the fluorescence spectrum of GalNap with fluorescence maximum wavelength 1. The 
solid green line represents the spectrum of Nap with maximum wavelength 2. The dashed red 
 
Figure 4.10 Schematic derivation of ratiometric fluorescence response of probe towards 






































































Figure 4.9 Normalized fluorescence spectra of 5 × 10–6 M GalNap (blue line) and 5 × 10–6 M 
Nap (green line) in 0.1 M PBS solution (pH = 7.4) with 1% DMSO as co-solvent. T = 25 ºC. 
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line represents the spectrum of some mixture of GalNap and Nap, which represents entry what I 
refers to as the intermediate spectrum of GalNap treated with -gal. An equation describing the 
relationship between fluorescence ratio and -gal concentrations is derived as follows.  
At any time point for a GalNap solution which is treated with -gal, the total concentration of the 






𝑅                                                        4.3.4.1 
 
where 𝐶0
𝑃  indicates the initial concentration of GalNap, 𝐶𝑡
𝑝
 indicates the concentration of 
unreacted GalNap at a specific time point (t), and 𝐶𝑡
𝑅 is the concentration of released Nap at the 
same specific time point (t). 
The released reporter concentration is proportional to enzyme concentration and time. 
𝐶𝑡
𝑅 = 𝑘𝑐𝑎𝑡 × [𝐸0] × 𝑡                                               4.3.4.2 
 
where 𝑘𝑐𝑎𝑡 is the catalytic constant, and [𝐸0] is the enzyme concentration. 
The fluorescence signal intensity at wavelength 1 (𝐼𝜆1) is solely contributed by GalNap (𝑘𝜆1
𝑅 𝐶𝑡
𝑅 = 


















                                                 4.3.4.5 
where 𝑘𝜆1
𝑝
 is the fluorescence constant of GalNap at wavelength 1, 𝑘𝜆2
𝑅  is the fluorescence 
constant of Nap at wavelength 2, and 𝑘𝜆2
𝑝
 is the fluorescence constant of GalNap at wavelength 
2.  
The fluorescence ratio (R) is defined as 𝐼𝜆2/𝐼𝜆1. Solving for R yields the calibration equation. 






























𝑝                                      4.3.4.6 
  Based on the acquired calibration equation, the fluorescence ratio is a function of both the 
incubation time (t) and the amount of -gal ([E0]). The predicted schematically defined curve 
shown in Figure 4.11 represents what is expected for conditions when one of the two variables is 
kept constant, with increasing enzyme concentration or time, the ratio rises slowly followed by a 
rapid increase before it plateaus. The plateau results from the complete consumption of GalNap, 
with the ratio approaching the value in 4.3.4.6. 
4.3.6 Experimental Investigations on the Ratiometric Response of GalNap Toward -gal 
To verify that the experimental response ratio is in agreement with the denoted equation (4.3.4.6), 
both the fluorescence ratio (F535–600/F430–495) change with time at a specific concentration of -gal 
and the ratio change with various amounts of -gal at a specific time were measured under 
physiological conditions (pH = 7.4).  As shown in Figure 4.12, GalNap (15 M) solutions were 
treated with various concentrations of -gal (1–12 U mL–1) and their fluorescence spectra were 
 
Figure 4.11 Prediction curve of response of GalNap towards -gal concentrations or time 












recorded every 2 min. The blue emission band F430–495 gradually decreases, corresponding to the 
 
Figure 4.12. Fluorescence spectral change of GalNap (15 M, ex = 415 nm) with time with the 
addition of -gal (1, 2, 3, 4, 6, 8, 10, and 12 U mL–1) in PBS solution (pH = 7.4). T = 25 ºC. 








































































































































































































-gal = 1 U mL–1
-gal = 4 U mL–1
-gal = 8 U mL–1
-gal = 3 U mL–1
-gal = 10 U mL–1
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hydrolysis of GalNap. Simultaneously, the green emission band F535–600 gradually increases, 
corresponding to the production of Nap. The fluorescence ratio (F535–600/F430–495) was first plotted 
against time with fixed -gal concentration, Figure 4.13. It was also plotted against -gal 
concentrations at a given fixed time, which showed an increase with enzyme concentration range 
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Figure 4.13 Plot of the emission intensity ratios (F535–600 nm/F430–495 nm) of GalNap (15 M) 
against time (up) or the concentration of -gal enzyme (1–12 U mL–1), in pH = 7.4, 0.1 M PBS, 
ex = 415 nm; T = 25 °C. 
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studied. Both plots showed that the ratio changed in a sigmoidal-like manner in response to the 
-gal catalysis, which agrees with the prediction of theory. When either the incubation time or -
gal amounts were increased, a plateau was attained due to the complete consumption of the -
gal substrate GalNap. 
4.3.7  Visualizing Endogenous -gal with GalNap as a Turn-on Probe in Ovarian Cancer Derived 
Cell Lines  
After demonstrating that GalNap is an effective probe for detecting -gal activities in vitro 
via both off-on and ratiometric modes, I sought to further investigate its ability to track endogenous 
-gal in human cells, specifically in a turn-on mode (monitoring reporter production).  The 
overexpression of -gal in primary ovarian cancer cells15 and the lack of -gal activity in Hela 
cells38 has been established previously.  Therefore, cellular imaging with confocal microscopy 
was performed with OVCAR3 (human ovarian cancer cells, -gal-expressing) and HEp2 (human 
Hela contaminant carcinoma cells, -gal non-expressing) cell lines. After OVCAR3 and HEp2 
 
Figure 4.14. Differential interference contrast (DIC) and confocal fluorescence images of 
OVCAR3 (-gal expressing) and HEp2 (-gal non-expressing) cells incubated with 10 M 
GalNap for 60 min at 37 ºC. Fluorescence images were obtained in the 506–640 nm emission 














were incubated with 10 M GalNap for 1 h in a humidified incubator with 5% CO2 at 37 ºC, they 
were fixed for further imaging with a confocal microscope. The fixed cells were measured in the 
506–640 nm emission range by exciting with a 458-nm laser. These excitation and emission 
settings assured that the measured fluorescence signal is solely from the released Nap instead 
of from GalNap. As shown in Figure 4.13, strong fluorescence in the OVCAR3 cell line was 
observed in contrast with virtually no fluorescence in the HEp2 cell line, which is in accordance 
with the high -gal activity in OVCAR3. To quanitify the Nap fluorescence signal in cells, the 
positive to negative (PNR) value, for OVCAR3 (33 cells) versus HEp2 (31 cells) was calculated 
to be 8.8 ± 1.1 (95% confidence). This imaging experiment corroborated that GalNap can 
effectively pass through the cellular membrane and rapidly react with -gal present inside cells. 
Although D-galactose of high concentration (mM levels) can competitively inhibited -gal activity, 
its application in cellular environment may also affect the cellular uptake of the probe.  
4.3.8  Visualizing -gal with GalNap as a Ratiometric Probe in Ovarian Cancer-Derived Cell 
Lines  
To demonstrate the applicability of GalNap as a ratiometric fluorescent probe for detecting 
-gal activities in cellular environments, ovarian cancer cell lines (SHIN3 and OVCAR5) 
expressing the -gal enzyme were also investigated, Figure 4.15.  Upon incubating the studied 
cell lines with GalNap under identical conditions, cellular fluorescence signals in the blue range 
(430–495 nm) and in the green range (535–600 nm) was collected using the same detector 
efficiency and the same 405-nm laser line excitation intensity. The ratiometric images were 
generated based on the blue and green range fluorescence following reported procedures.37 As 
shown in Figure 4.15, all of the acquired ratios for -gal-expressing cell lines (0.70 for OVCAR3 
and 0.47 for SHIN3) were significantly higher than that of -gal-non-expressing HEp2 (0.21) 
resulting from the production of Nap in -gal-expressing cell lines.  Moreover, the control probe 
MeNap was also used to treat all three cell lines.  As shown in Figure 4.16, bright fluorescence 
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was observed in the blue range indicating the effective penetration of MeNap into cells. However, 
virtually no fluorescence was observed in the green range indicating the lack of Nap production. 
The acquired ratios (0.24 for OVCAR3 and 0.16 for SHIN3) exhibited cellular ratios similar to that 
of HEp2 (0.13), which further demonstrated that MeNap cannot produce Nap. All these 
experiments demonstrated that the different cellular ratios acquired after the treatment with 




Figure 4.15 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2 
(negative) incubated with GalNap (10 M) for 60 min at 37 ºC. Blue images (430 – 495 nm 
range) and green images (535 – 600 nm range) were obtained with the 405 nm excitation. 






































4.4  Conclusion 
In summary, a previously unreported, well-described ratiometric fluorescent probe, 
GalNap, capable of selectively detecting -galactosidase, was developed by adding a 
galactopyranoside moiety to an ICT fluorophore Nap. Both GalNap and Nap have high quantum 
efficiencies (GalNap = 0.32 and Nap = 0.19) in aqueous solutions. When excited at the absorption 
maximum of the reporter, solutions of GalNap showed a rapid fluorescence increase upon 
reaction with -gal, indicating the ability of the probe to be hydrolyzed by -gal effectively and 
rapidly. By plotting the release rate of different concentrations of GalNap treated with a specific 
amount of -gal, the enzymatic kinetics parameters were acquired, which demonstrated that 
GalNap is a good substrate for -gal.  When excited at the isobestic point, GalNap exhibited an 
immediate spectral profile shift from blue emission range to green emission range. The resulting 
 
Figure 4.16 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2 
(negative) cells incubated with MeNap (10 M) for 60 min at 37 ºC. Blue images (430–495 nm 
range) and green images (535–600 nm range) were obtained with the 405 nm excitation. Ratio 




































ratiometirc response towards -gal was plotted, and agreed with my proposed theoretically 
derived equation. Its capability to measure and differentiate -gal-expressing cells was also 
demonstrated through confocal microscopy imaging of -gal-expressing ovarian cancer cell lines 
(OVCAR3 and SHIN3) and the HEp2 cell line that does not express -gal.  
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A RATIOMETRIC AND NEAR-INFRARED FLUORESCENT PROBE FOR SELECTIVE 
DETECTION AND QUANTIFICATION OF CYSTEINE IN HUMAN PLASMA 
 
5.1  Introduction 
Biological thiols are important biological components and they play crucial roles in 
maintaining cellular redox homeostasis.1 Free sulfhydryl groups (–SH) of proteins and amino 
acids can scavenge reactive oxygen species (ROS), thereby protecting cells from oxidative stress. 
Meanwhile, the sulfhydryl group is converted to its disulfide form (–S–S–). Glutathione (GSH), 
cysteine (Cys), and homocysteine (Hcy)—each having one sulfhydryl group—are the three major 
components of biological thiols. Aberrant levels of GSH, Cys, and Hcy are associated with a 
variety of pathological processes. 
Cys, which has versatile functions in protein synthesis and structure, is a metabolite 
derived from the amino acids serine and methionine. In the metabolic processes, Cys is produced 
through the transsulfuration of the hydroxyl group of serine by the sulfhydryl group from 
methionine.2 Although Cys is conventionally considered to be a non-essential amino acid, it can 
become an essential amino acid for infants, elders, and some individuals who suffer from 
metabolic diseases.3 Cys deficiency leads to a variety of disorders, such as lethargy, hair 
depigmentation, skin lesions, to name a few.4 Notably elevated levels of Cys are associated with 
neurotoxicity and cardiovascular diseases.5-6 The concentrations of Cys in human plasma for 
healthy individuals span from 135.8 to266.5 M.7 Therefore, fast, sensitive, and selective 
detection of Cys will greatly contribute to the insightful understanding of its biological and 
pathological functions. 
Several analytical techniques are employed to measure the presence of biological thiols, 
including high-performance liquid chromatography (HPLC),8 capillary electrophoresis,9-10 mass 
spectrometry,11-13 and spectrophotometry.14 Although these techniques are useful in detecting 
biological thiols, they often require tedious and time-consuming steps such as separation, 
derivatization, and determination. Due to their high sensitivity, ease of use, and low cost, 
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fluorescence-based probes have attracted intense interest and investigation. A large number of 
thiol-reactive reagents and probes were developed and evaluated over the past decade.15-19 
Relying on the strong nucleophilicity and low basicity of the sulfhydryl group, the strategies for 
developing fluorescent probes include Michael addition to maleimide and alkyne bonds,20-22 
exchange of disulfide and Se-N bonds,23-28 disruption of metal coordination,29-32 and cleavage of 
sulfonamide and sulfonate esters.33-36 Upon conjugation or fragmentation by thiols, the pro-
fluorogenic probes normally exhibit a strong increase in fluorescence intensity in the visible or 
near-infrared energy ranges. Albeit probes of this kind show some advantages in detecting 
biological thiols as a group, most have been limited to the selective detection of an individual thiol. 
Furthermore, in situations where low Cys concentrations are indicative of a health disease, such 
blood plasma levels associated with various diseases such as cardiovascular disease.37 The 
ability to determine Cys levels in the presence of high GSH concentrations is highly valuable. 
Because GSH, Cys, and Hcy play different physiological and pathological roles, it is of great 
significance to develop fluorescent probes to achieve the selective determination of thiols.  
To overcome this challenge, aldehyde-conjugated fluorophores were developed to 
achieve the selective detection of Cys and Hcy.38-40 Because both Cys and Hcy have amino and 
sulfhydryl groups, the aldehyde recognition group (a hard electrophil) is initially attacked by the 
hard nucleophilic amine group, followed by cyclization with the sulfhydryl group, which leads to 
the formation of a thiazolidine or thiazinane ring. The cyclization process of Cys and Hcy with 
aldehyde greatly changes probe photophysical properties, thus allowing the selective 
differentiation of Cys and Hcy from other amino acids. However, because the amine attack is the 
initial step, both Cys and Hcy have similar reactivities toward the designed fluorescent probes. 
Moreover, the aldehyde group suffers from attack by other interfering nucleophiles, thereby 
decreasing sensitivity, and thus, limit of detection. 
In 2011, Strongin’s group took advantage of the well-known condensation reaction of 
acrylates with Cys and use it to discriminate Cys from Hcy.41 In this design, the fluorophore, 
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(hydroxymethoxyphenyl)benzothiazole (HMBT), was conjugated to an acrylate recognition group. 
The hydroxyl group of HMBT can undergo excited state intramolecular proton transfer (ESIPT) 
when the molecule is irradiated at 304 nm, thus allowing HMBT to fluoresce in two different 
wavelength ranges (enol band and keto band). In the developed probe, keto band fluorescence 
was inhibited by cloaking the hydroxyl group, and the fluorescence of enol band was quenched 
by the alkene moiety through the photo-induced electron transfer (PeT) process. Because Cys 
and Hcy react differently with the acrylate group, Hcy increased the enol band fluorescence while 
Cys increased the keto band fluorescence under specific solution conditions. This novel design 
strategy made it possible to differentiate Cys from Hcy. Subsequently, the acrylate recognition 
group was exploited to develop several turn-on and ratiometric probe/reporter systems.42-49 
However, most of the probes exhibited quenched fluorescence by the alkene bond. Disruption of 
the alkene bond by other biological nucleophiles present cells can also induce the fluorescence 
increase, thus causing the probes to suffer from interference (low selectivity). In addition, most of 
the new acrylate-based probes had very short excitation and emission wavelengths, thus limiting 
their further applications in biological systems.  
Because near-infrared (NIR) light has the advantages of high tissue penetration depth, 
low tissue autofluorescence, and low tissue absorption, NIR fluorescent probes are more suitable 
for biological applications.  It would be of great value to have in hand an NIR probe that is selective 
for Cys, and one that may provide more quantitative information via use of ratiometric 
characteristics. Recently, a cyanine-based NIR fluorescent probe (CyAC) was developed in the 
hopes of selective detection and quantification of Cys over Hcy and GSH.50 Although the 
absorption and emission bands of CyAC are located in the NIR energetic range, the reporter 
formed by reacting Cys with CyAC has a hypsochromically shifted absorption band in the visible 
energy range. In addition, the fluorescence of the reporter was greatly affected by pH. Thus, new 




Scheme 5.1 Proposed Mechanism of the CysTCy Probe Reacting with Cysteine 
Herein, I present a new ratiometric and NIR fluorescent probe (CysTCy) for selective 
detection of Cys over GSH and Hcy, Scheme 5.1. The cysteine-selective acrylate moiety and pH-
independent and NIR fluorescent tricarbocyanine fluorophore (TCy) were connected through a 
fast and self-eliminating 4-hydroxybenzyl alcohol linker. In the developed probe/reporter system, 
both the CysTCy probe and the TCy reporter exhibited strong fluorescence efficiency (Probe = 
0.17 and Reporter = 0.31 in acetonitrile) in different energy ranges of the electromagnetic spectrum. 
Fluorescence quenching of CysTCy by the alkene bond was not observed thus pointing to the 
potential use of the CysTCy/TCy pair as a ratiometric Cys-responsive system. Upon treatment 
with Cys, solutions of CysTCy exhibited a ratiometric response in both their absorption and 
emission spectra in a quick fashion, accompanied by an obvious color change from light-green to 
dark blue. By plotting the fluorescence ratio as a function of various concentrations of Cys, it was 
observed that CysTCy provided a linear response curve for Cys concentrations over the range of 
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0–10 M. The limit of detection (LOD) of CysTCy toward Cys was determined to be 623 nM. The 
selectivity of CysTCy toward Cys over GSH and Hcy was also confirmed under physiological 
conditions. Further examination of CysTCy under a clinically relevant conditions (deproteinized 
human plasma) verified probe stability and its capability for detection and quantification of Cys. 
5.2  Experimental section 
 
Scheme 5.2 Synthetic Route of CysTCy 
5.2.1  Synthetic Materials and Methods  
All the chemicals and solvents in the synthesis were purchased from Sigma-Aldrich or 
Fisher Scientific, unless otherwise stated, and they were used without further purification. 
Preparative separation and purification of crude products was performed on a FlashMaster 
Personal (Biotage) with Biotage SNAP KP-Sil flash cartridges (50-g, 25-g, or 10-g size). 1H and 
13C NMR spectra were measured in deuterated chloroform (CDCl3) on a Bruker AVIII-500 nuclear 
magnetic resonance (NMR) spectrometer at 25 ºC. Mass spectra were measured with an Agilent 
6210 ESI-TOF mass spectrometer. 
5.2.2  Synthesis  
The tricarbocyanine compound (TCy) was obtained as described in Chapter 2.51 The 
intermediate compound 4 was synthesized via reported procedures with necessary 
modifications.42 The synthetic route of CysTCy is outlined as Scheme 5.2. The synthetic 
procedures for CysTCy are described as follows. Compound 4 (90 mg, 0.5 mmol) was dissolved 
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in 10 mL anhydrous THF solvent in a 25-mL round-bottom flask. The solution was cooled to 0 ºC 
in an ice-water bath, followed by the injection of 15% phosgene (caution: toxic) in toluene (4 mL, 
5 mmol). After 2 h, the solvent was removed in a rotary evaporator with aqueous NaOH solution 
(1 M) in the trap to neutralize any excess phosgene. The afforded residue was then dissolved in 
2 mL anhydrous DCM; the solution was added slowly to a solution of TCy (15 mg, 0.024 mmol) 
and N,N-diisopropylethylamine (DIPEA, 0.1 mL) in anhydrous DCM solution (10 mL) under 
nitrogen. The solution was stirred overnight at room temperature. The reaction color changed 
from blue to green. The solvent was removed in a rotary evaporator, and the crude product was 
purified using silica gel column with methanol/DCM (1:99 to 5:95) gradient to yield the green 
product CysTCy (16 mg, 80%). 1H NMR (500 MHz, CDCl3) (rotamers)  7.56 (d, J = 14.1 Hz, 2H), 
7.42–7.30 (m, 4H), 7.25–7.21 (m, 4H), 7.15 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.45 (d, 
J = 18.0 Hz, 1H), 6.39–6.11 (m, 3H), 5.95 (d, J = 11.1 Hz, 1H), 5.09 (s, 2H), 4.30–4.09 (m, 4H), 
3.27 (s, 3H), 2.81–2.57 (m, 4H), 2.11–1.87 (m, 2H), 1.63 (s, 6H), 1.51–1.33 (m, 12H). 13C NMR 
(126 MHz, CDCl3) (rotamers)  171.22, 164.42, 155.73, 155.33, 150.41, 142.00, 141.91, 141.41, 
141.22, 141.20, 133.94, 133.14, 132.93, 130.31, 129.18, 128.92, 128.78, 127.86, 127.74, 127.67, 
127.48, 125.28, 122.56, 122.36, 122.10, 121.72, 115.88, 110.75, 110.69, 101.28, 101.22, 66.93, 
49.22, 40.13, 40.03, 38.75, 38.49, 28.44, 28.35, 28.05, 27.96, 25.13, 24.88, 20.87, 12.60, 12.53. 
ESI-HRMS: for C58H69N4O5: expected m/z = 710.3958 [M]+; found m/z = 710.3948 [M]+; 1.4 ppm 
error. 
5.2.3  Spectroscopic Measurement Methods  
The stock solutions of CysTCy and TCy (1 mM in DMSO) were used to prepare their 
corresponding diluted sample solutions. Phosphate-buffered saline (PBS, 20 mM, pH = 7.4) was 
prepared with water (> 18 MΩ cm) from a Barnstead NANOpure Diamond water System. 
Spectroscopic measurements were performed on a Varian Cary-50 spectrophotometer and a 
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PerkinElmer LS55 spectrofluorometer. The absorption spectra and fluorescence spectra were 
recorded in a 10-mm path length quartz cuvette.  
3.3.4  Quantum yields measurement for Q3NTCy and TCy  
The method of measuring quantum yields was the same as described in Chapter 2 and 
Chapter 3.  The quantum yields of CysTCy and TCy in acetonitrile were measured relative to 
indocyanine green (ICG,  = 0.13 in DMSO) and the synthesized 1,1’,3,3,3’,3’-hexamethyl-3,5-
propylene-4-(dimethylamino)-2,2’-indotricarbocyanine perchlorate (HPDITCP) in ethanol ( = 
0.161).52-54  
5.3  Results and Discussion 
The synthetic route of CysTCy is depicted in Scheme 5.2. The in-house prepared 
tricarbocyanine TCy fluorophore was coupled to the acrylic benzyl alcohol compound 4 using 
phosgene with a high yield (80%). The structures of the synthesized molecules were confirmed 
with 1H, 13C NMR, and mass spectrometry. The purity of the CysTCy probe was also 
demonstrated by HPLC-MS. In the presence of Cys, CysTCy is proposed to undergo a cascade 
reaction-based fragmentation as shown in Scheme 5.1. As a soft nucleophile, the sulfhydryl group 
of Cys firstly attacks the ,-unsaturated acrylate moiety through Michael addition reaction. Then, 
the free, adjacent, hard nucleophile amine group attacks the hard electrophile carbon of the 
carbonyl bond to form a cyclized thiol-lactam compound. This process initiates the cleavage of 
the linker as a quinone methide and carbon dioxide gas, thus leading to the release of the highly 








5.3.1  Spectroscopic Characterizations of CysTCy and TCy 
























































































Figure 5.1 Absorption (black) and emission (red) spectra of CysTCy (A, 2 M) and TCy (B, 2 M) 
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 25 °C. 
With the synthesized CysTCy probe and TCy reporter in hand, their spectroscopic 
properties were further measured in aqueous solution, as shown in Figure 5.1. The absorption 
and emission maxima of CysTCy were at 787 nm and 808 nm, respectively; those of TCy were 
at 615 nm and 763 nm, respectively. The observed bathochromic shift of CysTCy in comparison 
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to TCy was attributed to the introduction of the electron-withdrawing carbamate bond to the meso 
position of TCy. The carbamate group significantly decreased the HOMO energy of CysTCy and 
led to a smaller HOMO-LUMO energy gap, which corresponded to its longer absorption and 
emission wavelength.51 The quantum efficiencies were also measured in acetonitrile and the  
were found to be 0.17 and 0.31 for CysTCy and TCy respectively. These photophysical properties 
of the CysTCy/TCy pair assured its suitability as a ratiometric system under such solution 
conditions. 
5.3.2  Spectral Response of CysTCy toward Cys 


















































Figure 5.2 Time-dependent (every 5 min for a 120-min time period) absorption (A) and emission 
(B) spectral changes of CysTCy (2 M) upon addition of Cys (40 M) in 20% (v:v) ethanol in PBS 





The solution of CysTCy was treated with 40 M Cys in an aqueous solution (20%  EtOH 
in PBS, v/v, pH = 7.4) at 37 ˚C, Figure 5.2. The addition of Cys induced a decrease in the 
absorption band at 787 nm indicative of reaction of CysTCy. At the same time, a new absorption 
band at 615 nm was formed indicating the production of TCy, leading to observation of an 
isosbestic point at 675 nm, Figure 5.2 A. The solution color changed from its initial light-green 
color to the dark blue color, Figure 5.2 A inset. A similar time-dependent response was found in 
the emission spectra of CysTCy, Figure 5.2 B. When excited at the isosbestic point 675 nm, 
solutions of CysTCy exhibited decreases of the emission band near 808 nm, accompanied by the 
appearance of a new emission band near 763 nm. Importantly, there was no observed 
fluorescence increase at 808 nm upon treatment with Cys, indicating lack of any PeT-based 
fluorescence quenching between the fluorophore and the alkene bond. This observation is of 
great significance; although other biological thiols without an adjacent amine group may 
competitively add to the alkene bond, such a reaction will not induce any fluorescence ratio 
changes. 
To investigate the proposed activation mechanism, the components of the Cys-treated 
CysTCy probe in the 20% ethanol in PBS (v/v, 20 mM, pH = 7.4) for 1 h at 37 °C were separated 
and identified using HPLC-MS. Only the TCy reporter was observed indicated by its mass weight 
(calculated m/z: 506.3535; observed m/z: 506.3523; error: 0.39 ppm). No residual CysTCy probe 
was left indicating an effective and efficient conversion from CysTCy to TCy induced by Cys. In 
sharp contrast, without addition of Cys, only the CysTCy probe (calculated m/z: 710.3958; 
observed m/z: 710.3951; error: 0.99 ppm) was observed in the mass spectra, indicating that the 
probe is structurally stable under aqueous solution conditions.  
5.3.3  pH Independence of the CysTCy/TCy Pair 
Because biological environments can have various pH, a pH-independent probe/reporter 
system is advantageous for detection of species of interest under biological conditions. The 
fluorescence intensity of CysTCy and TCy were examined in an aqueous solution in a wide pH 
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range (4.5–9.5), Figure 5.3.51 The outcomes did not show obvious fluorescence changes, 
because of their lack of pH responsive chemical moieties, such as amino or hydroxyl groups.  














































Figure 5.3 Plot of fluorescence intensity of CysTCy (2 M, ex = 725 nm) at 808 nm in 20% (v:v) 
ethanol in PBS (20 mM, pH = 7.4) at various pH (4.5–9.5). T = 37 °C. 
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Figure 5.4 Color changes (A), absorption spectra changes (B), and emission spectra changes 
(C) of CysTCy (2 M) upon 2 h incubation without addition or with addition of corresponding 
Cys (50 M), Hcy (50 M), and GSH (250 M) in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). 
T = 37 °C. 
GSH A Blank Cys Hcy 
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5.3.4  Selectivity of CysTCy Toward Cys over GSH and Hcy 
The selectivity of CysTCy toward Cys over GSH and Hcy was further examined. After 
incubation of 2 M CysTCy solution with 50 M Cys, 50 M Hcy, or 250 M GSH for 2 h at 37 °C, 
the color of the Cys-treated solution was changed to blue, while the other solutions treated with 
Hcy and GSH maintained the initial light-green color, Figure 5.4. This observation supports use 
of CysTCy as a colorimetric probe. The absorption and emission spectra of the treated solutions 
were further measured. Although solutions treated with Hcy and GSH had spectra having the 
same absorption and emission wavelengths as CysTCy, the solution treated with Cys possessed 
spectra whose absorption and emission maximal wavelengths were shifted from those of 
untreated CysTCy. The resulting absorption and emission spectra were identical to those of TCy. 
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Figure 5.5 Time-dependent fluorescence of 2 M CysTCy (ex = 600 nm and em = 750 nm) 
incubated with or without addition of corresponding Cys (50 M), Hcy (50 M), or GSH (250 M) 
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). Inset is time-dependent (every 5 min for a 120-
min time period) emission spectral changes of CysTCy (2 M) with the addition of Cys (50 M) 
with ex = 600 nm. T = 37 °C. 
Solutions of CysTCy were treated with Cys, Hcy, and GSH, and the production rate of TCy was 
recorded by monitoring the fluorescence increase at 750 nm (ex = 600 nm), Figure 5.5. Upon the 
addition of Cys, a rapid fluorescence increase was observed (t1/2 = 20 min, time to achieve 50% 


























of maximum fluorescence response) with the response becoming roughly invariant after ~ 60 min 
for times up to 120 min. In contrast, addition of GSH and Hcy, the two most common interfering 
species in the detection of cysteine, did not result in significant fluorescence increases. For 
example, at 60 min incubation time point, both the Cys/GSH and Cys/Hcy response ratios are 
about 15-fold. Although both GSH and Hcy have a sulfhydryl group that can attack the alkene 
bond through Michael addition, they are much less likely to initiate the cyclization with the free 
amine group in the following step, which unleashes the TCy reporter. For GSH, there is no free 
amine group to accomplish the cyclization. For Hcy, formation of the eight-membered ring is 
thermodynamically disfavored in comparison to the seven-membered ring formation with Cys, 
thus making Hcy-initiated reporter release exceedingly slow.  






















































Figure 5.6 (A) Time-dependent fluorescence spectra (ex = 675 nm) of CysTCy (every 5 min over 
a 120-min time period) in the simultaneous presence of Cys (40 M) and GSH (200 M) in 20% 
(v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C. (B) The corresponding fluorescence ratio as 
a function of increasing time. 
To examine the potential influence of GSH on the response of CysTCy in the presence of 
Cys, solutions of 2 M CysTCy were incubated with both 40 M Cys and 200 M GSH, Figure 
5.6. The GSH concentration is 5-fold high compared to Cys similar to the ratio in biological 
samples. A gradual increase in the fluorescence ratio (F765/F808) was observed. These outcomes 
indicate that Cys has an extremely high reactivity toward CysTCy than GSH in the presence of 5-
fold more GSH, a very important result.  The most likely explanation for this observation is that 
215 
 
the sulfhydryl group of Cys has a lower pKa value than those of GSH and Hcy. For Cys, the pKa 
is 8.3, due to its close proximity to the strong electron-withdrawing protonated amine group. In 
contrast, GSH and Hcy have pKa values of 9.63 and 10.0, respectively.55-56 The lower pKa value 
of Cys indicates that there is more Cys existing in the thiolate form (~ 13% for Cys, 0.6% for GSH, 
and 0.3% for Hcy), which favors reaction of Cys with the alkene.  
5.3.5  Quantification of Cys in an Aqueous Solution with the CysTCy/TCy Ratiometric System 
In contrast to a turn-on fluorescent probe, a ratiometric fluorescent probe can act as a 
“self-calibrated” probe for applications requiring quantification of species. Such truly ratiometric 
probes have the advantages of avoiding the negative effects resulting from changes in excitation 
light power and detector detection efficiency. Environmental factors, such as viscosity and polarity, 
which affect the emission efficiency of fluorophores, can also be avoided. Considering the 
advantages of ratiometric probes, the quantification potential of the CysTCy/TCy pair was further 
investigated in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). The changes of fluorescence intensity 
of 2 M CysTCy upon titration of different Cys concentrations (0–100 M) were recorded with the 
excitation wavelength at its isosbestic point (= 675 nm) after 1 h incubation, Figure 5.7. As the 
concentration of Cys increased, the fluorescence at 808 nm decreased accompanied by the 
increase at 763 nm. By plotting the ratio of fluorescence intensity at 763 nm to that of 808 nm as 
a function of different concentrations of Cys, a response curve was established. The ratio reached 
its maximum value at [Cys] ≥ 30 M, indicating maximal reaction rate. More importantly, the ratio 
of fluorescence exhibited a linear response in the concentration range of 0–10 M (Ratio = 
0.0939[Cys] + 0.0925; R2 = 0.9932) with a high slope (high sensitivity). The anticipated limit of 
detection (LOD) was computed to be 0.62 M using the equation LOD = 3/k. The LOD is much 
lower than the total Cys concentration in human plasma from healthy individuals (135.8–266.5 
M).57 The linear response, low LOD, and high sensitivity of the CysTCy/TCy ratiometric system 




































































Figure 5.7 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 hour 
incubation with different concentrations of Cys (1, 2, 4, 6, 8, 10, 15, 20, 30, 40, 60, and 100 
M) in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C; (B) Corresponding fluorescence 
ratio (F763/F808) changes toward different Cys concentrations. Inset is of the linear calibration 
(1–10 M); correlation coefficient is 0.0939. 



























5.3.6  Stability of CysTCy in Human Plasma  



































































































Figure 5.8 Time-dependent fluorescence (A) of 2 M CysTCy (ex = 600 nm and em = 750 nm) 
incubated with or without addition of Cys (50 M). Time-dependent (every 5 min for a 120-min 
time period) fluorescence spectra changes of 2 M CysTCy (B, ex = 600 nm; C, ex = 675 nm) in 
the presence of Cys (50 M). All the measurement was in 10% deproteinized human plasma in 
20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C. 
CysTCy was further investigated in deproteinized human plasma to examine its stability 
and suitability to measure Cys in an environment that mimics blood. In cellular milieu, GSH is 
more abundant (1–10 mM) than is Cys and Hcy (M level), which causes the biggest interference 
in the detection of cellular Cys using fluorescent probes. However, only minimal levels of GSH 
(3–5 M) are present in human plasma.58 This difference provides an additional advantage for 
CysTCy to selectively measure Cys in human plasma with less interference from GSH. Pooled 
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normal human plasma (10 mL) was deproteinized by adding the plasma to cooled ethanol (20 mL) 
at –20 °C for 3 h. The precipitated proteins were removed by centrifugation at 4000 rpm for 30 
min. The collected supernatant was diluted in 20% ethanol (v:v) in PBS solution (20 mM, pH = 
7.4) to make 10% deproteinized human plasma solution which was utilized for subsequent 
analysis. During this process, the human plasma was not reduced, which should provide for the 
minimal levels of unbound Cys in the prepared plasma. As shown in Figure 5.8, without the 
addition of Cys, no large fluorescence signal response was noted in the first 60 min of incubation, 
indicating its stability under the deproteinized plasma conditions. In contrast, with the addition of 
40 M Cys, a rapid increase in fluorescence was observed indicating the quick production of TCy. 
The time-dependent turn-on and ratiometric fluorescence spectra of CysTCy treated with Cys 
were also recorded, Figure 5.7 B and 5.7 C.  
5.3.7  Quantification of Cys in Human Plasma 
In 10% human plasma, the fluorescence response of CysTCy toward different 
concentrations of Cys was further investigated. Upon incubating CysTCy with different amounts 
of Cys for 1 h, CysTCy exhibited a similar ratiometric fluorescence change to in 20% (v:v) ethanol 
in PBS (20 mM, pH = 7.4), Figure 5.9. Its fluorescence ratio (F763/F808) was directly correlated to 
the amounts of Cys, corroborating its potential for Cys quantification in human plasma. 
Finally, CysTCy was used for quantification of Cys in reduced human plasma. Pooled 
normal human plasma (0.5 mL) was reduced by addition of 80 L 0.1 M triphenylphosphine in 
acetonitrile and 40 L 0.2 M HCl.49, 59 This process breaks disulfide bond and releases the bound 
Cys. The reduced human plasma was mixed with cooled ethanol (0.5 mL, – 20 °C) to precipitate 
the proteins, followed by centrifugation (4000 rpm) for 30 min. The supernatant was diluted (10%) 
and incubated with CysTCy (2 M) in ethanol/PBS (v:v, 2:8) at 37 °C, Figure 5.10. The 
fluorescence at 808 nm was gradually decreased, accompanied by the fluorescence increase at 
763 nm. The fluorescence ratio, 0.74, (F763/F808, 1-h incubation) was correlated to the Cys 
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response linear curve in Figure 5.7. The Cys level in human plasma was calculated to be 98.0 ± 
11.1 M. The determined Cys level is slightly lower than that present in human plasma might be 
caused by the loss of Cys during the preparation procedures. This outcome demonstrated that 
CysTCy is able to quantify Cys in deproteinized human plasma. 


























































Figure 5.9 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 h incubation 
with different concentrations of Cys (0, 1, 2, 3, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 70, 80, 100, 120, 
150, and 200 M); (B) Corresponding fluorescence ratio (F763/F808) for 1-h incubation of Cys with 
different Cys concentrations. All the measurements were performed in 10% deproteinized human 
plasma in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C. 





























































Figure 5.10 (A) Time-dependent (every 5 min for a 150-min time period) emission spectral 
changes of CysTCy (2 M, ex = 675 nm) (B) Two independent emission spectra of CysTCy upon 
1-h incubation. The measurement was performed in the 10% reduced human plasma in 20% (v:v) 




5.4  Conclusion 
The CysTCy/TCy pair was developed as a ratiometric probe/reporter system to selectively 
detect Cys over other thiols including Hcy and GSH. Its selectivity relied on its unique recognition 
pattern involving both the amino and the sulfhydryl groups of Cys to react with an acrylic 
recognition moiety. The unleashed reporter by Cys induced a huge color change and fluorescence 
switch, thus making it a dual colorimetric and fluorescent probe. The developed system also 
exhibited a linear response toward Cys, low LOD, and high sensitivity. Its usefulness was 
demonstrated by its application in measuring and quantifying Cys in human plasma. 
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SUMMARY, CONCLUSION, AND OUTLOOK 
 
6.1  Summary and Conclusion 
The overall goal of this research was to develop and implement activity-based substrate 
probes for the detection and imaging of cancer-associated enzymes (i.e., human NAD(P)H: 
quinone oxidoreductase isoenzyme 1 (hNQO1) and -galactosidase) in vitro and in vivo. The 
probes were designed to be either non-fluorescent, or fluorescent in a different energy range from 
their corresponding fluorescent reporters. Upon enzymatic activation, the developed probes are 
converted into highly fluorescent reporters—both selectively and rapidly. Because the targeted 
enzymes are upregulated in various cancer cells and tissues, catalysis of probes, and subsequent 
release of reporters, cause emission of visible or near-infrared (NIR) photons from the diseased 
cells, thus allowing the differentiation of diseased tumor cells from healthy cells.  
Because photons in NIR range are most suited for in vivo applications, I put my initial 
efforts into the design and synthesis of a probe, Q3STCy, which emits near-infrared light upon 
hNQO1 activation, as well as examining probe applicability in visualizing hNQO1-expressing cells 
and small tumors. Q3STCy has a tripartite structure (a quinone trigger, a 2-mercaptoethanol linker, 
and a heptamethine cyanine reporter). Spectroscopic measurements revealed that the probe and 
the reporter have distinct absorption and emission profiles, observations which were further 
studied with frontier molecular orbital calculations. Q3STCy has a low fluorescence efficiency, 
most likely due to donor-excited-photoinduced electron transfer (d-PeT) quenching. The d-PeT 
quenching was verified by outcomes based on photophysical studies and cyclic voltammetry (CV). 
Upon NQO1-catalyzed reduction, the probe exhibited a fast and large fluorescence increase in 
aqueous solutions. Enzymatic kinetic experiments indicated that Q3STCy is a good substrate for 
hNQO1, with unprecedented catalytic formation of the fluorescent reporter. Q3STCy also 
exhibited a high selectivity toward hNQO1 and pH-independence, which makes it advantageous 
in biological applications. The differentiation of NQO1-expressing cells (HT29, H596 (+), and 
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SHIN3) from NQO1-non-expressing cells (H596) with high integrity was also achieved with the 
application of Q3STCy using confocal and wide-field microscopy. Because two-dimensional (2D) 
cell culture lacks features of real tumor microenvironments, three-dimensional (3D) colorectal 
multicellular spheroids (MCTS) model can better mimic tumor characteristics. Q3STCy was 
successfully used to image clinically relevant MCTSs possessing spatially heterogeneous NQO1 
activities, and the probe was also applied in fluorescence-assisted identification of metastases in 
a preclinical mouse model of human ovarian serous adenocarcinoma.  
Moreover, I developed a probe, Q3NTCy, which is capable of reporting the activity of 
hNQO1 in a rapid, selective, and sensitive manner. In contrast to Q3STCy, the Q3NTCy probe 
exhibited strong fluorescence in a different energy range of the electromagnetic spectrum from 
the reporter. Enzymatic evaluation showed that Q3NTCy is a great substrate of hNQO1. The 
effective reduction of Q3NTCy by hNQO1 initiated a chain reaction, which rapidly produced the 
TCy reporter. Q3NTCy was also successfully employed in the differentiation of hNQO1-expressing 
cell lines (HT-29, A549, and SHIN3) from an hNQO1-nonexpressing cell line (H596) in both off-
on and on-on fluorescence modes. When tissue sections of living 3-D MCTSs were treated with 
Q3NTCy, the fluorescence response was found to be in agreement with the spatially 
heterogeneous hNQO1 expression as demonstrated by immunohistochemistry. Although both 
Q3STCy and Q3NTCy proved to be useful for imaging the small-sized young MCTSs, with the 
images reflecting the hNQO1 expression levels in sectioned MCTSs, they failed to diffuse inside 
intact MCTSs. When intact MCTSs having uniform hNQO1 distribution were treated with Q3STCy 
and Q3NTCy and subsequently sectioned, the peripheral layers were observed to be fluorescent 
and the interior regions were non-fluorescent in young MCTSs. Inability of the two probes to 
penetrate deep into tissues/mimics limits their applications in the evaluation of drug action, and 
drug efficacy, in this specific 3D tumor model. 
In an effort to diversify my research, I made a slight change in my research course from 
developing NQO1-activatable probes, to probes with the potential to provide quantitative 
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information on other enzyme/cofactor systems. First, I chose galactosidase (-gal) as the target 
enzyme. -gal is a transgene enzyme upregulated in senescent cells and in primary ovarian 
cancer cells. It has been exploited as a biomarker to develop small-molecule fluorogenic probes 
for detecting and imaging senescent cells and ovarian cancer cells. A -gal–responsive 
ratiometric fluorescent probe has the potential to provide a simple and sensitive way to quantify 
the activity of -gal under cellular conditions. Therefore, I developed a previously unreported, well-
defined ratiometric fluorescent probe, GalNap, capable of achieving real-time detection and 
imaging of endogenous -gal in human ovarian cancer cell lines in both off-on and ratiometric 
modes. I have demonstrated that GalNap, having a tripartite structure (a -gal recognizer, a self-
immolative linker, and an intramolecular charge transfer (ICT) fluorophore), is capable of being 
effectively recognized and rapidly hydrolyzed under physiological conditions by -gal, resulting in 
the production of an ICT fluorophore, as noted by obvious changes in the spectral profile. Using 
confocal microscopy, the capability of GalNap to reflect variations in cellular -gal activity was 
observed in -gal–overexpressing ovarian cancer cell lines, in both off-on and ratiometric modes.  
To further broaden my work, I developed a second ratiometric probe/reporter system 
(CysTCy/TCy), designed to selectively detect cysteine over other thiols, including homocysteine 
and GSH. Selectivity of the probe/reporter system relies on its unique recognition pattern that 
involves both the amino and the sulfhydryl groups of cysteine. The released reporter induced a 
significant change in color and fluorescence emission energy, thus making it a dual colorimetric 
and fluorescent probe. This system also exhibited a linear response toward change in 
concentration of cysteine, and low LOD and high sensitivity for detection of cysteine. Its 






6.2      Outlook 
My initial research was focused on the development of enzyme-activated fluorogenic 
molecular substrate probes and their use in differentiating diseased tissues from healthy tissues. 
My efforts resulted in the development of a molecular probe that successfully visualizing ovarian 
cancer–derived micrometastases in a xenograft mouse model. Although such probes may have 
promising impact in fluorescence–guided cytoreductive surgery, complete resection of all the 
small metastases in every patient is highly unlikely. To increase the efficiency, I thought about the 
possibility of developing a probe that can not only fluoresce, but can also be toxic toward hNQO1-
expressing tumor tissues. Certain dyes (i.e., photosensitizer, PS) can produce singlet oxygen (1O2) 
upon light illumination, thus allowing selective toxicity toward the illuminated tissues. Therefore, I 
decided to evaluate the possibility of achieving the simultaneous imaging and killing of hNQO1-
expressing cells by incorporating a PS molecule with an hNQO1-specific recognition moiety.  
Photodynamic therapy (PDT) is an important cancer treatment method that uses light, a 
PS, and molecular oxygen to produce toxic 1O2, thus eliciting cell death.1 The mechanism of 1O2 
formation is illustrated by a modified Jablonski diagram, Figure 6.1. Upon illumination with a 
suitable light source, the PS is excited from its ground state (S0) to its excited singlet state (S1), 
which can undergo fluorescence, heat release, or intersystem crossing to the long-lived triplet 
state (T1). PS in the triplet state can either transfer energy to a triplet state molecular oxygen (3O2) 
molecules to produce 1O2, or transfer an electron to oxygen to produce hydroxyl radical. Because 
 
Figure 6.1 Depiction of mechanism of singlet oxygen (1O2) formation by exciting a PS with light 
in the presence of molecular oxygen.  
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the half-life of 1O2 in aqueous solution is less than 1 ms, and the diffusion distance of 1O2 is about 
10–55 nm in cells, which limits 1O2 leaking out of the illuminated areas, PDT can achieve high in 
situ toxicity.2   
Conventionally, selective cell ablation is regulated by controlling the light illumination and 
PS delivery to the tumor area. However, it is difficult to precisely direct the light illumination to 
small targeted areas (e.g., small-sized tumors) without affecting the surrounding normal tissues. 
Most of the currently used PSs are based on porphyrins, which distribute in the human body in a 
nonspecific manner, leading to serious photo-damage to healthy tissues. To overcome this issue, 
PSs are conjugated with targeting groups (e.g., antibodies and peptides) to improve their 
tendency to accumulate in the targeted areas. However, they still cause photo-damage to normal 
tissues, due to the slow clearance of the unbound PSs. Activatable PSs (aPSs) that do not 
produce 1O2 until they are activated by specific disease-linked biomarkers, hold great promise to 
overcome the nonspecific phototoxicity issue.3-4 Recently, several cancer-associated enzymes 
have been targeted to design PSs, such as caspase 3,5-6 matrix metalloproteinase 7 (MMP-7),7 
-galactosidase,8-9 and -glutamyltranspeptidase.10    
Quinone propionic acid (Q3PA) is a selective and effective hNQO1 recognition group, as 
has been demonstrated in the development of fluorescent probes, and most importantly, it is 
electron-deficient in nature. By incorporating a suitable PS with the quinone moiety (Q3), I 
envisioned that 1O2 production by a PS can be inhibited through a photoinduced electron transfer 
(PeT) process.  Pyropheophorbide a (Pyro) is a PS that has both high fluorescence efficiency (F 
= 0.43 in benzene) and high 1O2 production efficiency ( = 0.45 in benzene), and thus displays 
dual functions – fluorescence imaging and photodynamic activity.3 Therefore, Pyro was selected 
as the PS to be conjugated with the quinone recognition group so as to afford an hNQO1-
responsive PS, Q3Pyro, Figure 6.2 A. In Q3Pyro, both the fluorescence and photosensitizing ability 
are anticipated to be blocked by the PeT process, but specific reduction and cleavage of the Q3 
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moiety by hNQO1 was thought to be restore the fluorescence and photosensitizing ability of Pyro. 
Because the two gem-dimethyl groups on Q3PA are the driving force for the cleavage upon 
reduction, I designed and synthesized an analog of Q3Pyro that lacks the two gem-dimethyl 
groups, Q1Pyro, as a control aPS. Q1Pyro was thought to be unable to release the PS upon 
hNQO1 reduction.  
The spectroscopic properties of Q3Pyro, Q1Pyro, and Pyro were measured in an aqueous 
solution (50% methanol: 50% 20 mM PBS, pH = 7.4). All the three compounds exhibited typical 
absorption spectra of porphyrin compounds with similar extinction coefficients, Figure 6.2 B. They 
showed an intense absorption band around 405 nm (the Soret band, S0 to S2) and four additional 
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Figure 6.2. (A) Design of an hNQO1-responsive aPS, Q3Pyro. Upon hNQO1 reduction, the 
toxic PS was released through the elimination of the quinone moiety. (B) Absorption spectra 
and (C) emission spectra (ex = 405 nm) of Q3Pyro (5 M), Q1Pyro (5 M), and Pyro (5 M) in 





absorption bands (Q bands, S0 to S1) in the longer wavelength range (500–700 nm). The intense 
absorption at 665 nm is in the near-infrared light range (650–900 nm). Pyro also fluoresces in the 
NIR range, with two emission maxima (675 nm and 725 nm), thus allowing it to be suitable for 
biological applications. Although Pyro exhibited strong fluorescence, Q3Pyro and Q1Pyro have 
very weak fluorescence under the same conditions, Figure 6.2 C. This observation confirmed that 
the fluorescence of Pyro is effectively quenched by the Q3 moiety, a primary requirement for the 
development of aPSs.  
The 1O2 production efficiency of Q3Pyro, Q1Pyro, and Pyro upon light illumination was 
studied with the use of 1,3-diphenylisobenzofuran (DPBF, abs = 405 nm) as the 1O2 trapping 
molecule, Figure 6.3. Solutions of the respective PS molecule (5 M) and DPBF (40 M) in an 
aqueous solution (50% methanol: 50% 20 mM PBS, pH = 7.4) was irradiated with light (665 ± 10 
 
Figure 6.3. Time-dependent (10-min interval) change in absorption spectra of DPBF (40 M) 
upon a light irradiation (665 ± 10 nm) in 50% (v:v) methanol in 20 mM PBS (pH = 7.4) in the 
presence of (A) Pyro (5 M), (B) Q3Pyro (5 M), or (C) Q1Pyro (5 M). (D) Relative 1O2 
production rate. The values were the normalized decrease slope of the absorption intensity at 
405 nm. T = 25 °C.  
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nm). The change of the DPBF concentration was monitored with absorption spectroscopy. For a 
solution of Pyro and DPBF, as irradiation time increased, the absorption at 405 nm gradually 
decreased, corresponding to the breakage of DPBF by the produced 1O2. In contrast, for both 
solutions of Q3Pyro and Q1Pyro in the presence of DPBF, light irradiation did not induce the 
decrease of the absorption intensity at 405 nm, indicating the less 1O2 production of Q3Pyro and 
Q1Pyro. By comparing the slope of the absorption decrease at 405 nm, Q3Pyro and Q1Pyro had 
about 11-fold lower 1O2 production efficiency than Pyro, Figure 6.3 D. These outcomes were in 
agreement with the hypothesis that the 1O2 production of Pyro can be quenched by the electron-
deficient Q3 moiety, most likely through a PeT process.   
After demonstrating that both the fluorescence and 1O2 production of Pyro were effectively 
quenched by the quinone moiety, I next sought to study the ability of Q3Pyro to be hNQO1 reduced 
to release the toxic Pyro. Fluorescence intensities at 670 nm (ex = 400 nm) of aqueous solutions 
of Q3Pyro and Q1Pyro in the presence and absence of hNQO1 (4 g mL–1, 2000 U mL–1) were 






















































Figure 6.4. The fluorescence intensity at 670 nm of solutions of Q3Pyro and Q1Pyro (5 M, ex 
= 400 nm) in 5% (v:v) DMSO in 20 mM PBS (pH = 7.4) containing 100 M NADH and 0.007% 
BSA was recorded with and without the addition of hNQO1 (4 g mL–1, 2000 U mL–1) at the 
20-min time point. Inset is the fluorescence spectral response of Q3Pyro toward hNQO1 during 
a 60-min time period. T = 37 ºC. 
































monitored. As shown in Figure 6.4 (red line), upon addition of a solution of Q3Pyro with hNQO1 
at the 20-min time point, an immediate increase in the fluorescence intensity at 670 nm, 
corresponding to the release of Pyro, was observed (t1/2 = 25 min, the time of Q3Pyro to achieve 
half of its maximum Pyro release).  In contrast, the control aPS, Q1Pyro, did not show a similar 
fluorescence increase pattern upon the addition of hNQO1; the small fluorescence increase may 
be caused by the reduced form of Q1Pyro. Moreover, upon continuous irradiation with 400-nm 
light (120 min) in the absence of hNQO1, neither of the solutions of Q3Pyro and Q1Pyro showed 
an increase in fluorescence intensity, indicating their photostability and low non-specific activation 
in aqueous solutions. 
 To demonstrate that Q3Pyro can be specifically activated by hNQO1 in vitro, a cellular 
imaging experiment was conducted on a wild-type non-small cell lung carcinoma cell line (H596 
(-), hNQO1-non-expressing) and an hNQO1-gene-transfected H596 cell line (H596 (+), hNQO1-
expressing). As shown in Figure 6.5, H596 (+) cells treated with Q3Pyro showed a strong cytosolic 
fluorescence signal, while H596 (-) treated with Q3Pyro showed minimal fluorescence signal under 
the same conditions. The target-to-background ratio (TBR) of H596(+) (29 Cells)/H596(-) (30 cells) 
was determined to be 2.6 ± 0.7 (95% confidence). In contrast, both H596 (+) and H596 (-) cell 
lines without aPS treatment (control) and such cells incubated with the control aPS, Q1Pyro, 
showed minimal fluorescence. This data clearly demonstrated that Q3Pyro can pass through the 
cellular membrane and be activated by hNQO1 inside cells, indicating its potential to function as 
both a profluorogenic probe and an aPS.  
 To determine the subcellular location of Pyro produced by the hNQO1-mediated activation 
of Q3Pyro, H596 (+) cells were treated with Q3Pyro and the organelle trackers (endoplasmic 
reticulum (ER) tracker, mitochondria tracker, and lysosome tracker) and cellular images were 
captured with confocal microscopy, Figure 6.6. The fluorescence signal from Pyro showed a high 
degree of colocalization with that from the ER tracker, and the Pearson correlation coefficient for 
colocalization (PCCC)11 was determined to be 0.83. In contrast, the fluorescence signal from Pyro 
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had poor colocalization with the lysosome-tracker and mitochondria-tracker; the PCCC values for 
Pyro/lysosome and Pyro/mitochondria were –0.01 and 0.34, respectively. The subcellular location 
of a PS plays an important role in the type of cell death mechanism (apoptotic, necrotic, and 
autophagy-associated cell death).2 The ER localization of Pyro may indicate that Q3Pyro can 
induce the cell death through autophagy-associated pathway. 
 I next examined via MTT assay the cell viability of H596 (-) cells, upon exposure to different 
concentrations of Q3Pyro and Pyro with or without light irradiation, Figure 6.7. The percentages 
were normalized to the cell viability of H596 (-) without the Q3Pyro or Pyro treatments. Both 
Q3Pyro and Pyro in the studied concentration range (1–10 M) had low dark toxicity, Figure 6.7 
A. In contrast, upon irradiation with a 665-nm LED light (10 mW cm–2) for 50 seconds, Q3Pyro had 
 
Figure 6.5. Fluroescence and differential interference contrast (DIC) images of H596 (-) and 
H596 (+) cells using confocal microsopy. Cells were incubated with Q3Pyro (5 M) or Q1Pyro 
(5 M) for 30 minutes under 5% CO2, humidified conditions in dark at 37 ºC. The treated cells 
were washed with DPBS twice, and then fixed by 4% PFA solution for 15 minutes. Control 
experiment represents the cells without the incubation with Q3Pyro or Q1Pyro. Fluorescence 
images were captured in the 675–750 nm emission range upon excitation by a 665-nm laser. 
Scale bar = 20 m. 
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a lower cell toxicity than Pyro in agreement with the decreased 1O2 production efficiency of Q3Pyro, 
Figure 6.7 B. 
 
 
Figure 6.6. Fluorescence and DIC images of live H596 (+) cells treated with Q3Pyro and 
organelle trackers. Cells were incubated with Q3Pyro (5 M) and the respective organelle 
tracker – ER-tracker Blue-White DPX (60 nM), Lysotracker Green DND-26 (30 nM), and 
Mitotracker Green (75 nM) for 30 min. The settings for capturing the Q3Pyro fluorescence 
images were 665 nm excitation and 670–750 nm emission; for ER images, the settings were 
405-nm excitation and 500–600 nm emission; for lysosome and mitochondria images, the 
settings were 488-nm excitation and 500–600 nm emission. Scale bar is 15 m or 20 m.  
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 So far, my preliminary results have shown that quinone propionic acid is capable of 
quenching the toxic singlet oxygen of the photosensitizer, and Q3Pyro has the potential to become 
an efficient targetable imaging and anti-cancer agent. The selectivity and efficacy of the Q3 moiety 
toward hNQO1 and its electron deficient property has been proved over and over again. And I 
believe that further exploration must be continued with the Q3 moiety. Its conjugation with other 
types of signal-generating molecules to develop NQO1-activatable contrast agents, such as 
photodynamic agents, chemiluminescent probes, and photoacoustic probes is an endeavor worth 
pursuing. 
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Figure 6.7. H596 (-) cell viability (A) in dark and (B) with light irradiation (665 nm LED, 0.5 J 
cm–2) of Q3Pyro and Pyro of various concentrations determined by MTT assay, compared with 
untreated cells. Error bars indicate the standard deviations (± s.d.) of triplicate experiments. 
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